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ABSTRACT  
Background: An updated psoriatic arthritis (PsA) core outcome set (COS) for randomized controlled trials 
(RCTs) was endorsed at the Outcome Measures in Rheumatology (OMERACT) meeting in 2016. 
Objectives: Synthesize the evidence on measurement properties of patient reported outcome measures 
(PROMs) for PsA and thereby contribute to development of a PsA core outcome measurement set (COMS) 
as described by the OMERACT Filter 2.0. 
Methods: A systematic literature search was performed in EMBASE, MEDLINE and PsycINFO on Jan 1st 
2017 to identify full-text articles with an aim of assessing the measurement properties of PROMs in PsA. 
Two independent reviewers rated the quality of studies using the COnsensus based standards for the 
Selection of health Measurement INstruments (COSMIN) checklist, and performed a qualitative evidence 
synthesis. 
Results: Fifty-five studies were included in the systematic review. Forty-four instruments and a total of 89 
scales were analysed. PROMs measuring COS domains with at least fair quality evidence for good validity 
and reliability (and no evidence for poor properties) included the Stockerau Activity Score for PsA 
(German), Psoriasis Symptom Inventory, visual analogue scale for Patient Global, 36 Item Short Form 
Health Survey Physical Function subscale, Health Assessment Questionnaire Disability Index, Bath 
Ankylosing Spondylitis Functional Index, PsA Impact of Disease questionnaire, PsA Quality of Life 
questionnaire, VITACORA-19,  Functional Assessment of Chronic Illness Therapy Fatigue scale and Social 
Role Participation Questionnaire.  
Conclusions: At least one PROM with some evidence for aspects of validity and reliability was available for 
six of the eight mandatory domains of the PsA COS.   
Keywords: psoriatic arthritis, OMERACT, COSMIN, patient reported outcome measures, measurement 
properties, systematic review 
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INTRODUCTION 
Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with a range of symptoms, co-
morbidities and reduced health related quality of life.[1-3] Based on patients’ and physicians’ perspectives 
as well as recent research developments, the Group for Research and Assessment of Psoriasis and Psoriatic 
Arthritis (GRAPPA) together with the Outcome Measures in Rheumatology (OMERACT) international 
consensus effort developed an updated core outcome set (COS) for PsA[4], describing the outcomes 
(domains) that should be measured and reported in all randomized controlled trials. The updated PsA COS 
was endorsed in May 2016 by OMERACT and includes the following mandatory (‘inner core’) domains: 
Musculoskeletal (MSK) disease activity, Skin disease activity, Pain, Patient global, Physical function, Health 
Related Quality of Life (HRQoL), Fatigue and Systemic inflammation. Four other domains (Participation, 
Economic cost, Structural damage and Emotional well-being) were considered important but not 
mandatory (middle COS circle), and four domains (Sleep, Independence, Stiffness and Treatment burden) 
were placed in the “research agenda” (outer COS circle).[5] 
The OMERACT Filter 2.0 provides guidelines for developing a core outcome measurement set 
(COMS) which comprises the appropriate instruments to assess each COS domain.[6]  Great heterogeneity 
exists in instruments used for measuring the core domains of PsA, and several have been “borrowed” from 
other diseases without confirming their measurement properties in PsA.[7] Instruments should have 
evidence of validity, reliability and responsiveness as described in detail by the COnsensus based standards 
for the Selection of health Measurement INstruments organisation (COSMIN).[8] In addition, an instrument 
needs to be feasible and yield interpretable results.[9] These qualities are summarized by the original 
OMERACT Filter as ‘Truth, Discrimination and Feasibility’.[10] As highlighted by the OMERACT Filter 2.0, the 
COS development was not influenced by considering how to measure the domains; neither the type of 
assessment nor the availability of specific instruments was taken into account. Development of the PsA 
COMS therefore implies that subsequently all available instruments per COS domain are identified, 
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evaluated and judged for overall applicability. To support this GRAPPA-OMERACT initiative, the objective of 
this systematic literature review was to synthesise the evidence for good measurement properties of 
patient reported outcomes measures (PROMS) in PsA and align instruments and COS domains.  
METHODS 
A protocol was uploaded to PROSPERO prior to initiation of the systematic review (PROSPERO: 
CRD42016032546). The review adheres to the COSMIN guidelines[11-13] and the Preferred Reporting 
Items for Systematic reviews and Meta-Analyses (PRISMA-statement).[14] 
Literature search  
A research librarian (EMB) and the first-author (PH) performed a systematic search in MEDLINE via 
PubMed from 1966, EMBASE via OVID from 1974, and PsycINFO via OVID from 1806, all to 1 January 2017. 
The search was designed to identify all types of outcome measurement instruments in PsA. The search was 
limited to humans and consisted of two overall terms:  (1) Target population: MeSH subheadings and free 
text words in title/abstract (ti/ab) were combined by the Boolean operator ‘OR’ to search for the target 
population (PsA) in the databases; (2) Measurement properties: Search filters have been developed to 
improve the search of studies on measurement properties in MEDLINE and EMBASE.[15] We used the 
highly sensitive filter validated for MEDLINE (sensitivity of 97.4%) and the filter for EMBASE optimized for 
this search. In PsycINFO only the target population was searched. The full search strategy is available in 
supplementary Table A.   
Eligibility criteria  
Per protocol, studies were considered eligible if published as full text articles in the English language with 
an aim of developing or assessing measurement properties of outcome measurements in PsA patients. 
However, for feasibility reasons and to ensure applicability of the COSMIN guidelines, it was subsequently 
decided to evaluate only patient reported instruments in this review, and allocate the assessment of the 
remaining instruments to parallel work streams.  The stepwise eligibility and inclusion process is depicted 
in Figure 1. Studies evaluating instruments used solely for screening or diagnostic purposes were not 
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eligible. Only studies including ≥50% patients with PsA or reporting PsA subgroup results separately were 
included.  
Selection of articles 
PH eliminated duplicates and the remaining references were assessed for eligibility by two independent 
reviewers (PH, KH). Titles, abstracts and full-text articles (when appropriate) were reviewed and selection 
was performed by consensus with involvement of co-authors (RC, LK, EMB, A-MO) if needed. Additional 
studies identified by co-authors or reviews were considered for inclusion. Search results were handled by 
Reference Manager 12 (Thomson Reuters, USA). 
Extraction of study characteristics and description of PROM characteristics  
PH and KH independently extracted data on the characteristics of the studies (number, age and gender of 
participants, study setting and language). Characteristics of the PROMs (e.g., items, scoring, feasibility and 
availability) were obtained by PH from the questionnaires, background literature, user manuals or 
European League Against Rheumatism (EULAR) Outcome Measures Library[16] or by contacting 
authors/copyright holders.  
Mapping the PROMs to corresponding COS domains 
The working group, including Patient Research Partners (PRPs) (NG, MdW) reviewed the PROMs to achieve 
consensus on how to present them by COS domains.  Separate scales within a multi-scale instrument as 
well as summed scale scores were perceived as unique instruments and mapped by their corresponding 
COS domains.  Measurements of HRQoL were categorized as either health status surveys or health 
value/preference/utility assessments.  The latter were reported within the COS domain ‘economic cost’. 
  
Extraction and evaluation of the methodological study quality per measurement property per 
instrument 
The COSMIN checklist enables a critical evaluation of the methodological quality of studies investigating 
measurement properties[11]. A four-point system is provided to score the methodological quality of a 
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study per measurement property as ‘excellent’, ‘good’, ‘fair’ or ‘poor’.[13] Four independent reviewers 
worked in teams of two (PH/LK, PH/AMO, PH/YYL) to reach consensus on the COSMIN ratings.  A third 
reviewer (CT or RC) resolved disagreements. Information on score interpretation (mean (SD) of scores, 
floor and ceiling effects, minimally (clinically) important difference/improvement (M(C)ID/MCII), minimal 
detectable change (MDC) and Patient Acceptable Symptom State (PASS)) was extracted. 
Evaluation of the result of the measurement properties  
The results of measurement properties per instrument were evaluated (concurrently with the rating of the 
study methodology) as positive (+), indeterminate (?) or negative (-) per study in accordance with the 
quality criteria described by the ‘COSMIN & Core Outcome Measures in Effectiveness Trials (COMET) 
collaboration’.[17]  
Level of evidence for the quality of the measurement properties of PROMs in PsA  
To determine the overall level of evidence for a measurement property of an instrument, data were 
synthesized by combining the quality of the measurement property results, the methodological study 
qualities and the consistency of the findings[18,19] (Table 1).  
 
Table 1  Level of evidence for the quality of a measurement property 
Strong (+++) 
 
Strong (- - -) 
Consistent findings of good measurement property in multiple studies of good methodological 
quality or in one study of excellent methodological quality.  
Consistent findings of poor measurement property in multiple studies of good methodological 
quality or in one study of excellent methodological quality.  
Moderate (++) 
 
Moderate (- -) 
Consistent findings of good measurement property in multiple studies of fair methodological 
quality or in one study of good methodological quality. 
Consistent findings of poor measurement property in multiple studies of fair methodological 
quality or in one study of good methodological quality. 
Limited (+) 
Limited (-) 
One study of fair methodological quality with findings of good measurement property. 
One study of fair methodological quality with findings of poor measurement property 
Conflicting (±) Conflicting findings on the measurement property quality results across studies. 
Unknown (?) Only studies of poor methodological quality were identified. 
 
Reporting the results of the evidence synthesis 
As described by OMERACT[9], the COSMIN & COMET collaboration[17] and the Food And Drug 
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Administration (FDA)[20] guidelines, evidence on validity (especially content validity) and reliability should 
be prerequisites for an instrument to be considered for further evaluation/application. If an instrument 
does not measure what it intends to or produces unreliable estimates, it is irrelevant to test for e.g., 
responsiveness. Thus, in the result section of this systematic review, we have chosen to highlight the 
‘candidate’ instruments per COS domain that have at least limited evidence on reliability and validity and 
no evidence for any poor measurement properties.  
The main evidence synthesis includes all studies of a PROM but conflicting evidence on measurement 
properties across language versions is described for ‘candidate’ PROMs. Available values for Cronbach-α, 
interclass correlation coefficients (ICC) and floor/ceiling effects are described in the text while remaining 
results on measurement properties and score interpretation can be obtained from the tables. 
RESULTS 
Study selection 
As illustrated in Figure 1; from 5844 unique references identified, 334 studies were eligible for further 
assessment.  Of these, 77 reviews were excluded, as were 87 abstracts/conference papers without full-
text. An additional 11 papers were added from experts and reference lists resulting in 181 studies for full-
text reading. Eighty of these failed the inclusion criteria due to reasons depicted in Figure 1. Of the 
remaining 101 studies, clinician-reported (n=18) and composite (n=28) measures were excluded due to the 
focus on PROMs only, leaving 55 studies for final inclusion.  
Study characteristics 
The included studies were published between 1992 and 2016 and were mainly observational cohorts of 
PsA patients in their 4th and 5th decades of life. Most studies were performed in English speaking countries 
and evaluated more than one PROM (Table 2).  
Characteristics of the PROMs 
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A total of 44 instruments covering 89 separate PROMs were evaluated (supplementary Tables B1, B2).  
Each PROM was mapped to the corresponding COS domain. The content, scoring and feasibility aspects of 
each PROM are described in supplementary Table B2. 
Rating of the methodological quality and measurement property results of each study 
The methodological quality ratings and ratings of the measurement property results are presented for each 
PROM in supplementary Table C. A further description of the rating rationale and values for score 
interpretation are listed per PROM in supplementary Table D.  
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Table 2 Characteristics of the studies 
N Sources (55 in total) PROM(s)  Na PsA(%) Age,mean(SD) Women(%) Language Country Setting 
1 Duffy (1992)[21] AIMS1 145 100 48(13) 43 English Canada OPC 
2 Blackmore (1995)[22] HAQ-DI, HAQ-S, VAS 
stiffness(HAQ), VAS pain(HAQ) 
114 100 49(13) 39 English Canada OPC 
3 Husted (1995)[23] HAQ-SK 118 100 49(13) 39 English Canada OPC 
4 Husted (1996)[24] AIMS2  124 100 48(13) 40 English Canada OPC 
5 Husted (1996)[25] AIMS1, AIMS2  65 100 46(12) 42 English Canada OPC 
6 Husted (1997)[26] SF-36  113 100 51(13) 38 English Canada OPC 
7 Taccari (1998)[27] HAQ-DI, AIMS1  72 100 55(13) 31 Italianb Italyb OPC 
8 Husted (1998)[28] AIMS2, HAQ-DI, VAS pain(HAQ), 
SF-36  
70 100 46(11) 39 English Canada OPC 
9 Navsarikar (1999)[29] DASH 50 100 49(12) 44 English Canada OPC 
10 McKenna (2004)[30] PsAQoL 286 100 50(13) 68 English UK OPC 
11 Taylor (2004)[31] BASDAI 133 100 46(19)/52(25)c 41/53c English New Zealand OPC 
12 Chandran (2007)[32] FACIT-Fatigue 135 100 52(13) 41 English Canada OPC 
13 Taylor (2007)[33] HAQ-DI, SF-36 PF 276 49 52(14)d 43d English New Zealand  OPC 
14 Leung (2008)[34] HAQ-DI, BASFI, DFI, SF-36 PF 108 100 49(13) 52 Chinese China OPC 
15 Healy (2008)[35] PsAQoL 28 100 47(11) 50 English UK OPC 
16 Dominguez(2009)[36] PASE 190 19 NS NS English USA OPC 
17 F.-Sueiro (2010)[37] BASDAI 203 49 55(13)d 36d Spanish Spain OPC 
18 Minnock (2010)[38] NRS Fatigue 41 100 45(13) 54 English Irelandb OPC 
19 Eder (2010)[39] BASDAI 201 100 53(14) 37 English Canada OPC 
20 Leung (2010)[40] SF-36, MCS, PCS 168 100 48(12) 46 Chinese China OPC 
21 Billing (2010)[41] PsAQoL 123 100 51(15) 53 Swedish Sweden OPC 
22 Brodszky (2010)[42] PsAQoL, HAQ-DI, EQ-5D-3L 183 100 50(13) 57 Hungarian Hungary OPC 
23 Kwok (2010)[43] VAS-pain/sleep/global/ 
fatigue, HAQ-DI 
200 100 51(14) 59 English Canada OPC 
24 El Miedany (2010)[44] MultiP scales (NRS pain, NRS 
global (joints), NRS fatigue, 
mRAI, PR-TJC, NRS stiffness, 
462 26.6 60(10) 72 English UK, Egypt OPC 
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CIAQ-QoL, CIAQ-FI) 
25 Kvamme (2010)[45] EQ-5D-3L, VAS-global/pain, 
mHAQ, SF-6D 
4225 20.1 48(12)d 47c Norwegian Norway OPC 
26 Hu (2010)[46] WTP  59 100 Range: 23-89 44 English USA OPC 
27 Adams (2010)[47] EQ-5D-3L, SF-6D 504 32 45(13) 52 English Ireland OPC 
28 Adams (2011)[48] EQ-5D-3L 504 32 45(13) 52 English Ireland OPC 
29 Cauli (2011)[49] VAS-global/skin/joints 319 100 52(13) 42 Multiple Several OPC 
30 Leung  (2011)[50] SF-36, VAS pain, VAS global, 
HAQ-DI 
20 100 48(13)/52(11)e 46/37e Chinese China OPC 
31 Mease (2011)[51] HAQ-DI 161 100 47(11) 52 English  USA  RCT 
32 Davis (2011)[52] SRPQ 109 60 53(11) 37 English Canada OPC 
33 Leung (2012)[53] NRS-global 125 100 48(12) 48 Chinese China OPC 
34 Leung  (2013)[54] EQ-5D-3L, SF-6D 86 100 49(13) 52 Eng/Chin Singapore OPC 
35 Wink (2013)[55] PsAQoL 183 100 55(13) 45 Dutch Netherlands OPC 
36 Coaccioli (2014)[56] PAIP 123 66 50 (22-82) 53 Italian Italy OPC 
37 Osterhaus (2014)[57] WPS 409 100 48(11) 55 Multiple Several RCT 
38 Gossec (2014)[58] PsAID-9, PsAID-12 474 100 50(13) 50 Multiple Several OPC 
39 Torre-Al.(2014)[59] VITACORA-19  323 65 50(19)d 43d Spanish Spain OPC 
40 Katchamart(2014)[60] HAQ-DI 47 100 49(10) 55 Thai Thailand OPC 
41 Lebwohl(2014)[61] PSD 29/16g 34/50g 39(22-59)f 31f English USA OPC 
42 Chiricozzi (2015)[62] PsoDisk  31 61.3 52(14)f 42f Italian Italy OPC 
43 Lubrano (2015)[63] VAS-global 124 100 52(42-61) 53 Italian Italy OPC 
44 Talli (2015)[64] NRS-global/joints/skin 223 100 51(13) 51 Multiple Several OPC 
45 Leeb (2015)[65] SASPA 152 100 54(26-80) 46 German Austria OPC 
46 Naegeli (2015)[66] Worst Itch NRS 34 65 54(14) 50 English USA OPC 
47 Wilson (2015)[67] PSI 154 100 52(11) 63 English USA/Canada RCT 
48 de Wit (2015)[68] PsAID 474 100 50(13) 50 Multiple Several OPC 
49 Tander (2016)[69] VITACORA-19 61 100 47(12) 64 Turkish Turkey OPC 
50 Piaserico (2016)[70] PASE 298 19-28 NS 44f Italian Italy OPC 
51 Leung (2016)[71] PsAQoL 98 100 52(14) 49 Eng/Chin Singapore OPC 
52 Salaffi (2016)[72] PsAIDtouch 159 100 55(12) 61 Italian Italy OPC 
53 di Carlo (2016)[73] PsAID 144 100 51(13) 44 Italian Italy OPC 
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a, Number of patients (n) often differs across the analyses within a study N in this table refers to the highest number of participants included; b,Presumed, not clearly 
stated; c, Axial PsA/Peripheral PsA; d, For the PsA group; e, Patient treated with TNFI <12 weeks/patients treated >12 weeks; f, Reported for all patients (not only PsA); g, 
Patients in the “concept elicitation”/“cognitive interview” investigation. Abbreviations: AIMS, Arthritis Impact Measurement Scale; BASDAI, Bath Ankylosing Spondylitis 
Activity Index; BASFI, Bath Ankylosing Spondylitis Functional index; Chin, Chinese; CIAQ-FI, Combined Inflammatory Arthritis – Functional Impairment questionnaire; CIAQ-
QoL, Combined Inflammatory Arthritis – quality of life questionnaire; DASH, Disabilities of the Arm, Shoulder and Hand Outcome Measure; DFI; Dougados Functional Index; 
EQ-5D-3L, EuroQoL 5 Dimensions questionnaire with 3 response levels; Eng, English; FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy-Fatigue Scale;  Fi, 
Functional Index; HAQ, Health Assessment Questionnaire (HAQ-S: Spondyloarthropathy, HAQ-SK: Skin, HAQ-DI: Disability Index); IPBOD, Inverse Psoriasis Burden of Disease 
questionnaire; mRAI, Modified Rheumatology Attitude Index; MultiP, Multidimensional Patient Reported Outcome Questionnaire; NRS, Numeric Rating Scale; NS, Not 
stated; OPC, Outpatient Clinic; PAIP, Psoriatic Arthritis Impact Profile; PASE, PsA Screening and Evaluation Questionnaire; PsoDisk, abbreviation not further explained; PR-
TJC, Patient-reported-tender-joint-count; PsA, Psoriatic Arthritis; PsAID, Psoriatic Arthritis Impact of Disease questionnaire; PsAQoL, PsA Quality of Life instrument; RCT, 
Randomised controlled trial; SASPA, Stockerau Activity Score for Psoriatic Arthritis; SF-6D, utility tool derived from SF-36 comprising six multi-level dimensions; SF-36, 
Medical Outcome Survey Short Form 36-item Health Survey (SF-36 MCS: Mental Component Summary, PCS: Physical Component Summary, PF: SF-36 physical function 
subscale; PSI, Psoriasis Symptom Inventory; SRPQ, Social Role Participation Questionnaire; VAS, Visual Analogue Scale;  VITACORA-19, Spanish acronym, full name not 
available; WTP, Willingness to Pay Questionnaire; WPS, Work Productivity Survey.
54 
55 
Cohen (2016)[74] 
Cooper (2016)[75] 
IPBOD 
EQ-5D-3L  
16 
255 
50 
15 
56(17) 
49(14) 
69 
62 
English 
Sweden 
USA 
Swedish  
OPC 
OPC 
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Level of evidence on the measurement properties for each of the evaluated PROMs  
Table 3 presents the overall evidence synthesis. Generally, most studies were of poor or fair quality 
resulting in limited or unknown evidence for the evaluated measurement properties. According to the 
results of the COSMIN analyses (supplementary Table D), frequent methodological limitations were small 
sample sizes, lack of information on handling of missing data, lack of information on unidimensionality 
when assessing internal consistency, insufficient methods for examining/reporting content validity, 
inappropriate statistical methods for testing responsiveness, and lack of hypotheses and psychometric 
information on comparators when testing construct validity. 
Evidence for PROMS measuring PsA core domains  
MUSCULOSKELETAL DISEASE ACTIVITY.  
The core domain of musculoskeletal disease activity is currently measured using a combination of physician 
assessments (clinical examination) and PROMs, and depending on the purpose of the study also biologic 
inflammatory markers and/or assessments of PsA pathophysiology using tissue imaging techniques. Six 
PROMs that aim to evaluate the concept of patient reported disease activity were retrieved (Table 3). The 
Stockerau Activity Score for Psoriatic Arthritis (SASPA) in German was currently the best candidate based 
on limited evidence for unidimensionality, internal consistency (Cronbach-α=0.875) as well as structural 
validity by factor analysis (supplementary Table C and D). SASPA is short, free and easy to score 
(supplementary Table B2). The main limitations of SASPA are the unknown content validity and only the 
original German version was evaluated. SASPA is available in English but without information on the quality 
of the translation or cross-cultural validation.  
SKIN DISEASE ACTIVITY 
Three instruments were found that aim to measure patient reported skin disease activity (Table 3). Strong 
evidence for content validity of the Psoriasis Symptom Diary (PSD) was obtained while information on 
remaining measurement properties was not available in PsA. Based on results from Rasch and principal 
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component analysis, the Psoriasis Symptom Inventory (PSI) appeared the best available PROM having 
moderate evidence for unidimensionality, internal consistency (Cronbach α=0.95) and structural validity, 
and limited evidence for responsiveness, test-retest reliability (ICC=0.70) and construct validity (external 
relationships and known group validity). The main limitations of PSI include item floor effects (up to 37% at 
baseline) (supplementary Table D).  
PAIN 
Six PROMs were evaluated (Table 3). None of these had evidence on both reliability and validity. The 
Medical Outcome Survey Short Form 36-item Health Survey Bodily Pain subscale (SF-36 BP) was evaluated 
by Chinese and English studies generating moderate and limited evidence for construct validity regarding 
internal and external relationships, respectively. Evidence for unidimensionality of the BP scale was not 
provided by the studies reporting on Cronbach-α (0.80-0.91) leading to no overall evidence for internal 
consistency.  Information on floor effects (1.2%), ceiling effects (3.0%) and MID was provided 
(supplementary Table D).  The main limitations of SF-36 BP are the unknown evidence for reliability and 
content validity, and the requirement of software to calculate scores (supplementary Table B2). The visual 
analogue scale (VAS) of pain (1 week recall time) had limited evidence for construct validity (external 
relationships) (Table 3), and MID was reported (Table 3, and  supplementary Table C and D). 
PATIENT GLOBAL 
Eight measures of Patient Global (PtG) were identified and included VAS and numeric rating scales (NRS) 
with varying recall periods. The phrasing of the PtG item addressed the impact on overall well-being of 
either 1) arthritis, 2) psoriasis, or 3) PsA (as a whole) as described in supplementary Table B2.  Only the VAS 
of PtG due to PsA (1 week recall) had evidence of both validity and reliability in PsA including limited 
evidence for construct validity (external relationships) and moderate evidence for test-retest reliability (ICC 
(95%CI) =0.87(0.83-0.90)). Values of MID, PASS and MCII were reported across languages and recall 
versions of VAS PtG (Table 3, supplementary Tables C-E). The NRS of PtG due to PsA (1 week recall) had 
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moderate evidence for construct validity (external relationships and known group validity) and floor/ceiling 
effects were reported up to ~ 8 %/3 % (Table 3 and supplementary Table D).  
PHYSICAL FUNCTION 
Twenty-three PROMs were evaluated (Table 3), and three of these had evidence on both reliability and 
validity including the Bath Ankylosing Functional Index (BASFI), the SF-36 Physical Function subscale (SF-36 
PF) and the Health Assessment Questionnaire Disability Index (HAQ-DI). Based on evidence from English 
and Chinese studies using Rasch analysis and principal component analysis, the SF-36 PF was the best 
candidate with strong evidence for unidimensionality, internal consistency (Cronbach α=0.91-0.92) and 
good structural validity. Evidence for construct validity was moderate and limited for internal and external 
relationships, respectively (Table 3).  Floor and ceiling effects were less than 10% and MID was reported 
(supplementary Table D). The HAQ-DI was the most frequently assessed instrument for this domain and 
had strong evidence for good internal consistency and structural validity (Table 3). However Rasch analysis 
suggested better properties for the SF-36 PF in a study that compared the two instruments.[33] HAQ-DI 
was limited by floor effect (up to 50%) and had conflicting evidence on construct validity across languages 
(supplementary Tables C-E).  
HEALTH RELATED QUALITY OF LIFE/LIFE IMPACT 
Ten PROMs were identified (Table 3). Of these, the Psoriatic Arthritis Impact of Disease (PsAID) 
questionnaire, the PsA Quality of Life instrument (PsAQoL) and the VITACORA-19 (Spanish and Italian 
versions) all had some evidence on both reliability and validity. PsAID was translated and evaluated in 
several languages during the development phase and appeared a good candidate based on strong 
evidence for content validity and moderate evidence for good test-retest reliability and for good construct 
validity (external relationships) of the 12-item version (PsAID-12). Similar findings existed for PsAID-9 
except that evidence for construct validity was limited. Floor/ceiling effects of PsAID were <1%, and values 
for PASS were provided (supplementary Table D). The PsAQoL was assessed in several language versions 
(supplementary Tables C-E) generating strong evidence for unidimensionality and internal consistency 
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(Cronbach α=0.91) and moderate evidence for test-retest reliability and structural, construct validity 
(external relationships and known group validity) (Tables 3). Moderate and strong evidence for content 
validity was available for the English and Swedish versions of PsAQoL, while limited evidence for poor con-
tent validity was achieved by a Dutch study where approximately half of the patients suggested a lack of 
items, resulting in overall conflicting evidence for this property (supplementary Tables C-E). Floor effect of 
PsAQoL was up to 19% (supplementary Table D). VITACORA-19 was evaluated in Spanish (origin) and in 
Turkish resulting in moderate evidence for test-retest reliability (ICC=0.94), content validity and construct 
validity (external relationships) as well as limited evidence for unidimensionality, internal consistency 
(Cronbach α= 0.95) and good structural validity. Floor/ceiling effects were <1% and MCID was defined 
(supplementary Table D). No formal English translation or cross-cultural validation was available.  
FATIGUE 
Four instruments were identified (Table 3). Evidence for validity and reliability was only available for the 
Functional Assessment of Chronic Illness Therapy-Fatigue scale (FACIT-Fatigue) including limited evidence 
for good test-retest reliability (ICC=0.95) and construct validity (external relationships) (Table 3, 
supplementary Table D).  
PROMs measuring domains of the middle circle of the PsA COS  
PARTICIPATION 
Eleven PROMs were evaluated (Table 3). The three subscales of the Social Role Participation Questionnaire 
were the only measurements with evidence of both reliability and validity including limited evidence for 
good test-retest reliability, content validity and construct (external relationships and known group) validity. 
The Work Productivity Survey had limited evidence for good construct validity and responsiveness but high 
floor effects found for certain items (73.7% (item 2) and 77.3% (item 8)) (Table 3, supplementary Table D). 
The SF-36 role emotional, role physical and social functioning subscales had moderate evidence for good 
construct validity (hypotheses testing regarding known groups, internal and external relationships).  
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EMOTIONAL WELL-BEING 
Nine instruments were identified from Chinese and English studies but none had evidence on both validity 
and reliability (Table 3).  The most information was available for the SF-36 Mental Health subscale (SF-36 
MH) and the SF-36 mental component summary (MCS) including moderate evidence for good construct 
(internal relationships) and structural validity, respectively (Table 3, supplementary Table D).  
ECONOMIC COST 
Four instruments were available (Table 3) but none of these had evidence for both reliability and validity. 
Evidence for construct validity (external relationships) was available for the EuroQol-5 Domain 3 level (EQ 
5D-3L) (moderate) and the SF-6D (derived from SF-36) and Willingness-to-pay questionnaire (both limited). 
Differences in utility estimates from EQ-5D versus SF-6D, score distribution, floor/ceiling effects, PASS and 
MCII information were reported (supplementary Table D).  
PROMs measuring domains of the COS research agenda (outer circle) 
SLEEP 
One study assessed VAS Sleep providing information on score interpretation (Table 3, supplementary Table 
D). 
STIFFNESS 
Two measurements, VAS Stiffness and the NRS Stiffness were evaluated (Table 3) but the evidence for 
measurement properties remained unknown (Table 3, supplementary Table D). 
PROMS measuring domains not included in the COS  
SF-36 general health subscale (GH) and the Arthritis Impact Measurement (AIMS 2) Social Support scale 
were evaluated but evidence for measurement properties was not achieved (Tables 3, supplementary 
Table D). 
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Table 3  Level of evidence for measurement properties per PROM  listed by matching COS domain  
PROMs by COS 
Domains (n=89) 
Reliability 
 COSMIN BOX (A-C) 
Validity 
 COSMIN BOX (D-H) 
Responsiveness 
COSMIN BOX (I) 
Info on score 
interpretation  
(values are provi-
ded in suppl. 
Table D)  
Internal 
consistency 
Relia 
bility 
Measure-
ment 
error 
Content 
validity 
Structural 
validity 
Hypothe-
ses 
testing 
Cross-
cult. 
Validity 
Crite-
rion 
validity 
Sensitivity to 
change 
 A B C D E F G H I  
MSK DISEASE ACTIVITY, patient reported aspects (n=6)        
BASDAI[31,37,39]   ?     ±   ? F/C 
SASPA[65]  +    + ?   ?  
PASE-total[36,70]   ?    + A  +  
PASE-symptom[36,70]   ?    + A  +  
PASE-function[36,70]   ?    + A  +  
PR-TJC[44]   ?  ?     
SKIN DISEASE ACTIVITY, patient reported aspects (n=3)        
PSI[67] ++ +   ++ +   + F/C 
PSD[61]    +++       
Worst itch NRS[66]    +       
PAIN (n=6)           
VAS Pain (1 week recall)[22,28,43,50]     +   ? MID 
VAS Pain (recall NS)[45]         MCII, PASS 
NRS Pain (1 week 
recall)[44]  
 ?  ?  ?     
SF-36 BP[26,28,40,50] ?     +/++ b   ? MID, F/C 
AIMS1 Pain[21,25,27]      ++   ?  
AIMS2 Pain[24,25,28] ?     +   ?  
PATIENT GLOBAL (n=8)          
Patient global due to psoriasis          
NRS (1 week recall)[64]     +    F/C  
VAS (1 week recall)[49] ++    ?     
Patient global due to arthritis          
NRS (1 week recall)[64]     +    F/C 
NRS (1 day recall)[44]   ?  ?     
VAS (1 week recall)[49] ++    ?     
Patient global due to PsA          
NRS (1 week recall)[53,64]     ++    F/C 
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  VAS (1 week recall)[43,49,50,63]  ++    +   ? MID 
VAS (recall NS)[45]           MID, PASS, MCII 
Table 3 cont. 
 
PROMs by COS 
Domains 
Reliability 
 COSMIN BOX (A-C) 
Validity 
 COSMIN BOX (D-H) 
Responsiveness 
COSMIN BOX (I) 
Info on score 
interpretation  
(values are provi-
ded in suppl. 
Table D) 
Internal 
consistency 
Relia
bility 
Measure-
ment 
error 
Content 
validity 
Structural 
validity 
Hypothe-
ses 
testing 
Cross-
cult. 
Validity 
Crite-
rion 
validity 
Sensitivity to 
change 
 A B C D E F G H I  
PHYSICAL FUNCTION (n=23)         Interpretability 
DFI[34]  – –    – – ?    F/C 
DASH[29]       – –     
BASFI[34]  ++    ++ ?    F/C  
HAQ-DI 
[22,27,28,33,34,42,43,5
0,51,60] 
+++    +++ ±   ? F/C, MID 
HAQ-S[22]        –     
HAQ-SK[23]      ?     
mHAQ[45]           PASS, MCII 
SF-36 
PF[26,28,33,34,40,50] 
+++    +++ +/++b   ? F/C, MID 
SF-36 PCS[40,50]     ++ ?   ?  
MultiP CASQ-FI[44] ?    ? ?     
AIMS1 Mobility[21]      -     
AIMS1 Physical[21,27]      ±     
AIMS1 Dexterity[21]      +     
AIMS1 House[21]     +     
AIMS1 ADL[21]      –     
AIMS1 PC[25]         ?  
AIMS2 PC[25,28]          ?  
AIMS2 Mobility[24]      +     
AIMS2 Physical[24]      +     
AIMS2 Dexterity[24]     +     
AIMS2 Selfcare[24]      –     
AIMS2 House[24]      –     
AIMS2 Arm F.[24]     +     
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Table 3 cont.  
PROMs by COS 
Domains  
Reliability 
 COSMIN BOX (A-C) 
Validity 
 COSMIN BOX (D-H) 
Responsiveness 
COSMIN BOX (I) 
Info on score 
interpretation  
(values are provi-
ded in suppl. 
Table D) 
Internal 
consistency 
Relia
bility 
Measure-
ment 
error 
Content 
validity 
Structural 
validity 
Hypothe-
ses 
testing 
Cross-
cult. 
Validity 
Crite-
rion 
validity 
Sensitivity to 
change 
 A B C D E F G H I  
HRQoL/LIFE IMPACT (n=10)         
PsAQoL[30,35,41,42,55,
71]  
+++ ++ ? ± ++ ++ a  ? F/C 
AIMS1 Global[27]       ?     
PsAID-9[58,68]  c ++  +++  + a  ? PASS, F/C  
PsAID-12[58,68,73]  c ++  +++ c ++ a  ? PASS, F/C    
touchPsAID-12[72]       +  +d          MDA cut-off 
PAIP[56]       ?     
VITACORA-19[59,69]  + ++  ++ + ++ a  ?  MCID, F/C 
PsoDisk[62]          ?  
MultiP CIAQ-QoL[44]  ?  ?  ?     
IBOD[74]  c   ?  ?     
FATIGUE (n=4)           
FACIT-Fatigue[32] ? +    +     
NRS fatigue[38,44]   ?  ?  ?   ?  
VAS fatigue[43]          MID 
SF-36 VT[26,40,50]  ?     –/++b    MID, F/C 
PARTICIPATION (n=11)           
SRPQ-IM[52]  ? + ? +  +    MDC 
SRPQ-ST[52] ? + ? +  +    MDC 
SRPQ-SR[52] ? + ? +  +    MDC 
WPS[57]       +   + F/C 
AIMS1 SA[21]       ?     
AIMS2 SA[24]      ?     
AIMS2 Work[24]      ?     
AIMS2 SC[28]          ?  
SF-36 RE[26,40,50]  ?     ?/++ b   ?  
SF-36 RP[26,40,50]  ?     –/++ b   ?  
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Empty cells reflect that the measurement property was not evaluated by any study for the given instrument.  Table 2 explains the grading of evidence (+/-/?).   
aOnly translation, no cross-cultural validation. According to COSMIN, only studies that address measurement invariance (e.g. multiple group factor analyses or DIF) between 
countries (or other groups) are considered real cross-cultural validity studies. bConstruct validity – hypotheses testing was assessed regarding the internal relationships 
SF-36 SF[26,28,40,50]  ?     ?/++ b   ?  
Table 3 cont 
PROMs by COS 
Domains  
Reliability 
 COSMIN BOX (A-C) 
Validity 
 COSMIN BOX (D-H) 
Responsiveness 
COSMIN BOX (I) 
Info on score 
interpretation  
(values are provi-
ded in suppl.  
Table D) 
Internal 
consistency 
Reliabi
lity 
Measu-
rement 
error 
Content 
validity 
Structural 
validity 
Hypothe-
ses 
testing 
Cross-
cult. 
Validity 
Crite-
rion 
validity 
Sensitivity to 
change 
 A B C D E F G H I  
EMOTIONAL WELL-BEING (n=9)         
SF-36 MH[26,28,40,50] ?     ++ b   ? MID 
SF-36 MCS[40,50]      ++ ?   ?  
MultiP mRAI[44]  ?  ?  ?     
AIMS1 Psyc.C.[25]         ?  
AIMS1 Anxiety[21]      ?     
AIMS1 Depression[21]       ?     
AIMS2 Mood[21]      ?     
AIMS2 Tension[21]      ?     
AIMS2 Psyc.C.[25,28]             ?  
ECONOMIC COST (n=4)           
EQ-5D 
[42,45,47,48,54,75] 
     ++   ? MCII, PASS, F/C 
EQ-5D-revised[48]      ?   ? Score distribution 
SF-6D[45,47,54]      +   ? PASS, MCII, F/C 
WTP[46]     ?  +     
SLEEP (n=1)           
VAS sleep[43]          MID 
STIFFNESS (n=2)           
NRS stiffness[44]    ?  ?     
VAS stiffness[22]     ?     
NON-COS Domains (n=2)          
SF-36 GH[26,40,50] ?     – /– – b     
AIMS2 Social Support[24]     ?     
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(scale assumptions) and not relation to external measurements. c Questionnaire seems to be based on a formative model why scoring of internal consistency and structural 
validity is not relevant. d PsAID touch version was compared to paper version which was considered as gold standard. Abbreviations: AIMS, Arthritis Impact Measurement 
Scales (ADL, Activity of daily living; Arm F., Arm Function; House, Household; PC, Physical component score; Psyc.C., Psychological component score; SA, Social Activity, SC, 
Social component score); BASDAI, Bath Ankylosing Spondylitis Activity Index; BASFI, Bath Ankylosing Spondylitis Functional index; CIAQ-FI, Combined Inflammatory Arthritis 
– Functional Impairment questionnaire; CIAQ-Qol, Combined Inflammatory Arthritis – quality of life questionnaire; COSMIN, COnsensus-based Standards for the selection of 
health Measurement INstruments; DASH, Disabilities of the Arm, Shoulder and Hand Outcome Measure; DFI, Dougados Functional Index; EQ-5D-3L, EuroQoL 5 Dimensions 
questionnaire with 3 response levels; FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy-Fatigue scale; F/C, Floor/Ceiling effect;  HAQ, Health Assessment 
Questionnaire (HAQ-S: Spondyloarthropathy, HAQ-SK: Skin, HAQ-DI: Disability Index); IPBOD, Inverse Psoriasis Burden of Disease questionnaire; MCID, Minimal clinically 
important difference; MDA, Minimal disease activity; MDC, minimal detectable change; MCII, Minimal clinical important improvement; MIC, Minimal important change; 
MID, Minimal important difference; mRAI, Modified Rheumatology Attitude Index; MultiP, Multidimensional Patient Reported Outcome Questionnaire; NRS, Numeric 
Rating Scale; NS, Not stated; PAIP, Psoriatic Arthritis Impact Profile; PASE, PsA Screening and Evaluation Questionnaire; PASS, Patient acceptable symptom state; PGA, 
Patient Global Assessment; PR-TJC, Patient-reported-tender-joint-count; PsAID, Psoriatic Arthritis Impact of Disease questionnaire; PsAQoL, PsA Quality of Life instrument; 
PSD; Psoriasis symptom diary; PSI, Psoriasis Symptom Inventory; Psodisk questionnaire, no full spelling available;  SASPA, Stockerau Activity Score for Psoriatic Arthritis; SF-
6D, utility tool derived from SF-36 comprising six multi-level dimensions; SF-36, Medical Outcome Survey Short Form 36-item Health Survey (SF-36 subscales: BP, Bodily 
Pain; GH, General Health; MCS, Mental Component Summary; MH, Mental Health;  PCS, Physical Component Summary, PF, physical function; RE, Role Emotional; RP, Role 
Physical; SF, Social Functioning;  VT, Vitality); SRPQ, Social Role Participation Questionnaire; VAS, Visual Analogue Scale;  VITACORA-19, Spanish acronym, full name not 
available; WTP, Willingness to pay questionnaire; WPS, Work Productivity Survey. 
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DISCUSSION  
Core outcome measurement sets (COMS) aim to ensure the best possible evaluation of the domains in a 
core outcome set (COS) for a specific disease, providing comparability across study results and 
enhancement of evidence-based health care decisions. While previous studies have provided overviews of 
commonly used instruments in PsA,[76,77] this review provides a systematic identification, 
characterization and evidence synthesis of measurement properties of all PROMs evaluated in PsA, which 
constitutes an important step in the GRAPPA-OMERACT process of developing a PsA COMS.   
PROMs with at least some evidence on both reliability and validity are available for six of the eight 
mandatory (“inner circle”) COS domains including MSK disease activity (SASPA), skin disease activity (PSI), 
patient global (VAS global), physical function (SF-36 PF, HAQ-DI, BASFI), HRQoL/life impact (PsAID-9, PsAID-
12, PsAQoL, VITACORA-19) and fatigue (FACIT-Fatigue).  
Instruments with strong evidence for any measurement property included HAQ-DI and SF-36 PF (physical 
function domain), PSD (skin disease activity domain), PsAID-9, PsAID-12 and the English version of PsAQoL 
(HRQoL/life impact domain).  The PSD, PsAID-9, PsAID-12, and English PsAQoL had strong evidence on 
content validity, a property that was sparsely investigated for most other PROMs. Content validity is 
considered a prerequisite for applicability of PROMS in PsA clinical trials as emphasized by the FDA, 
OMERACT and the COSMIN-COMET initiative.[17,20,78]  Thus, unknown content validity of PROMS is a 
serious shortcoming that needs attention in PsA – as well as in other rheumatic diseases.[58,79,80]  
No PROM with evidence on both reliability and validity was available for the mandatory COS domains of 
systemic inflammation and pain. The absence of a good PROM for assessment of pain is especially critical 
as clinicians and patients have considered this patient-reported domain extremely important according to 
former studies.[5,58] Future research should gain more information on the measurement properties of the 
SF-36 pain subscale, VAS pain and the AIMS pain scale that all had some evidence of validity in PsA 
according to this SLR.  
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Furthermore, data from the PsAID study could provide additional evidence for use of the individual NRS for 
several of the COS domains, including pain. The applicability of the Patient Reported Outcomes 
Measurement Information System (PROMIS) for measuring pain as well as other domains of the PsA COS 
may also be considered.[81] PROMIS provides multiple unidimensional instruments that can be 
administered as fixed short forms as well as computer adaptive tests. The SF-36 subscales assess three 
inner core domains (pain, physical function and fatigue/vitality) and a visual representation of the multiple 
life impact/HRQoL domains can be generated through spydergrams.[82] It may seem practical to use a 
questionnaire with multiple scales that cover several domains in one application. However, it is more 
important to endorse the best instrument per domain and further research must be done on the 
measurement properties of SF-36 subscales in PsA.  
All language versions of a PROM were lumped in the main evidence synthesis of this review to achieve as 
much information as possible per instrument. This strategy underscores the importance of collecting 
sufficient evidence on cross-cultural validity prior to international application of a PROM. For instance, the 
German SASPA (MSK disease activity) and the Italian/Turkish VITACORA-19 (HRQoL) both have some 
evidence for reliability and validity but translation (and cross-cultural validation) into the most common 
languages (English at least) is warranted. Furthermore, the evidence for content validity of PsAQoL and 
construct validity of HAQ-DI was rated as conflicting in the overall synthesis mainly due to diverging results 
across language versions. Given the limited number and quality of the included studies, future studies of 
high methodological standards should clarify if such differences truly exist and if they are cross-culturally 
related. Several studies evaluated the measurement properties of a translated questionnaire but according 
to COSMIN, only studies that address measurement invariance (e.g. multiple group factor analyses or DIF) 
between countries (or other groups) are considered real cross-cultural validity studies.     
Few studies with sufficient methodology for assessing responsiveness were identified. Although reliability 
and validity were considered preconditions for potential PROMs, the COMS is being developed for clinical 
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trials for which measuring the true amount of change in a construct during an intervention is often the 
primary goal. Therefore, responsiveness of promising instruments needs to be clarified in future studies.      
The evidence for measurement properties of PROMs measuring skin disease activity was limited since we 
included only studies with at least 50% of the population comprising PsA patients (or PsA subgroup 
results). This strategy may be conservative, for instance additional information on the candidate 
instrument PSI as well as on PSD would have been achieved by including studies of psoriasis.[83-86] 
Nevertheless, our strategy ensures that the evidence obtained applies to patients with PsA as a whole.  
Strengths of this GRAPPA-OMERACT study constitute the international collaboration including experts in 
PsA, measurement and systematic review technique as well as patient research partners. Adherence to the 
COSMIN guidelines guaranties homogeneity and transparency in the assessment of methodology and 
rating of measurement properties across studies. Study limitations include, as for reviews in general, that 
negative findings might have been underreported due to publication bias. Selection bias due to exclusion 
of non-English full-text papers may have led to underreporting of the (cross-cultural) evidence for some 
instruments. However we believe this was minimized as only five studies were excluded for this reason. 
This review did not include RCTs or longitudinal observational studies that only provide indirect evidence 
for measurement properties of instruments used for assessing the outcomes of interest. We acknowledge 
that great amounts of indirect evidence are available and valuable in the COMS development. However the 
identification, selection and evaluation strategies needed for such studies do not comply with the 
methodology of the current review. Further analyses are currently underway by parallel work streams 
evaluating the data from PROMs collected in recently conducted RCTs of interventional therapies in PsA to 
fully adhere to the OMERACT procedure of COMS development.  
This study provides an evidence based overview of measurement properties of PROMs per COS domain. 
We have highlighted the current knowledge gaps, and provided an overview of available data on score 
interpretation, feasibility and content for each PROM. This constitutes a relevant starting point for 
stakeholders to decide on the overall applicability of the PROMs, and provides opportunities to improve 
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existing data by targeted research strategies.[6,10] This is indeed warranted as several of the PROMs with 
elusive measurement properties are widely used in PsA trials and clinics today. [77] Some COS domains 
may be more appropriately assessed by non-PROM instruments such as biomarkers and clinical 
assessments, and parallel work streams within GRAPPA-OMERACT are collecting psychometric evidence for 
the use of such tools in PsA.  These research initiatives will in addition to the psychometric evidence for 
PsA PROMs presented in this review inform the consecutive stages of developing a COMS for PsA.  
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Supplementary material:  
 
Supplementary Table A: Search strategy 
SEARCH STRATEGY INCORPORATING THE MEASUREMENT PROPERTY FILTERS BY TERWEE et al1 
Final search (#5) "Search (#1 OR #2 OR #3) AND #4" 
PUBMED SEARCH FILTER (SEPARATED INTO 3 SECTIONS FOR CLARITY) 
Search #1: ((replicab*[Title/Abstract] OR repeated[Title/Abstract]) AND (measure[Title/Abstract] OR measures[Title/Abstract] OR 
findings[Title/Abstract] OR result[Title/Abstract] OR results[Title/Abstract] OR test[Title/Abstract] OR tests[Title/Abstract])) OR ("meaningful 
change"[Title/Abstract]) OR ((small*[Title/Abstract]) AND (real[Title/Abstract] OR detectable[Title/Abstract]) AND (change[Title/Abstract] OR 
difference[Title/Abstract])) OR ((minimal[Title/Abstract] OR minimally[Title/Abstract] OR clinical[Title/Abstract] OR clinically[Title/Abstract]) 
AND (important[Title/Abstract] OR significant[Title/Abstract] OR detectable[Title/Abstract]) AND (change[Title/Abstract] OR 
difference[Title/Abstract])) 
Search #2:  (((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((stability[Title/Abstract]) OR interrater[Title/Abstract]) OR inter-
rater[Title/Abstract]) OR intrarater[Title/Abstract]) OR intra-rater[Title/Abstract]) OR intertester[Title/Abstract]) OR inter-
tester[Title/Abstract]) OR intratester[Title/Abstract]) OR intra-tester[Title/Abstract]) OR interobserver[Title/Abstract]) OR inter-
observer[Title/Abstract]) OR intra-observer[Title/Abstract]) OR intraobserver[Title/Abstract]) OR intertechnician[Title/Abstract]) OR inter-
technician[Title/Abstract]) OR intra-technician[Title/Abstract]) OR intratechnician[Title/Abstract]) OR interexaminer[Title/Abstract]) OR 
intraexaminer[Title/Abstract]) OR intra-examiner[Title/Abstract]) OR inter-examiner[Title/Abstract]) OR interassay[Title/Abstract]) OR inter-
assay[Title/Abstract]) OR intra-assay[Title/Abstract]) OR intraassay[Title/Abstract]) OR interindividual[Title/Abstract]) OR inter-
individual[Title/Abstract]) OR intra-individual[Title/Abstract]) OR intraindividual[Title/Abstract]) OR interparticipant[Title/Abstract]) OR intra-
participant[Title/Abstract]) OR inter-participant[Title/Abstract]) OR intraparticipant[Title/Abstract]) OR kappa*[Title/Abstract]) OR 
repeatab*[Title/Abstract]) OR generaliza*[Title/Abstract]) OR generalisa*[Title/Abstract]) OR concordance[Title/Abstract]) OR 
((intraclass[Title/Abstract] AND correlation*[Title/Abstract]))) OR (("intra-class"[Title/Abstract] AND correlation*[Title/Abstract]))) OR 
discriminative[Title/Abstract]) OR "known group"[Title/Abstract]) OR "factor analysis"[Title/Abstract]) OR "factor analyses"[Title/Abstract]) OR 
dimension*[Title/Abstract]) OR subscale*[Title/Abstract]) OR ((multitrait[Title/Abstract] AND scaling[Title/Abstract]) AND 
(analysis[Title/Abstract] OR analyses[Title/Abstract])))) OR "item discriminant"[Title/Abstract]) OR "inter scale correlation*"[Title/Abstract]) OR 
"interscale correlation*"[Title/Abstract]) OR error[Title/Abstract]) OR errors[Title/Abstract]) OR "individual variability"[Title/Abstract]) OR 
((variability[Title/Abstract] AND analysis[Title/Abstract]))) OR ((variability[Title/Abstract] AND values[Title/Abstract]))) OR 
((uncertainty[Title/Abstract] AND (measurement*[Title/Abstract] OR measuring[Title/Abstract])))) OR sensitiv*[Title/Abstract] OR 
responsive*[Title/Abstract])) OR "ceiling effect"[Title/Abstract]) OR "floor effect"[Title/Abstract]) OR "item response model"[Title/Abstract]) 
OR "Item Response Theory"[Title/Abstract]) OR Rasch[Title/Abstract]) OR "differential item functioning"[Title/Abstract]) OR "computer 
adaptive testing"[Title/Abstract]) OR "item bank"[Title/Abstract]) OR "cross-cultural equivalence"[Title/Abstract])) 
Search #3:  (((((((((((((((((((((((((instrumentation[MeSH Subheading]) OR methods[MeSH Subheading]) OR Validation studies[Publication Type]) 
OR Comparative study[Publication Type]) OR "psychometrics"[MeSH Terms]) OR psychometr*[Title/Abstract]) OR clinimetr*[Title/Abstract]) 
OR clinometr*[Title/Abstract]) OR "outcome assessment (health care)"[MeSH Terms]) OR "outcome assessment"[Title/Abstract]) OR "outcome 
measure*"[Text Word]) OR "observer variation"[Text Word] OR "health status indicators"[MeSH Terms]) OR "reproducibility of results"[MeSH 
Terms]) OR reproducib*[Title/Abstract]) OR "discriminant analysis"[MeSH Terms]) OR reliab*[Title/Abstract]) OR unreliab*[Title/Abstract]) OR 
valid*[Title/Abstract]) OR coefficient[Title/Abstract]) OR homogeneity[Title/Abstract]) OR homogeneous[Title/Abstract] OR "internal 
consistency"[Title/Abstract]) OR "cronbach* alpha*"[Title/Abstract] OR ((item*[Title/Abstract]) AND (selection*[Title/Abstract] OR 
correlation*[Title/Abstract] OR reduction*[Title/Abstract])) OR agreement[Title/Abstract]) OR precision[Title/Abstract]) OR 
imprecision[Title/Abstract]) OR "precise values"[Title/Abstract]) OR "test retest"[Title/Abstract] 
TARGET POPULATION  
Search #4:  ((((((((((((((((((((psoriatic arthritis[MeSH Terms]) OR psoriatic arthrit*[Title/Abstract]) OR psoriatic arthropath*[Title/Abstract]) OR 
Psoriatic spondylarthropath*[Title/Abstract]) OR Psoriatic joint[Title/Abstract]) OR Psoriatic joints [Title/Abstract])  OR 
(Psoriasis[Title/Abstract] AND spondylarthropath*[Title/Abstract])) OR arthritis psoriatica[Title/Abstract]) OR psoriatic 
polyarthritis[Title/Abstract]) OR psoriatic rheumatism[Title/Abstract]) OR psoriatic spondylit*[Title/Abstract]) OR psoriatic 
spondylo*[Title/Abstract]) OR arthropathic psoriasis[Title/Abstract]) OR arthritis mutilans[Title/Abstract]) OR (psoriasis[Title/Abstract] AND 
arthritis[Title/Abstract])) OR (psoriasis[Title/Abstract] AND arthropath*[Title/Abstract])) OR (psoriatic joint*[Title/Abstract])) OR (psoriasis 
pustulosa arthropat*[Title/Abstract])) OR (psoriasis[Title/Abstract] AND enthes*[Title/Abstract])) OR (psoriasis[Title/Abstract] AND 
dactylit*[Title/Abstract])) OR (psoriasis[Title/Abstract] AND spondylit*[Title/Abstract])) OR (psoriasis[Title/Abstract] AND 
spondylo*[Title/Abstract])) OR (psoriasis[Title/Abstract] AND SpA[Title/Abstract])) OR (psoriasis[Title/Abstract] AND PsA[Title/Abstract]) OR 
(psoriasis[Title/Abstract] AND (joint[Title/Abstract] OR joints[Title/Abstract])) 
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EMBASE SEARCH STRATEGY  
Final search (#3): Search (#1 AND #2) 
MEASUREMENT PROPERTY FILTER FOR EMBASE 
 
SEARCH #1:  intermethod comparison*.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword] OR inter method comparison*.mp. [mp=title, abstract, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword] OR data collection method*.mp. [mp=title, abstract, heading 
word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] OR. data collection method/ or 
interview/ or observational method/ or questionnaire/ OR validation study.mp. [mp=title, abstract, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword] OR feasibility study.mp. [mp=title, abstract, heading word, drug 
trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] OR pilot study.mp. [mp=title, abstract, 
heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] OR psychometr*.mp. 
[mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] OR 
exp psychometry/ OR reproducib*.ti,ab. OR audit.ti,ab. OR clinometr*.ti,ab. OR clinimetr*.ti,ab. OR observer variation.ti,ab. OR exp observer 
variation/OR discriminant analysis.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword] OR exp discriminant validity/ or exp predictive validity/ or exp content validity/ or exp face 
validity/ or exp construct validity/ or exp qualitative validity/ or exp validity/ or exp external validity/ or exp consensual validity/ or exp 
convergent validity/ or exp concurrent validity/ or exp internal validity/ or exp criterion related validity/ OR exp reliability/ OR reliability.ti,ab. 
OR coefficient.ab,ti. OR internal consistency.ab,ti. OR (cronbach and alpha*).ti,ab. OR item correlation*.ti,ab. OR item selection*.ti,ab. OR item 
reduction*.ti,ab. OR exp diagnostic accuracy/ or exp measurement accuracy/ or exp  accuracy/ or exp dimensional measurement accuracy/ or 
exp diagnostic test accuracy study/ OR imprecision.ti,ab. OR (test and retest).ti,ab. OR interrater.ti,ab. OR inter-rater.ti,ab.OR intra-rater.ti,ab. 
OR intrarater.ti,ab.OR interobserver.ti,ab. OR inter observer.ti,ab. OR intra observer.ti,ab. OR intraobserver.ti,ab. OR interexaminer.ti,ab. OR 
inter examiner.ti,ab. OR intra examiner.ti,ab. OR intraexaminer.ti,ab. OR interindividual.ti,ab.OR inter-individual.ti,ab.OR 
intraindividual.ti,ab.OR intra-individual.ti,ab.OR interparticipant.ti,ab.OR inter participant.ti,ab. OR intra participant.ti,ab. OR 
intraparticipant.ti,ab. OR intertechnician.ti,ab.OR inter technician.ti,ab. OR  intratechnician.ti,ab. OR intra technician.ti,ab. OR (kappa and 
value).ti,ab. OR (kappa and statistics).ti,ab. OR (repeated and measure*).ti,ab. OR (repeated and finding*).ti,ab. OR (repeated and 
result*).ti,ab. OR (repeated and test*).ti,ab. OR repeatab*.ti,ab. OR (replicab* and measure*).ti,ab. OR (replicab* and finding*).ti,ab. OR 
(replicab* and result*).ti,ab. OR (replicab* and test*).ti,ab. 
(intra-class and correlation).ti,ab. OR (intraclass and correlation).ti,ab. OR factor structure.ti,ab. OR  factor analys*.ti,ab. OR 
dimensionality.ti,ab. OR multitrait scaling analys*.ti,ab. OR item discriminant.ti,ab. OR interscale correlation*.ti,ab. OR inter-scale 
correlation*.ti,ab. OR (error* and measurement).ti,ab. OR  interval variability.ti,ab. OR responsiveness.ti,ab. OR minimal detectable.ti,ab. OR 
meaningful change.ti,ab. OR ceiling effect.ti,ab. OR floor effect.ti,ab. OR item response model.ti,ab. OR item response theory.ti,ab. OR 
rasch.ti,ab. OR differential item functioning.ti,ab. OR touch screen.ti,ab. OR item bank.ti,ab. OR cross-cultural equivalence.ti,ab. OR 
crosscultural equivalence.ti,ab. 
 
TARGET POPULATION  
Search #2 exp psoriatic arthritis/ OR arthritis psoriatica.ti,ab. OR psoriatic arthritis.ti,ab. OR psoriatic polyarthritis.ti,ab. OR psoriatic 
rheumatism.ti,ab. OR psoriatic spondylit*.ti,ab. OR psoriatic joint.ti,ab. OR psoriatic spondylo*.ti,ab. OR psoriatic joints.ti,ab. OR psoriatic 
spondylarthropath*.ti,ab. OR (psoriasis and spondylo*).ti,ab. OR psoriasis pustulosa arthropat*.ti,ab. OR (psoriasis and spondylit*).ti,ab. OR 
arthropathic psoriasis.ti,ab. OR psoriatic arthropath*.ti,ab. OR arthritis mutilans.ti,ab. OR (psoriatic and arthritis).ti,ab. OR (psoriasis and 
enthes*).ti,ab. OR (psoriasis and dactylit*).ti,ab. OR  (psoriasis and spondylarthropath*).ti,ab. OR  (psoriasis and SpA).ti,ab. OR (psoriasis and 
PsA).ti,ab. OR (psoriasis and joints).ti,ab. OR  (psoriasis and joints).ti,ab. OR  (psoriasis and arthropath*).ti,ab. 
Abbreviations: Ti,ab.: Title, abstract. Exp: explode 
 
PsycINFO SEARCH STRATEGY:  Only the target population (as described above) was used as search criteria (no measurement property terms 
applied). 
1)Terwee CB, Jansma EP, Riphagen II, de Vet HC. Development of a methodological PubMed search filter for finding studies on measurement 
properties of measurement instruments. Qual Life Res 2009 Oct;18(8):1115-23.  (Slight modifications of the original filters have been 
performed in order to optimise the search strategy of the current study. 
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Supplementary Table B1: Identified questionnaires (n=44) 
 
 
 
 
 
 
AIMS, Arthritis Impact Measurement Scales; BASDAI, Bath Ankylosing Spondylitis Activity Index; BASFI, Bath Ankylosing Spondylitis Functional index; DASH, Disabilities of 
the Arm, Shoulder and Hand Outcome Measure; DFI, Dougados Functional Index; EQ-5D-3L, EuroQoL 5 Dimensions questionnaire with 3 response levels; FACIT-Fatigue, 
Functional Assessment of Chronic Illness Therapy-Fatigue Scale; F/C, HAQ-DI, Health Assessment Questionnaire Disability Index, HAQ-S: HAQ Spondyloarthropathy, HAQ-SK: 
HAQ Skin; IPBOD, Inverse Psoriasis Burden of Disease questionnaire; MultiP, Multidimensional Patient Reported Outcome Questionnaire; NRS, Numeric Rating Scale; NS, 
Not stated; PAIP, Psoriatic Arthritis Impact Profile; PASE, PsA Screening and Evaluation Questionnaire; PsAID, Psoriatic Arthritis Impact of Disease questionnaire; PsAQoL, 
PsA Quality of Life instrument; PSD; Psoriasis symptom diary; PSI, Psoriasis Symptom Inventory; PsoDisk questionnaire, no full spelling available;  SASPA, Stockerau Activity 
Score for Psoriatic Arthritis; SF-6D, utility tool derived from SF-36 comprising six multi-level dimensions; SF-36, Medical Outcome Survey Short Form 36-item Health Survey; 
SRPQ, Social Role Participation Questionnaire; VAS, Visual Analogue Scale;  VITACORA-19, Spanish acronym, full name not available; WTP, Willingness to pay questionnaire; 
WPS, Work Productivity Survey. *1 week recall. ** 1 day recall. *** recall not stated 
1 AIMS 1 AIMS 2 BASDAI BASFI DASH DGI 
2 EQ-5D-3L FACIT-Fatigue HAQ-DI HAQ-SK HAQ-S IPBOD 
3 mHAQ MultiP NRS global* NRS global (joints)* NRS global (joints)** NRS global (skin)* 
4 NRS fatigue Worst itch NRS NRS pain PAIP PASE PSI 
5 PSD PsAID-9 PsAID-12 PsAIDtouch PsAQoL Psodisk 
6 SASPA SF-6D SF-36 SRPQ VAS global* VAS global*** 
7 VAS global (joints)* VAS global (skin)* VAS fatigue VAS pain VAS sleep VITACORA-19 
8 WPS WTP     
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Supplementary Table B2: Characteristics of the included measurements 
 
  
PROMs listed by  
COS domains* 
Scales, items, scoring, recall time Description of PROM  
(items, subscales) 
Develop-
ed for 
Feasibility, availability 
and links to more information 
MSK DISEASE ACTIVITY    
Bath Ankylosing 
Spondylitis 
Disease Activity 
Index (BASDAI) 
[31,37,39] 
Scales and items: 1 scale (6 items). Rating by 
NRS (0–10) or VAS (0–100 mm). Anchors: 
“none” and “very severe.” Stiffness rated as 
hours (0 to >2).   
Scoring: The scores for severity and duration of 
morning stiffness are averaged before 
calculating the total average score (0-10). No 
subscale score.  Higher BASDAI scores indicate 
worse disease activity.  
Recall time: 1 week. 
The BASDAI includes items of 
fatigue, pain, swelling, tenderness 
and stiffness.  
Generates 1 total disease activity 
score.  
 
AS Completion: <2 min. 
Ease of scoring: Easy. 
Availability: Free of charge to 
academic users but not to industry. 
More info: www.asas-group.org. 
http://oml.eular.org 
Stockerau 
Activity Score for 
PsA (SASPA)[65] 
Scales and items: 1 scale (5 items), modified 
from the RADAI-5 (RA Disease Activity Index). 
Rating by a 0-10 scale. 
Scoring: Total score is the average of item 
scores.  
Recall time: 1 day. 
Includes items on pain, swelling, 
global health, morning stiffness, 
skin disease.  
Generates 1 total disease activity 
score.  
 
PsA Completion: <2 min.  
Ease of scoring: Easy 
Availability: Free to use for daily 
purpose. Copyright: own by Dr.PM 
Handl and Dr. B Leeb: 
Burkhard.Leeb@stockerau.lknoe.at 
PsA Screening 
and Evaluation 
Questionnaire 
(PASE)[36,70] 
 
Scales and items: Two subscales (15 items in 
total). Rating by a 5-point Likert scale, anchors 
“strongly disagree” and “strongly agree”.   
Scoring: Maximal scale scores: 35 (symptom 
scale) and 40 (function scale). Total score (max 
75).  
Recall time: 1 day 
A PsA screening and evaluation 
tool. Symptom scale includes 
items of pain, fatigue, burning 
sensation and swelling. Function 
scale includes work ability, self-
care, mobility, physical function 
and stiffness. 2 sub-scores and 1 
total disease activity score are 
generated. 
PsA (and 
psoriasis) 
Completion: < 5 min 
Ease of scoring: Easy 
Availability: Copyright: Brigham 
and Women’s Hospital  
 
Multi-P. Patient 
Reported-Tender 
Scales and items: One diagram with 76 boxes 
representing peripheral joints. This PROM is 
Boxes corresponding to painful 
joints are ticked by the patient 
RA,PsA, 
IBD 
Completion: < 5 min 
Ease of scoring: Easy 
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joint count (PR-
TJC) (72)[44] 
part of the Multidimensional “MultiP” described 
below. 
Scoring: Total tender joint count 
Recall: 1 day  
and the total PR-TJC is summed.  arthritis Availability: From the MultiP 
Questionnaire (described above)  
SKIN DISEASE ACTIVITY    
Psoriasis 
Symptom 
Inventory 
(PSI)[67] 
Scale and items: 1 scale (8 items), rating by a 5-
point scale (0-4).  
Scoring: Total score is the sum of the 8 item 
ratings (0-32).   
Recall time: 1-7 days 
Includes items on 
itch, redness, scaling, burning, 
stinging, cracking, flaking and 
pain. Generates 1 total skin 
disease activity score.  
Psoriasis Completion: < 3 min 
Ease of scoring: Easy 
Availability: Development of PSI 
was sponsored by AMGEN, fee for 
use not clarified. 
Psoriasis 
Symptom Diary 
(PSD)[61] 
Scale and items: 20 NRS scales/items each rated 
0-4.  
Scoring: Each scale scored separately 
Recall time: 1 day 
Includes items assessing the 
severity and bother of psoriasis 
related symptoms and impact.  
Psoriasis Completion: < 5 min 
Ease of scoring: Easy 
Availability: for info contact 
chad.gwaltney@ert.com 
Numeric Rating 
Scale (NRS) of 
itch[66] 
Scales and items: 1 scale/1 item, rating by a NRS 
(0-10). 
Scoring: Higher scores reflect worse itching. 
Recall time: 1 day 
A single item generating 1 total 
itch  score (itch related to 
psoriasis activity) 
Psoriasis Completion <1 min 
Ease of scoring: Easy 
Availability: Free of use. Corres-
pondence to: naegelian@lilly.com 
PAIN     
Visual Analogue 
Scale of pain 
[43,45,50] 
Scales and items: 1 scale/1 item, rating by a VAS 
(0-100 mm) 
Scoring: Higher scores reflect worse pain. A 
score of 0 is “no pain”.  
Recall time: 1 week (or not stated) 
A single item generating 1 pain 
score. 
PsA/ 
Generic 
Completion <1 min 
Ease of scoring: Easy 
Availability: Free of use  
 
Arthritis 
Measurement 
Impact Scale 
versions 1 and 2 
(AIMS 1/2) of 
pain[21,24,25,27,
28] 
Scales and items: AIMS 1: 1 subscale (4 items) 
scored on a 6 point VRS (1-6).  AIMS2: 1 
subscale (5 items) scores on a 5 point VRS (1-5). 
Scoring: Scores within the subscale are summed 
and a recoding and normalization procedure is 
performed to gain scores (0-10) (higher scores  
indicate worse pain) 
Recall time: 1 months 
AIMS 1: 4 items on the severity 
and distribution of pain and 
stiffness. 
AIMS 2: 5 items on the severity, 
frequency, distribution and 
duration of pain and stiffness and 
impact on sleep. 
RA/OA Completion <1 min 
Ease of scoring: Difficult 
Availability: See description of 
AIMS below 
Numeric Rating Scales and items: 1 NRS (0-10) 1 item: “How much pain have you PsA/RA/ Completion < 1 min 
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Scale (NRS) of 
pain[44] 
Scoring: Higher scores indicate worse pain 
Recall time: 1 week 
had because of your arthritis over 
the past week”  
IBD 
arthritis 
Ease of scoring: Easy 
Availability: See MultiP below 
SF-36 Bodily Pain 
(BP)[26,28,33,34,
40,50] 
Scales and items: 1 subscale, 2 items (SF-36 
item 7 and 8) scores on a 6 and 5 point VRS.  
Scoring: See description of SF-36 below. 
Recall: 4 weeks 
1 item of pain magnitude and 1 
item of pain interference on 
normal activities/work, 1 total 
score. 
Generic Completion < 1 min for this scale 
Ease of scoring: Difficult 
Availability: See SF-36 below 
VAS Pain 
(assessed with 
HAQ)[22,28] 
Scales and items: 1 scale/1 item, rating VAS (0-
100 mm) (no pain=0 and severe pain =100) 
Scoring: A pain score is calculated by measuring 
the distance (cm) from 0 to the respondent’s 
mark of pain severity on the line, and multiply 
with 0.2 to obtain a value from 0-3. 
Recall time: 1 week 
1 item, 1 total score. RA Completion <1 min 
Ease of scoring: Easy-moderate 
Availability: Free of use  
 
PATIENT GLOBAL     
Due to psoriasis      
Patient Global 
Assessment of 
skin impact by 
Numeric Rating 
Scale[64] 
Scales and items: 1 scale/1 item, rating by a NRS 
(0-10). 
Scoring: Higher scores reflect worse global 
health due to psoriasis 
Recall time: 1 week   
1 item: “Considering all the ways 
psoriasis (skin disease) affected 
you during the last week, circle 
the number that best describes 
how you have been doing” 
PsA Completion <1 min 
Ease of scoring: Easy 
Availability: Free of use 
Patient Global 
Assessment of 
skin impact by 
Visual analogue 
Scale[49] 
Scales and items: 1 scale/1 item, rating by a VAS 
(0-100 mm) 
Scoring: Higher scores reflect worse global 
health.due to psoriasis 
Recall time: 1 week. 
1 item: “In all the ways your 
PSORIASIS affects you, how 
would you rate the way 
you felt over the past week” 
PsA Completion <1 min 
Ease of scoring: Easy 
Availability: Free of use  
 
Due to arthritis     
Patient Global 
Assessment of 
joint impact by 
Numeric Rating 
Scale[44,64] 
Scales and items: 1 scale/1 item, rating by a NRS 
(0-10). 
Scoring: Higher scores reflect worse global 
health due to PsA joint disease 
Recall time: 1 week  or 1 day 
1 item: “considering all the ways, 
your joints affected you during 
the last week, circle the number 
that best describes how you have 
been doing” 
PsA Completion <1 min 
Ease of scoring: Easy 
Availability: Free of use 
Patient Global 
Assessment of 
Scales and items: 1 scale/1 item, rating by a VAS 
(0-100 mm) 
1 item:  “In all the ways your 
ARTHRITIS affects you, how 
PsA Completion <1 min 
Ease of scoring: Easy 
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joint impact by 
Visual Analogue 
Scale[49] 
Scoring: Higher scores reflect worse global 
health due to PsA joint disease 
Recall time: 1 week. 
would you rate the way 
you felt over the past week.” 
Availability: Free of use  
 
Due to Psoriatic Arthritis    
Patient Global 
Assessment of  
PsA impact by  
Visual Analogue 
Scale[43,45,49,50
,63] 
Scales and items: 1 scale/1 item, rating by a VAS 
(0-100 mm). 
Scoring: Higher scores reflect worse global 
health.  
Recall time: 1 week (most often). 
1 item. Example of wording: “In 
all the ways your PSORIASIS and 
ARTHRITIS, as a whole, affects 
you, how would you rate the way 
you felt over the past week” 
PsA/ 
Generic  
Completion <1 min 
Ease of scoring: Easy 
Availability: Free of use  
Patient Global 
Assessment of  
PsA impact by  
Numeric Rating 
Scale[53,64] 
Scales and items: 1 scale/1 item, rating by a NRS 
(0-10). 
Scoring: Higher scores reflect worse global 
health. 
Recall time: 1 week   
1 item: “Considering all the ways 
PsA affected you during the last 
week, circle the number that best 
describes how you have been 
doing”   
PsA/ 
Generic  
Completion <1 min 
Ease of scoring: Easy 
Availability: Free of use  
 
PHYSICAL FUNCTION    
Dougados 
Functional index 
(DFI)[34] 
Scales and items: 1 scale (20 items). 3 point 
verbal response scale (each item scored 0-2), 
higher scores reflect worse function. 
Scoring: Total score is the sum of item scores 
(0–40).   
Recall time: NS. “Usual abilities”.  
Includes items on physical and 
daily activities, mobility, and 
ability to care for one self, turn in 
bed, breathe deeply and cough. 
Generates one total score of 
physical function.  
AS/ 
AxSpA 
Completion: <3 min. 
Ease of scoring: Easy 
Availability: online (in multiple 
translations). 
More info: Correspondence to: 
Prof. M. Dougados:  maxime. 
dougados@aphp.fr 
Disability of Arm, 
Shoulder and 
Hand Outcome 
Measure 
(DASH)[29] 
Scales and items: 1 scale (30 items). Rating by 5-
point scales. Additional 2 optional scales (4 
items each). 
Scoring: Formula for calculating total score is 
available in user’s manual. Total score range 0-
100, higher scores indicate worse function. 
Recall time: 1 week 
Includes items on physical and 
daily activities, mobility, 
dexterity, participation in work, 
social and leisure activities, sleep 
and sexual problems, pain, 
weakness and stiffness.  
Generates 1 total 
symptom/disability score.   
2 optional scales can be applied 
to assess participation in work 
RA, OA, 
distal 
radius 
fracture 
Completion: <5 min. 
Ease of scoring: Moderate 
Availability: Copyright:  
www.dash.iwh.on.ca/. Free of 
charge for non-commercial use; 
license for commercial use. 
More info: www.dash.iwh.on.ca/ 
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and sports/arts activities, these 
generate 2 separate scores.  
Bath Ankylosing 
Spondylitis 
Functional Index 
(BASFI)[34] 
Scales and items: 1 scale (10 items). Rating by 
NRS (0-10) or VAS (0–10 cm) Anchors: “easy” 
and “impossible.”  
Scoring: The mean of the 10 item scores 
provides the overall index score (0-10). 
Recall time: 1 week. 
Includes items on physical and 
daily activities and the ability to 
care for one self. Generates 1 
total score.  
 
AS Completion:  <3 min. 
Ease of scoring: Easy 
Availability: Free of charge to 
academic users but not industry. 
More info: www.asas-group.org. 
http://oml.eular.org  
Health 
Assessment 
Questionnaire – 
Disability Index  
(HAQ-
DI)[22,27,28,33,34
,42,43,50,51,60] 
 
 
 
 
Scales and items: 1 scale (20 items) of 8 
categories of function. 2 subscales: VAS pain 
and VAS global (0-100mm). Each HAQ-DI item is 
rated 0-3 (higher scores reflect worse disability). 
Scoring: The highest score within a category is 
used to calculate the mean score of all 
categories (total score 0-3). Dependence on 
physical assistance or equipment raises a cate-
gory score to 2.  
VAS scored separately. 
Recall time: 1 week.   
Includes items on physical 
function categorized in 8 areas: 
Dressing & grooming, arising, 
eating, walking, hygiene, reach-
ing, gripping, common activities. 
Generates 1 disability score.  
 Separate additional scales of 
Patient Global and Pain are often 
presented with HAQ.    
RA Completion: <10 min. 
Ease of scoring: Moderate 
Availability: Copyrighted by 
Stanford University. There is no 
charge from Stanford for permis-
sion to use HAQ. The HAQ 20-item 
disability scale is available at 
http://patienteducation.stanford.e
du/research/haq20.html. 
More info: http://oml.eular.org 
Health 
Assessment 
Questionnaire–
Skin 
(HAQ-SK)[23] 
Scales and items: 1 scale (23 items), with 3 
items added to HAQ-DI to assess skin related 
disability. 2 subscales: VAS global and VAS pain 
(0-100mm).  
Scoring: As for the original HAQ-DI.   
Recall time: 1 week 
Includes the same items as HAQ 
(described above) plus 3 items on 
physical function in relation to 
psoriasis.  Separate additional 
scales of Patient Global and Pain 
are often presented with HAQ 
RA, skin 
items for 
PsA  
Completion: <10 min. 
Ease of scoring: Moderate 
Availability: NS 
More info: See reference.   
 
Health 
Assessment 
Questionnaire –
Spondylo-
arthropathy 
(HAQ-S)[22] 
Scales and items: 1 scale (25 items) with 5 items 
added to the original HAQ-DI to assess 
spondylitis related disabilities.    
2 subscales: Stiffness and Pain (VAS: 0-100 mm) 
Scoring: As for the original HAQ-DI.  
Recall time: 1 week. 
Includes the same items as HAQ 
(described above) plus 5 items on 
physical function in relation to 
spondylitis. Separate additional 
scales of Stiffness and Pain are 
presented with HAQ-S.  
RA (SpA 
items for 
AS) 
Completion: <10 min. 
Ease of scoring: Moderate 
Availability: NS 
More info: http://oml.eular.org 
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Modified Health 
Assessment 
Questionnaire 
(mHAQ)[45] 
Scales and items: This scale is modified from 
HAQ to include only 8 questions  
Scoring: The score of mHAQ ranges  
from 0-3.  
Recall: 1 week.  
Includes 1 item from each of the 
8 areas of physical function 
presented in the HAQ-DI 
(described above).  
 Completion: <5 min. 
Ease of scoring: Moderate 
Availability: NS 
More info: http://oml.eular.org, 
 t.pincus@rhul.ac.uk 
SF-36 Physical 
Function Scale 
(SF-36 PF) 
[26,28,33,34,40,5
0] 
Scales and items: 1 subscale (10 items) from the 
SF-36 questionnaire (described below).  
Scoring: Item ratings (raw scores) are summed 
and transformed to obtain a 0-100 scale score.  
Recall time: 1 month.  
Includes 10 items assessing 
different levels of physical and 
daily activities. Generates 1 
physical function score.  
Mixed 
popula 
tion 
Completion: < 3 min.  
Ease of scoring: Difficult 
Availability and more info: As for 
SF-36 (described below) 
SF-36 Physical 
Component 
Summary (PCS) 
[40,50] 
Scales and items: The PCS of SF-36 is derived as 
an aggregate of the 8 subscale scores. 
Scoring: Z-scores are determined for each of the 
8 scale scores and these are multiplied by a 
factor scoring coefficient and subsequently 
summed.  
Recall time: 1 month. 
Based on the 8 SF-36 subscale 
scores. Generates one aggregate 
of physical function.  
Mixed 
popula 
tion 
Completion, scoring, availability 
etc.  As for the SF-36 (described 
below.  
MultiP Combined 
Inflammatory 
Arthritis – 
Functional 
Impairment 
questionnaire 
(CIAQ-FI)[44] 
Scales and items: 1 scale (10 items), VRS (0-3). 
Part of the MultiP Questionnaire (described 
below) 
Scoring: Average of the 10 scores with higher 
score representing worse function. 
Recall time: 1 week 
Includes 10 items assessing the 
difficulty of performing activities 
of daily living. Generates 1 score 
of function 
RA, PsA 
IBD-
arthritis 
Completion: < 5 min.  
Ease of scoring: Easy 
Availability and more info: Freely 
available for clinicians and industry 
AIMS1 and 
AIMS2  
Physical Function  
(AIMS physical) 
[21,24,25,27,28] 
Scales and items: The AIMS1 contains 4 
subscales of physical/daily function (4-7 items 
per scale). VRS (2-3 categories). 
The AIMS2 contains 6 subscales of physical/daily 
function (4-5 items per scale).  5 point VRS (1-5).  
Scoring: Each function scale is scored separately 
as for the overall AIMS (described below). 
Recall time: 1 month 
Physical function scales of:  
AIMS 1 and 2:  
Mobility (getting around) 
Walking/Bending 
Hand/Finger function 
Household 
Selfcare/ADL 
AIMS 2:  
Arm Function 
RA/OA Completion: <2 min. per scale 
Ease of scoring: Difficult 
Availability and more info: Free 
(see info for the full AIMS below) 
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A separate score is generated for 
each scale. 
AIMS2 Physical 
component score 
(AIMS PC)[25,28] 
Scales, items, scoring: The Physical component 
score is the average of the 6 AIMS2 function 
subscale scores (described above).  
Recall: 1 month 
Scores from following scales are 
averaged: Mobility, 
walking/bending, hand/finger 
function, arm function, self care, 
and household tasks.  
RA/OA Completion: < 10 min 
Ease of scoring: Difficult 
Availability and more info: Free 
(see info for the full AIMS below) 
 HRQoL/Life impact     
Psoriatic Arthritis 
Quality of Life 
instrument 
(PsAQoL) 
[30,35,41,42,55,7
1] 
Scales and items: 1 scale (20 items). Rating: 
‘true’ or ‘false’ for each item.  
Scoring: Total number of ‘true’ responses. 
Higher scores indicate poorer QoL. 
 Recall time: 1 day  
Includes items on emotional well-
being, participation, fatigue, 
independence and stiffness. 
Generates 1 total HRQoL score. 
PsA Completion: <5 min 
Ease of scoring: Easy 
Availability: Use with permission 
for a cost: smckenna@galen-
research.com 
Arthritis Impact 
Measurement 
Scale (AIMS1) 
[21,25,27] 
 
 
Scales and items: 66 items in total. The first 45 
items are broken down into 9 subscales (4-7 
items per scale). Additional items cover general 
estimates of health status/health perceptions, 
overall arthritis impact, medication, 
comorbidity, and demographics.  
Scoring: A recoding and normalization 
procedure is needed to express all 9 subscale 
scores in the range of 0-10. Higher score reflect 
worse disease impact. Scoring manual available. 
Summary Scores: A physical, psychological and 
Pain component score can be calculated by 
lumping scale scores from similar domains. A 
manual is available.  
Recall time: 1 month 
Assess disease impact by 
following 9 subscales: 
1) Mobility  
2) Physical activity 
3) Dexterity 
4) Household activities 
5) Social activities 
6) Activities of daily living 
7) Pain 
8) Depression 
9) Anxiety 
All scales are scored separately 
but a global AIMS-1 score can be 
generated as the mean of the 9 
scores. 
RA/OA Completion: <20 min.  
Ease of scoring: Difficult 
Availability: Free access. 
Correspondence to: Robert 
Meenan: rmeenan@bu.edu 
More info: www.proqolid.org/ 
http://oml.eular.org 
Arthritis Impact 
Measurement 
Scale-2 (AIMS2) 
[24,25,28] 
Scales and items:  78 items with the first 57 
items broken down into 12 subscales (4-5 items 
per scale).  Additional items assess satisfaction, 
health perceptions, arthritis impact, general 
Assess the impact of disease  by 
following subscales:  
1) Mobility level 
2) Physical activity  
RA/OA  Completion: <20 min. 
Ease of scoring: Difficult 
Availability: Free access, 
Correspondence to: Robert 
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health perception, medication and arthritis/co-
morbidity, demographics.  
Scoring:  A recoding and normalization 
procedure is needed to calculate scale scores (0-
10). Higher scores reflect worse disease impact. 
Scoring manual available.  
Summary scores: Factor analysis has suggested 
a 3 and a 5 component model which group the 
AIMS measures into general categories.  The 3 
component model measures Physical Function, 
Psychological Status and Pain.  
Recall time: 1 month 
3) Dexterity  
4) Arm function  
5) Self-care  
6) Household tasks  
7) Social activities 
8) Social support  
9) Arthritis pain  
10)Work ability  
11)Level of tension 
12)Mood  
All scales are scored separately. 
Meenan: rmeenanbu.edu 
More info: www.proqolid.org/ 
http://oml.eular.org 
https://eprovide.mapi- 
trust.org/instruments/arthritis-
impact-measurement-scales 
PsA Impact of 
Disease 
Questionnaire 
(PsAID-9 and 
PsAID-12) 
[58,68,72,73] 
Scales and items: Two versions: 1 scale (12 
items) for routine care and 1 scale (9 items) for 
trials. Rating by NRS (0-10).  
Scoring: Item scores are multiplied by a 
weighing score. Sum of the final item scores 
yield a total score from 0-10, higher scores 
reflect worse impact.  
Recall time: 1 week 
Assesses the impact of disease 
and includes items on pain, 
fatigue, skin disease activity, 
participation (work/leisure), 
physical function, sleep and 
emotional well-being. 
Generates 1 total score.   
 
PsA Completion: <5 min 
Ease of scoring: Moderate 
Availability: English as well as 
translated versions and scoring 
instructions freely available. 
More info: http://oml.eular.org 
Psoriatic Arthritis 
Impact Profile 
(PAIP)[56] 
Scales and items: 1 scale (23 items) with “4 
special parts”. Rating by a 4-point scale, higher 
scores reflect worse disease impact.  
Scoring: Total score is the sum of the scores in 
the 4 special parts and range from 0-84, higher 
score indicate worse impact.  
Recall time: NS 
Assesses impact of disease and 
includes items on physical 
function, emotional well-being, 
sleep, pain, participation, 
independence and socio-
economic impact of disease. 
Generates 1 total score. 
Furthermore, PAIP includes items 
on demographics, treatment 
attitude and side effects. 
PsA 
(psoria-
sis) 
Completion: <15 min 
Ease of scoring: Moderate 
Availability: Developed in Italian, 
non-validated translation of PAIP 
available in the reference. 
Correspondence to: 
Stefano.coaccioli@uniog.it  
 
 
VITACORA-
19[59,69] 
Scales and items: 1 scale, (19 items), rating by a 
5 point Likert scale (“always” to “never”).  
Scoring: Summed score from 0 (worst HRQoL) to 
Assesses HRQoL and includes 
items on physical function, pain, 
fatigue, participation, emotional-
PsA Completion: < 10 min  
Ease of scoring: Easy 
Availability:  Spanish version 
38 
 
100 (best HRQoL).   
Recall time: 1 week.  
wellbeing, disease activity, 
inflammation, sleep, 
independence and economy.  
Generates 1 total score.  
 
available from the author 
jctorre@telecable.es 
English version not validated  
 
Psodisk[62] Scales and items: 1 scale (10 items), rating by 
VAS (0-100 mm), anchors “absolutely no” and 
“definitely yes”.   
Scoring: Scores are joined by a line forming a 
polygon. A large polygon equals a low quality of 
life, and decrease of disease burden is visualised 
by a shrinking of the polygon.  
Recall time: 1 week.  
Assesses HRQoL and includes 
items on physical function, global 
health, emotional well-being, 
fatigue, participation, sleep, pain, 
joint and skin disease activity and 
economic costs. Generates 1 total 
“score”.  
 
PsA Completion: <5 min 
Ease of scoring: Easy 
Availability:  AbbVie sponsored the 
PsoDisk and made it freely 
available (as an APP). 
More info:  Priv. - Doz. Mag. Dr. 
Michael Dennis Linder Adjunct 
Professor, Medical University of 
Graz, Graz, Austria 
Multi-
dimensional 
Questionnaire for 
PROMs 
(MultiP)[44] 
Scales and items: 9 subscales (77 items). 
Different rating options for the subscales (NRS 
(0-10)/ 3- point Likert/ joint diagram)   
Scoring:  Mean scores for each subscale are 
calculated. 
Recall time: Current/past week/past month. 
Assess disease impact on life by 
following subscales: 
1) Physical function (10 items) 
2) Quality of life (10 items) 
3) Pain (1 item) 
4) Fatigue (1 item) 
5) Global health (1 item) 
6) Stiffness (duration) (1 item) 
7) Joint tenderness (1 diagram) 
8) Disease attitude (10 items) 
9) Co-morbidities (43 items) 
Separate scores for each scale are 
calculated. The PROM also 
contains general information 
including co-morbidities and 
medication. 
Arthritis  
(RA, PsA, 
IBD- 
related) 
Completion: <15 min (mean(SD) 
completion time was 8.25(0.25) 
minutes according to reference) 
Ease of scoring: Moderate 
Availability:  There are no cost for 
using it, whether clinician or 
industry.  
MultiP Combined 
Inflammatory 
Arthritis – Quality 
Scales and items: 1 scale, 10 items  
Scoring: 4 point VRS (scores are 0-3), total scale 
score is the average of items score (0-3) and 
10 items concerning ability to get 
a good night’s sleep (1 item), and 
9 items concerning ability to cope 
Arthritis  
(RA, PsA, 
IBD- 
Completion: <5 min for this scale   
Ease of scoring: Easy 
Availability: There are no cost for 
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of Life (CIAQ-
QoL)[44] 
higher scores represent worse quality of life  
Recall time: 1 week 
with stressors,  social activities, 
feelings/anxiety, low self-
esteem/feeling blue, get going in 
the morning, usual work, worries 
about future, continuing usual 
activities, relationship with 
partner.   
related) using it, whether clinician or 
industry.   
The 36 item 
Short Form 
Health Survey 
(SF-36) 
[26,28,33,34,40,5
0] 
Scales and items: Different versions of SF-36 
have been developed. All versions have 8 
subscales (35 items), which each generate 
separate scale scores. There are 36 items in 
total one item concerns the change in health. A 
mental and a physical summary score can be 
calculated from the subscales. The rating 
options vary between items (verbal or numeric 
scales)  
 Scoring. The RAND, MOS and SF-36V2 present 
minor differences in rating and scoring. The 
most important differences are seen for the 
Role physical and Role emotional items where 
the SF-36V2 has 5 response options compared 
to dichotomous response options in former 
versions. Raw scores are transformed by a 
scoring key into values between 0-100 and 
subscale scores are derived by averaging the 
values of the items included in the particular 
scale. Higher scores reflect better health state. A 
scoring manual is available, including norm-
based scoring algorithms.  Different normative 
databases also exist. 
Recall time: 4 weeks. 
Assesses HRQoL by 3 overall 
dimensions: Functional status, 
Emotional well-being and General 
health perceptions). Eight 
separate scales are presented 
and generate 8 scale scores:  
1)Physical function (daily and 
vigorous activities)  
2)Role limitation due to physical 
health 
3) Bodily pain 
4) Social functioning 
5) General mental health 
6) Role limitations due to 
emotional  
7)Vitality (energy/fatigue) 
8) General health perception  
 
Mixed 
popula-
tion  
Completion: <15 min. 
Ease of scoring: Difficult 
Availability: The MOS/RAND 36-
Item Short-Form Health Survey (SF-
36) is free of charge, while an 
annual licence fee applies to the 
SF-36v2. 
More info: http://oml.eular.org 
http://www.sf-36.com/ 
https://www.rand.org/health/surv
eys_tools/mos/36-item-short-
form.html 
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Inverse Psoriasis 
Burden of 
Disease 
questionnaire 
(IPBOD)[74] 
Scales and items: 7 items on general 
information and 16 VAS (0-100 mm) items with 
anchors “never” and “all the time” referring to 
how often a given problem/symptom has 
interfered.   
Scoring: The VAS items are averaged to yield 
total scale score and/or 5 subscales with 1-4 
items in each.  
Recall time:  None 
Assesses the overall burden of 
inverse psoriasis by VAS scoring 
of how much of the time 
following conditions have been 
present or affected: Itch, 
cracking, skin maceration, odor, 
intimacy, body self-image, shame, 
physical contact, clothing choices, 
personal hygiene, school/work, 
recreational activities, pain, close 
relationships, depression/anxiety, 
finances. 
PsA PsO Completion: < 10 min 
Ease of scoring: Easy 
Availability: Free to academic 
users but contact to developers 
required. Copyright held by  Joseph 
F. Merola, MD MMSc 
Brigham and Women's Hospital 
Harvard Medical School.  
JFMEROLA@BWH.HARVARD.EDU 
FATIGUE     
Functional 
Assessment of 
Chronic  Illness 
Therapy Fatigue 
scale  (FACIT-
Fatigue)[32] 
Scale and items: 1 scale (13 items) rating by a 5-
point Likert scale (0-4). 
Scoring: Items scores are summed to generate a 
total scale score (0- 52). Higher scores reflect 
more fatigue. 
Recall time: 1 week  
Assesses fatigue by items on 
tiredness, ability to 
do/start/finish activities, energy, 
need for help, participation in 
social life and frustration. 
Generates 1 total score.  
Cancer 
Anaemia  
 
Completion: <5 min 
Ease of scoring: Easy 
Availability: English version is free 
to use, a fee is payable for non-
English versions in commercial 
studies. http://www.facit.org/ 
Numeric Rating 
Scale (NRS) of 
fatigue [38,44] 
Scales and items: 1 scale/1 item, rating by a NRS 
(0-10). 
Scoring: Higher scores reflect worse fatigue.  
Recall time: NS 
Includes 1 item of fatigue 
generating 1 single score. 
RA/PsA 
Generic 
 
Completion: <1 min 
Ease of scoring: Easy 
Availability: Free of use  
 
Visual Analogue 
Scale (VAS) of 
fatigue[43] 
Scales and items: 1 scale/1 item rating by a VAS 
(0-100 mm). 
Scoring: Higher scores reflect worse fatigue.  
Recall time: 1 week 
Includes 1 item of fatigue 
generating 1 single score. 
PsA/ 
Generic  
Completion <1 min 
Ease of scoring: Easy 
Availability: Free of use  
SF-36 Vitality  
(SF-36 VT) 
[26,40,50] 
Scales and items: 1 scale (4 items) 
Scoring: VRS (1-6) with higher scores reflect 
more vitality (less fatigue). Item scores are 
summed and recoded 0-100 (manual available)  
Recall: 1 months 
Includes 4 items concerning 
feeling full of life, having energy, 
being worn out, and feeling tired. 
Mixed 
populati
on 
Completion: < 3 min.  
Ease of scoring: Difficult 
Availability and more info: As for 
SF-36 (described above) 
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PARTICIPATION     
Social Role 
Participation 
Questionnaire 
(SRPQ) 
(including the 3 
scales: SRPQ-
IM,SRPQ-ST, 
SRPQ-SR)[52] 
Scales and items: 3 subscales (12 items per 
scale) rating by a 5-point Likert scale.  
Scoring: Mean scores are calculated separately 
for each of the 3 scales if a person respond to at 
least 9/12 domains.  
Recall period: Today 
Assesses participation by the 
following 3 scales:  
1) Importance of participation  
2) Restrictions in role 
participation  
3) Satisfaction in social perfor-
mance. Separate scores are 
calculated for each scale. 
OA Completion: 10 min 
Ease of scoring: Moderate  
Availability: Free of charge for use 
in research or clinic, a fee may 
apply for commercial use/ trial. 
Copyright owner:  M.Gignac and 
colleges: 
mgignac@iwh.on.ca 
Work 
Productivity 
Survey (WPS) 
[57] 
Scale and items: 8 subscales (8 items), 12 items 
in total. The scales/items are rated as “number 
of days” or by a 0-10 rating scale, anchors “no 
interference” and “complete interference” (of 
PsA on productivity)   
Scoring: Each of the scales are scored 
individually.  
Recall time: 1 month. 
Assesses work productivity by 
following scales: 
1) Missed work 
2) Reduced work productivity  
3) Interference of PsA on work 
4) Missed household work 
5) Reduced household 
productivity 
6)Missed family activities 
7) Need for hiring outside help 
8) Interference of PsA on 
household 
Each scale generates a separate 
score. The PROM also includes 
information on employment 
status and occupation.  
RA Completion: <5 min 
Ease of scoring: Easy 
Availability: The WPS for PsA is 
originally developed for RA 
(copyright licence 
Pharmacia/Pfizer).  
 
AIMS1 and 
AIMS2 Social 
Activity (SA) Scale 
[21,24,25,27,28] 
Scale and items: AIMS1: 1 subscale (4 items) 6 
point VRS (1-6). AIMS2: 1 subscale (5 items) 5 
point VRS (1-5).  
Scoring: Recoding and normalization to a  (0-10) 
scale score with higher scores representing less 
social activity. 
Recall: 1 month 
For both AIMS versions, the social 
scales assess the frequency of 
social activities including having 
visitors/visit others and being on 
the telephone. 
 Completion: < 5 min for this scale 
Easy of scoring and availability: 
See description of AIMS 
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AIMS2 
Work[24] 
Scale and items: 1 subscale (5 items), 5-6 point 
VRS.  
Scoring:  Recoding and normalization to a (0-10) 
scale score with higher scores representing less 
ability to perform work.  
Recall: 1 month 
Includes 5 items on the type of 
work and the ability to work in a 
normal way, have a full day of 
work and doing the work as 
carefully as usual.  
 Completion: < 5 min for this scale 
Easy of scoring and availability: 
See description of AIMS 2. 
AIMS2 Social 
component (SC) 
score[25,28] 
Scales, items, scoring: The Social component 
score is the average of the 2 social AIMS 2 
subscale scores. 
Recall: 1 month 
Scores from the social activity and 
the social support scales are 
averaged:  
RA/OA Completion: < 15 min 
Ease of scoring: Difficult 
Availability and more info: Free 
(see info for the full AIMS below) 
SF-36 Role Emoti-
onal (SF-36 
RE)[26,40,50] 
Scales and items: 1 subscale (3 items) 
Scoring: Dichotomous response (1 Yes/2 No) 
(elaborated to 5 response categories in the SF-
36v2). Recoding of these into a 0-100 scale 
(manual available). 
Recall: 1 months 
Includes 3 items concerning the 
impact of emotional problems on 
time spent on work/other 
activities, accomplishing things, 
doing things carefully. 
Mixed 
populati
on 
Completion: < 3 min.  
Ease of scoring: Difficult 
Availability and more info: As for 
SF-36 (described above) 
SF-36 Role 
Physical (SF-36 
RP)l[26,40,50] 
Scales and items: 1 subscale (4 items) 
Scoring: Dichotomous response (1 Yes/2 No) 
(elaborated to 5 response categories in the SF-
36v2). Recoding of these into a 0-100 scale 
(manual available). 
Recall: 1 months 
Includes 4 items concerning the 
impact of physical problems on 
time spent on work/other 
activities, accomplishing things, 
limitations in work/other 
activities, difficulties performing 
work/other activities.   
Mixed 
populati
on 
Completion: < 3 min.  
Ease of scoring: Difficult 
Availability and more info: As for 
SF-36 (described above) 
SF-36 Social 
Functioning (SF-
36 
SF)[26,28,40,50] 
Scales and items: 1 subscale (2 items) 
Scoring: VRS (1-5) higher values representing 
more interference of normal social activities 
(less participation) 
Includes 2 items concerning the 
extent and amount of time that 
physical and emotional problems 
interfered with normal social 
activities. 
Mixed 
populati
on 
Completion: < 3 min.  
Ease of scoring: Difficult 
Availability and more info: As for 
SF-36 (described above) 
EMOTIONAL WELL-BEING    
43 
 
SF-36 Mental 
Health (SF-36 
MH)[26,28,40,50] 
Scale and items: 1 subscale (5 items), VRS (1-6) 
Scoring:  Recoding of items scores into a 0-100 
scale (manual available). 
Recall: 1 month 
 
5 items addressing nervousness, 
and the presence of feeling 
“down in the dumps”, 
peaceful/calm, downhearted, 
happy. 
 Completion: < 3 min.  
Ease of scoring: Difficult 
Availability and more info: As for 
SF-36 (described above) 
SF-36 Mental 
Component 
Summary (SF-36 
MCS)[40,50] 
Scales and items: The MCS of SF-36 is derived as 
an aggregate of the 8 subscale scores. 
Scoring: Z-scores are determined for each of the 
8 scale scores and these are multiplied by a 
factor scoring coefficient and subsequently 
summed.  
Recall time: 1 month. 
Based on the 8 SF-36 subscale 
scores. Generates one aggregate 
of emotional well-being.  
Mixed 
popula 
tion 
Completion, scoring, availability 
etc.  As for the SF-36 (described 
below.  
AIMS1 and 
AIMS2 
Anxiety/Tension 
Scales[21,24,25,2
7,28] 
Scale and items: AIMS 1: 1 subscale (6 items), 6-
point VRS (1-6). AIMS 2: 1 subscale (5 items), 5 
point VRS.   
Scoring:  Recoding and standardization to a (0-
10) score, higher scores indicate worse anxiety.  
 Recall: 1 month 
Items of both AIMS1 and AIMS2 
concern the frequency of 
tension/anxiety symptoms 
(feeling tense, bothered by 
nervousness, difficulty relaxing, 
feeling calm)   
 Completion: < 5 min for this scale 
Easy of scoring and availability: 
See description of AIMS 
AIMS1 and 
AIMS2 
Depression/ 
Mood 
Scales[21,24,25,2
7,28] 
Scale and items: AIMS 1: 1 subscale (6 items), 6-
point VRS (1-6). AIMS 2: 1 subscale (5 items), 5 
point VRS.   
Scoring:  Recoding and standardization to a (0-
10) score, higher scores indicate worse mood.  
 Recall: 1 month 
Items of both AIMS1 and AIMS2 
depression/mood scales concern 
the frequency of depressive sym-
ptoms (enjoying things, feeling 
low in spirits, feeling nothing 
turned out right, down in dumps)    
 Completion: < 5 min for this scale 
Easy of scoring and availability: 
See description of AIMS 
AIMS2 
psychological 
component 
(Psyc.C) score 
[25,28] 
Scale, items and scoring: This component score 
is the average of the anxiety/tension and the 
Mood/Depression subscale scores. 
Recall: 1 month  
See description of the Tension 
and the Mood AIMS scales for 
more information on content.  
 
 
 
 Completion: < 10 min  
Easy of scoring and availability: 
See description of AIMS 
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MultiP Modified 
Rheumatology 
Attitude Index 
(mRAI)[44] 
Scales and items: 1 scale, 10 items  
Scoring: 10 point NRS, higher scores represent 
worse emotional well-being. 
Recall: 1 week 
10 items concerning the presence 
of worries (related to the 
disease.)      
Arthritis  
(RA, PsA, 
IBD- 
related) 
Completion: <5 min for this scale   
Ease of scoring: Easy 
Availability: There are no cost for 
using it, whether clinician or 
industry.   
ECONOMIC COST     
EuroQol-5D-3L (E 
EQ-
5D)[42,45,47,48,54
,75]  
 
 
 
 
 
 
EQ-5D-
revised[48] 
Scales and items: 1 descriptive scale (5 items) 
and 1 subscale (VAS). Rating of descriptive scale: 
3 level (EQ-5D-3L) or 5 level (EQ-5D-5L) Likert 
scale. VAS (0-100 mm), anchors “best” and 
“worst” health state. 
Scoring:  Scores can be converted into a 
summary (EQ-5D ‘Index’) that uses a utility-
weighted scoring system. EQ-5D VAS scores can 
be converted into Quality-Adjusted-Life-Year.   
Recall time: Today 
A revised scoring system for EQ-5D(UK) time 
trade off, further described by the authors[48] 
Assesses HRQoL and includes 
items on physical function, 
independence, participation, pain 
and emotional well-being. This 
scale generates 1 total score. A 
subscale of Patient Global health 
is scored separately. 
General 
pop-
ulation 
Completion: < 10 min 
Ease of scoring: Difficult 
Availability:  User fees determined 
by the EuroQol Executive Office 
userinformationservice@euroqol.o
rg 
More info: 
http://www.euroqol.org/eq-5d-
products.html 
(User’s guide etc.) 
 SF-6D[45,47,54]  Scales and items: 1 scale/ index (11 items) 
measuring 6 of the 8 SF-36v2 domains.  
Scoring: The SF-6D index is scored from 0.0 
(worst health state) to 1.0 (best health state).  
Recall time: 4 weeks 
Includes items  SF-36v2 scales:  
1)Physical functioning (3a,3b,3j) 
2)Role participation (combined 
RP and RE, 4c, 5b)  
3)Social functioning (10)  
4) Bodily pain (7,8) 
5)Mental health (9b, 9f) 
6)Vitality (9e) 
A single score is generated. 
Mixed 
popu-
lation 
Completion: <3 minutes 
Ease of scoring: Difficult  
Availability: For commercial 
applications there is a per study 
license (https://www.optum.com) 
 
Willingness to 
pay  
questionnaire 
(WTP)[46] 
Scales and items: 8 subscales (27 items) and 2 
VAS (0-100 mm) subscales. Items of the 8 
subscales rated by “amount of money willing to 
pay for a health problem to resolve”   
Scoring: Amount of money willing to pay for 
resolution of each item provides information on 
Assesses health related quality of 
life by following scales: 
1) Intimacy 
2) Physical comfort (including 
aspects of pain and skin 
symptoms) 
PsA 
(other 
WTP 
PROMs 
pre-
viously 
Completion: <30 min 
Ease of scoring: Moderate 
Availability: Reprint request: AA 
Qureshi, Harvard Medical School, 
Department of Dermatology, 
Brigham and Women’s Hospital, 
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the impact of PsA for each aspect of HRQoL.  
Recall time: None 
3) Self-care (physical tasks)  
4) Work/Family (participation) 
5) Concentration 
6) Emotional health 
7) Social comfort (participation) 
8) Sleep  
Besides these scales, the PROM 
includes a subscale of  Patient 
Global Health and general 
information on demographics, 
economy and disease 
characteristics. 
used in 
e.g., 
psoriasis) 
US. 
aqureshi@bics.bwh.harvard.edu 
WTP and instructions are depicted 
in the reference. 
SLEEP     
Visual Analogue 
Scale (VAS) of 
sleep[43] 
Scales and items: 1 scale/1 item rating by a VAS 
(0-100 mm) 
Scoring: Higher scores reflect worse sleep 
problems.  
Recall time: 1 week 
Main construct: Sleep 
Scale domain: Sleep 
PsA/ 
Generic 
Completion <1 min 
Ease of scoring: Easy 
Availability: Free of use  
 
STIFFNESS     
NRS stiffness[44] Scales and items: 1 item (From the 
multidimensional MultPROM, described above) 
Scoring: Minutes or hours of morning stiffness 
Recall: 1 week   
1 item addressing the presence 
and duration of morning stiffness     
Arthritis  
(RA, PsA, 
IBD- 
related) 
Completion: <1 min for this scale   
Ease of scoring: Easy 
Availability: There are no cost for 
using it, whether clinician or 
industry.   
HAQ-S VAS 
stifness[22] 
Scales and items: 1 scale/1 item rating by a VAS 
(0-100 mm). 
Scoring: Higher scores reflect worse stiffness.  
Recall time: NS 
Includes 1 item of stiffness. PsA/ 
Generic  
Completion <1 min 
Ease of scoring: Easy 
Availability: Free of use  
NON-COS DOMAINS    
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*COS domain: Domains listed and phrased according to the revised PsA “Core Outcome Set”.  Original target population refers to the population in which the PROM was 
developed. AS, ankylosing spondylitis; AxSpA, Axial Spondyloarthritis;  IBD,  Inflammatory bowel disease; Min, Minutes;  mm, millimeter; MSK, Muscular skeletal; NS, Not 
Stated; OA, osteoarthritis; PsA, Psoriatic Arthritis; RA, Rheumatoid arthritis VRS; verbal response scale.  
 
 
 
 
 
 
 
 
 
 
 
SF-36 General 
Health(GH) 
[26,40,50] 
Scales and items: 1 subscale (5 items) 
Scoring: 5 point VRS. Scores are transformed to 
a (0-100) scale (manual available)-  
Recall: Today/“generally” 
5 items concerning perception of 
general health status  
Mixed 
populati
on 
Completion: <1 min for this scale   
Ease of scoring: Difficult 
Availability: As or SF-36 (described 
above) 
AIMS-2 Social 
Support[24] 
Scales and items: 1 subscale (4 items). 
Scoring: Each item is scored on a VRS (1-5). 
Total scale score is the average of items scores, 
converted to a 0-10 score, higher scores 
represent less social support. 
Recall: 1 month 
4 items addressing if patients are 
satisfied with the (frequency of) 
support, assistance and 
understanding provided by their 
friends and family 
RA/OA Completion: < 10 min  
Easy of scoring and availability: 
See description of AIMS 
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Supplementary Table C:  Methodological quality (excellent, good, fair, poor) of each study per measurement property per PROM and scoring of the 
measurement property results (+/-/?)   
Identified PROMs listed 
according to Domain 
category 
Reliability 
BOX (A-C) 
Validity 
BOX (D-H) 
Responsiveness 
BOX (I) 
Info on score 
interpretation 
(values are provi-
ded in Suppl. 
Table D) 
Internal 
consistency 
 
Reliability 
Measure-
ment 
error 
Content 
validity 
Structu-
ral valid-
ity 
Hypothe-
ses testing 
Cross-cult. 
Validity 
Criterion 
validity 
Responsiveness, 
Sens. To change 
 A B C D E F G H I  
MSK DISEASE ACTIVITY           
BASDAI Eng[31]      Fair/-    F/C 
BASDAI Span[37] Poor/?     Fair/-   Poor/? F/C 
BASDAI Eng[39]      Fair/+     
SASPA Germ[65] Fair/+    Fair/+ Poor/?   Poor/?  
PASE-total Eng[36]  Poor/?    Poor/?   Poor/?  
PASE-symptom Eng[36]  Poor/?    Poor/?   Poor/?  
PASE-function Eng[36]  Poor/?    Poor/?   Poor/?  
PASE-total Ital[70]      Fair/+ a   Fair/+   
PASE-symptom Ital[70]      Fair/+ a   Fair/+  
PASE-function Ital[70]      Fair/+ a  Fair/+    
PR-TJC Eng[44]    Poor/?  Poor/?     
SKIN DISEASE ACTIVITY           
PSI Eng[67] Good/+ Fair/+   Good/+ Fair/+   Fair/+ F/C 
PSD[61]    Excellent/+       
NRS ITCH Eng[66]    Fair/+       
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PAIN           
VAS pain (1 week recall) Eng[43]         MID 
VAS pain (recall unknown) Norw[45]         MCII, PASS 
VAS pain (1 week recall) Chin[50]        Poor/? MID 
VAS Pain  
 (HAQ, 1 week recall), Eng[28] 
     Poor/?   
VAS Pain  
(HAQ, 1 week recall), Eng[22] 
   Fair/+      
NRS pain (1 week recall) Eng[44] Poor/?  Poor/?  Poor/?     
SF-36 BP Eng[26] Poor/?     Fair/+     
SF-36 BP Eng[28] Poor/?        Poor/?  
SF-36 BP Chin[40] Poor/?     Good/+b    F/C 
SF-36 BP Chin[50]         Poor/? MID 
AIMS1 Pain Eng[21]      Fair/+     
AIMS1 Pain Eng[25]         Poor/?  
AIMS1 Pain Ital[27]      Fair/+     
AIMS2 Pain, Eng[24]      Fair/+     
AIMS2 Pain Eng[28] Poor/?        Poor/?  
AIMS2 Pain Eng[25]         Poor/?  
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Table C cont.   
Identified PROMs listed 
according to Domain 
category  
Reliability 
COSMIN BOX (A-C) 
Validity 
COSMIN BOX (D-H) 
Responsiveness 
COSMIN BOX: I 
Info on score 
interpretation 
(values are provi-
ded in suppl. 
Table D) 
Internal 
consistency 
Reliability 
 
Measure-
ment error 
Content 
validity 
Structural 
validity 
Hypothe-
ses testing 
Cross-cult. 
Validity 
Criterion 
validity 
Responsiveness, 
Sens. To change 
 A B C D E F G H I  
PATIENT GLOBAL         
Patient global (Psoriasis)         
NRS skin (1 week recall) Eng[64]     Fair/+    F/C 
VAS skin (1 week recall) Eng[49] Good/+    Poor/?     
Patient Global (Arthritis)          
NRS joints (1 week recall) Eng[64]     Fair/+    F/C 
NRS joints (1 day recall) Eng[44]   Poor/?  Poor/?     
VAS joints (1 week recall) Eng[49] Good/+    Poor/?     
Patient Global (PsA)           
PGA by NRS (1 week recall) Eng[64]     Fair/+    F/C 
PGA by NRS (1 week recall) Chin[53]     Fair/+     
PGA by VAS (1 week recall) Eng[43]         MID 
PGA by VAS (1 week recall) Eng[49] Good/+    Poor/?     
PGA by VAS (1 week recall) Ital[63]     Fair/+     
PGA by VAS (recall unknown) Norw[45]         PASS, MCII 
PGA by VAS (1 week recall) Chin[50]        Poor/? MID 
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Table C cont.             
PHYSICAL FUNCTION           
DFI Chin[34] Good/-    Good/- Poor/?    F/C 
DASH Eng[29]      Good/-     
BASFI Chin[34] Good/+    Good/+ Poor/?    F/C 
HAQ-DI Eng[22]      Fair/-     
HAQ-DI Eng[28] Poor/?        Poor/?  
HAQ-DI Eng[33] Good/+    Good/+     F/C 
HAQ-DI Eng[43]          MID 
HAQ-DI Eng[51]          MID 
HAQ-DI Ital[27]       Fair/-     
HAQ-DI Chin[34] Good/+    Good/+ Poor/?    F/C 
HAQ-DI Hung[42]      Fair/+     
HAQ-DI Chin[50]         Poor/? MID 
HAQ-DI Thai[60] Poor/?     Fair/+    F/C 
HAQ-S Eng[22]      Fair/-     
HAQ-SK Eng[23]      Poor/?     
mHAQ Norw[45]          MCII,  PASS 
SF-36 PF Eng[33] Good/+    Good/+     F/C 
SF-36 PF Chin[34] Good/+    Good/+ Poor/?    F/C 
SF-36 PF Eng[26] Poor/?     Fair/+     
SF-36 PF Eng[28] Poor/?        Poor/?  
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Table C cont.             
SF-36 PF Chin[40] Poor/?     Good/+b    F/C 
SF-36 PF Chin[50]         Poor/? MID 
SF-36 PCS Chin[40]      Good/+ Poor/?     
SF-36 PCS Chin[50]          Poor/? MID 
CIAQ-FI[44]  Poor/?  Poor/?  Poor/?     
AIMS1 Mobility Eng[21]      Fair/-     
AIMS1 Physical Eng[21]      Fair/+     
AIMS1 Dexterity. Eng[21]      Fair/+     
AIMS1 House Eng[21]      Fair/+     
AIMS1 ADL Eng [21]      Fair/-     
AIMS1 PC Eng[25]        Poor/?  
AIMS1 Physical Ital[27]      Fair/-     
AIMS2 PC Eng[28]         Poor/?  
AIMS2 Mobility Eng[24]       Fair/+     
AIMS2 Physical Eng[24]     Fair/+     
AIMS2 Dexterity. Eng[24]      Fair/+     
AIMS2 Selfcare Eng[24]      Fair/-     
AIMS2 House Eng[24]      Fair/-     
AIMS2 Arm F. Eng[24]      Fair/+     
AIMS2 PC Eng[25]        Poor/?  
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Table C cont.   
Identified PROMs listed 
according to Domain 
category 
Reliability 
COSMIN BOX (A-C) 
Validity 
COSMIN BOX (D-H) 
Responsiveness 
COSMIN BOX: I 
Info on score 
interpretation 
(values are provi-
ded in Suppl. 
Table D) 
Internal 
consistency 
Reliability 
 
Measure-
ment error 
Content 
validity 
Structural 
validity 
Hypothe-
ses testing 
Cross-cult. 
Validity 
Criterion 
validity 
Responsiveness, 
Sens. To change 
 A B C D E F G H I  
HRQol/Life Impact           
PsAQoL Eng[30] Good/+ Fair/? Excellent/+ Good/+ Fair/+     
PsAQoL Eng[35]      Poor/?   Poor/?  
PsAQol Eng/Chin[71] Poor/? Fair/+  Poor/?  Fair/+ a    
PsAQoL Swe[41] Good/+ Poor/?  Good/+  Fair/+ a   F/C 
PsAQoL Hung[42]      Fair/+     
PsAQoL Dutch[55] Poor/? Good/+ Good/? Good/-  Fair/+ a    
AIMS1 Global Eng[27]      Poor/?     
PsAID-9 Eng[58] c Good/+    Fair/+ a  Poor/? PASS 
PsAID-12 Eng[58] c Good/+    Fair/+ a  Poor/? PASS 
PsAID Eng[68]    Excellent/+       
PsAID-12 Ital[73] c    c Fair/+    Cut off values 
PsAID-12touch Ital[72] c        Fair/+  Fair/+  MDA Cut-off  
PAIP Ital[56]      Poor/?     
VITACORA-19 Span[59] Fair/+ Good/+  Good/+ Fair/+ Fair/+   Poor/? F/C,MCID 
VITACORA-19 Turk[69] Poor/? Fair/+   Poor/? Fair/+ a    
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PsoDisk Ital[62]         Poor/?  
CIAQ-Qol Eng[44]  Poor/?  Poor/?  Poor/?     
IPBOD[74] Poor/?   Poor/?  Poor/?     
FATIGUE           
FACIT-Fatigue Eng[32] Poor/? Fair/+    Fair/+     
NRS fatigue (recall NS) Eng[38]     Poor/?   Poor/?  
NRS fatigue (recall NS) Eng[44] Poor/?  Poor/?  Poor/?     
VAS fatigue (1 week recall) Eng[43]         MID 
SF-36 VT Eng[26] Poor/?     Fair/-     
SF-36 VT Chin[40] Poor/?     Good/+b       F/C 
SF-36 VT Chin[50]         Poor/? MID 
PARTICIPATION           
SRPQ-IM Eng[52] Poor/? Fair/+ Fair/? Fair/+  Fair/+    MDC 
SRPQ-ST Eng[52] Poor/? Fair/+ Fair/? Fair/+  Fair/+    MDC 
SRPQ-SR Eng[52] Poor/? Fair/+ Fair/? Fair/+  Fair/+    MDC 
WPS Eng[57]      Fair/+   Fair/+ F/C 
AIMS1 SA Eng[21]     Fair/?d     
AIMS2 SA Eng[24]     Fair/?d      
AIMS2 Work Eng[24]     Fair/?d      
AIMS2 SC. Eng[28]              Poor/?  
SF-36 RE Eng[26] Poor/?     Fair/?     
SF-36 RE Chin[40] Poor/?     Good/+b    F/C 
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SF-36 RE Chin[50]         Poor/? MID 
SF-36 RP Eng[26]      Fair/-     
SF-36 RP Chin[40] Poor/?     Good/+b    F/C 
SF-36 RP Chin[50]         Poor/? MID 
SF-36 SF Eng[26]      Fair/?     
SF-36 SF Eng[28] Poor/?        Poor/?  
SF-36 SF Chin[40] Poor/?     Good/+b    F/C 
SF-36 SF Chin[50]         Poor/? MID 
EMOTIONAL WELL-BEING           
SF-36 MH Eng[26] Poor/?     Fair/?     
SF-36 MH Eng[28] Poor/?        Poor/?  
SF-36 MH Chin[40] Poor/?     Good/+b     
SF-36 MH Chin[50]         Poor/? MID 
SF-36 MCS Chin[40]     Good/+ Poor/?     
SF-36 MCS Chin[50]         Poor/? MID 
AIMS1/2 Psyc.C. Eng[25]        Poor/?  
AIMS1 Anxiety Eng[21]     Fair/?d     
AIMS1 Depression Eng[21]     Fair/?d     
AIMS2 Mood Eng[24]     Fair/?d     
AIMS2 Tension Eng[24]     Fair/?d     
AIMS2 Psyc. C. Eng[28]            Poor/?  
mRAI (MultiP) Eng[44] Poor/?  Poor/?  Poor/?     
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Empty cells reflect that the measurement property was not evaluated by any study for the given instrument.  Table 2 explains the grading of evidence (+/-/?).  
aOnly translation, no cross-cultural validation. According to COSMIN, only studies that address measurement invariance (e.g. multiple group factor analyses or 
ECONOMIC COST           
EQ-5D-3L Norw[45]          PASS, MCII 
EQ-5D-3L Eng[47]      Poor/?   Poor/? Score distribution 
EQ-5D-3Lrev Eng[48]       Poor/?   Poor/? Score distribution 
SF-6D Eng[47].      Poor/?   Poor/? Score distribution 
EQ-5D-3L Swe[75]          PASS 
EQ-5D-3L Hung[42]      Fair/+     
EQ-5D-3L Eng/Chin[54]      Fair/+    F/C 
SF-6D Eng/Chin[54]      Fair/+    F/C 
SF-6D Norw[45]           MCII, PASS 
WTP Eng[46]    Poor/?  Fair/+     
SLEEP           
VAS sleep (1 week recall) Eng[43]         MID 
STIFFNESS           
NRS stiffness (1 day recall) Eng[44]     Poor/?     
VAS stiffness (assessed with HAQ, 1 week recall) Eng[22]   Poor/?     
NON-COS Domains           
SF-36 GH Eng[26] Poor/?     Fair/-     
SF-36 GH Chin[40] Poor/?     Good/-b     
SF-36 GH Chin[50]         Poor/? MID 
AIMS2 Social Support Eng[24]     Fair/?d     
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DIF) between countries (or other groups) are considered real cross-cultural validity studies.bConstruct validity – hypotheses testing was assessed regarding 
the internal relationships (scale assumptions) and not relationship to external measures cQuestionnaire based on formative model why internal consistency 
and structural validity are not rated.  d Only relations to measures of other constructs presented. AIMS, Arthritis Impact Measurement Scales (ADL, Activity of 
daily living; Arm F., Arm Function; House, Household; PC, Physical component score; Psyc.C., Psychological component score; SA, Social Activity, SC, Social 
component score); BASDAI, Bath Ankylosing Spondylitis Activity Index; BASFI, Bath Ankylosing Spondylitis Functional index; Chin, Chinese; CIAQ-FI, Combined 
Inflammatory Arthritis – Functional Impairment questionnaire; CIAQ-QoL, Combined Inflammatory Arthritis – quality of life questionnaire; COSMIN, 
COnsensus-based Standards for the selection of health Measurement INstruments; DASH, Disabilities of the Arm, Shoulder and Hand questionnaire; DFI, 
Dougados Functional Index; Eng, English; EQ-5D-3L, EuroQoL 5 Dimensions questionnaire with 3 response levels; FACIT-Fatigue, Functional Assessment of 
Chronic Illness Therapy-Fatigue Scale; F/C, Floor/Ceiling effect; Germ, German;  HAQ, Health Assessment Questionnaire (HAQ-S: Spondyloarthropathy, HAQ-
SK: Skin, HAQ-DI: Disability Index); Hung, Hungarian; IPBOD, Inverse Psoriasis Burden of Disease questionnaire Ital, Italian; MCID, Minimal Clinically Important 
Difference;  MDC, minimal detectable change; MCII, Minimal clinical important improvement; MIC, Minimal important change; MID, Minimal important 
Difference; mRAI, Modified Rheumatology Attitude Index; MultiP, Multidimensional Patient Reported Outcome Questionnaire; Norw, Norwegian; NRS, 
Numeric Rating Scale; NS, Not stated; PAIP, Psoriatic Arthritis Impact Profile; PASE, PsA Screening and Evaluation Questionnaire; PASS, Patient acceptable 
symptom state; PGA, Patient Global Assessment; PR-TJC, Patient-reported-tender-joint-count; PsAID, Psoriatic Arthritis Impact of Disease questionnaire; 
PsAQoL, PsA Quality of Life instrument; PSI, Psoriasis Symptom Inventory; PsoDisk questionnaire, no full spelling available;  SASPA, Stockerau Activity Score 
for Psoriatic Arthritis; SF-6D, utility tool derived from SF-36 comprising six multi-level dimensions; SF-36, Medical Outcome Survey Short Form 36-item Health 
Survey (SF-36 scales: BP, Bodily Pain; GH, General Health; MCS, Mental Component Summary; MH, Mental Health;  PCS, Physical Component Summary, PF, 
physical function; RE, Role Emotional; RP, Role Physical; SF, Social Functioning;  VT, Vitality); Span, Spanish; SRPQ, Social Role Participation Questionnaire; 
Swe, Swedish; Turk, Turkish; VAS, Visual Analogue Scale;  VITACORA-19, Spanish acronym, full name not available; WTP, Willingness to Pay questionnaire; 
WPS, Work Productivity Survey. 
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Supplementary Table D:  Methodological quality of each study per measurement property (excellent/good/fair/poor) of each instrument assessed, 
and scoring of the measurement property results (+/-/?)  
 
 
Identified PROMs listed 
according to Domain 
category 
Reliability 
 COSMIN BOX (A-C) 
Validity 
 COSMIN BOX (D-H) 
Responsiveness 
 COSMIN BOX I 
 
 
(I) 
Relevant 
info on 
score in-
terpre-
tation 
Internal 
consistency 
(A) 
Reliability 
 
(B) 
Measure-
ment error 
(C) 
Content 
validity 
(D) 
Structural 
validity 
(E) 
Hypothe-
ses testing 
(F) 
Cross-cult. 
validity 
(G) 
Criterion 
validity 
(H) 
MSK DISEASE ACTIVITY A B C D E F G H I  
BASDAI Eng[31]      Fair/-    F/C 
Results: Box F: Vague hypotheses and sparse information about measurement properties of comparators. Group with axial PsA was small (n = 37).  
BASDAI showed greatest correlation with other PROMs (e.g., PGA r = 0.73) and not with measures of disease activity or damage. No difference in 
correlation between BASDAI score and patient’s perception of arthritis activity in axial vs. peripheral PsA.  
Interpretability: N = 133.  Missing data: 16.3%.  Median(IQR) score: 2.95(1.50–4.84). Median score peripheral vs axial PsA: 3.07 vs 4.08. Floor effect: 
1.3%, Ceiling effect: 0% 
BASDAI Spanish[37] Poor/?     Fair/-   Poor/? F/C 
Results: Box A: Unidimensionality not checked. Cronbach-α = 0.647 (AxPsA) and 0.783 (Peripheral PsA). Box F: Vague hypotheses and sparse 
information about measurement properties of comparators. The correlation to other measures of disease activity (PGA, PhGA, spinal pain, BASFI, 
HAQ, SF-36 PF.) was similar in axPsA and pePsA (unexpected). Box I: Not clear if a proportion of patients had changed over time, no correlation 
between change scores. The change in BASDAI score did not show correlation to disease state at follow up for peripheral or axial PsA.  
Interpretability:  N = 100 (Axial and peripheral PsA). Missing data: 0%. Mean(SD) median score: Peripheral PsA: 1.7(1.8),1.2, Axial PsA: 2.7(1.9),2.6.  
Time frame (responsiveness), mean(SD): 12.1(2.1) months. Floor effect: 33% for peripheral PsA; 14.3% for axial PsA. Ceiling effect: 0% 
BASDAI Eng[39]      Fair/+     
Results: Box F: Vague hypotheses and sparse information about properties of comparators however the PGA, PhGA and need for treatment change 
seem to be fair indicators of disease activity (face validity). In AxPsA the BASDAI correlated highly with PGA (r = 0.81) and moderately with PhGA (r = 
0.53) and BASDAI predicted high disease activity measured by: 1) Physician rating: BASDAI OR =1.53, AUC (95%CI): 0.78 (0.67-0.88), 2) Patient rating: 
BASDAI OR = 2.54, AUC(95%CI): 0.92(0.88-0.95), and 3)Change in treatment:  BASDAI R2 = 1.31, AUC(95%CI): 0.69(0.63-0.76).  
Interpretability:  N = 201 (axial PsA). Missing data: max 5.4% (excl.). Mean(SD) score: 3.5(2.4). Floor/ceiling effect: NS.   
SASPA German[65] Fair/+    Fair/+ Poor/?   Poor/?  
Results: Box A, E: Unidimensionality checked. Cronbach-α = 0.875.  FA: Sample size <100. Eigenvalue 3.628. Explained variance (3.628/6) = 60%. High 
factor loadings. Box F,I: No hypotheses and no information about measurement properties of comparators. Statistically significant difference in 
median SASPA score was seen between different levels of PatSat (defined as “Patient’s satisfaction with disease state”) but no exact results were 
provided (only box plots). Only 19 patients in the sensitivity to change analysis, no a priori hypothesis about expected magnitude of effect, but SMD 
found to be 2.1.Interpretability:   N = 152. Missing data: NS. Mean(range) score: 2.66(0-9.2).  Mean(range) score for patients undergoing treatment (n 
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= 19): Baseline 4.51(1.6-7.2) and after therapy 1.87(0.2-4.4).  Time frame (responsiveness), mean: 4.1 months. Floor/Ceiling effect: NS.  
PASE, 3 scales (symptom, function 
total scale) Eng[36] 
Poor/?    Poor/?   Poor/?  
Results: Box B: Small sample (n = 23) (not clear how many patients had PsA vs Pso) and time interval not clear (> 2 weeks). ICC = 0.9 for the entire 
PASE Score, not reported for the separate scales.  Box F,I: Only assessed by know-group validity approach and without a priori hypotheses. Both the 
functional, the symptom and the total median PASE scale scores were higher in PsA vs non-PsA patients ( p<0.05).  Box I: Small sample size (n = 24) in 
the analysis of responsiveness. PASE scores were significantly different in PsA vs. Psoriasis patients and decreased more in PsA vs Psoriasis patients 
after treatment.  
Interpretability:  N = 37 with PsA (190 in total). Missing data: 2% (excl.). Median(IQR) score (PsA): Functional score: 26(22-30), symptom score: 24(23-
27), total score: 51(44-57).  Time frame: Test-retest: >2 weeks, responsiveness: 19 weeks (median). Floor/ceiling effect: NS.  
PASE, 3 scales (symptom, function 
total scale) Ital[70] 
    Fair/+ Poor/?  Fair/+  
Results: Internal consistency and reliability only reported for the total population where PsA were less than 50% and were therefore not included in 
this review (Cronbach-α = 0.90-0.95,Test-retest, ICC = 0.91-0.93) for scales.  Box F: Known-group validity and a priori hypothesis confirmed as patients 
with PsA had significantly higher PASE scores compared to those with psoriasis only however no measures of distribution were presented. For the 
overall population (PsA <50%) convergent validity was demonstrated with correlation to scores of VAS pain 0.51-0.53.  Box G: Only translation no 
cross-cultural validation. No description of pre-testing (cognitive interview) after translation was reported.  
 Box I: Known group approach showing significant differences in the improvement of PASE scores according to rating of clinical improvement (for the 
overall population), and patients with PsA diagnosis improved more in PASE scores compared to those without PsA. Hypotheses about excepted 
differences were vaguely stated. Interpretability:  N = 298 (PsA n= 28-56). Missing data: NS. Mean(SD) PASE scores: Functional score: 21.3, symptom 
score: 19.6, total score: 40.9. SD not stated.  Time frame responsiveness: 3 months. Floor/ceiling effect: NS. 
PR-TJC Eng[44]   Poor/?  Poor/?     
Results: Box D: Not enough information available to rate the study or results regarding content validity. Box F: No information on measurement 
properties of comparators (Physician assessed 28 TJC), sparse hypotheses and description of the joint diagram. However a strong correlation between 
the Patient Reported and Physician assessed TJC (r=0.799) was shown. 
Interpretability:  Total N = 462 (PsA 123, 26.6%). Number of PsA patients not reported for all analyses. Missing data: NS. Floor/Ceiling effect: NS.  
SKIN DISEASE ACTIVITY A B C D E F G H I  
PSI Eng[67] Good/+ Fair/+   Good/+ Fair/+   Fair/+ F/C 
Results: Box A,E: Unidimensionality checked. Cronbach-α = 0.95 (baseline) and 0.97 (week 12). PCA: Comparative Fit Index>0.90, weighted root mean 
square residual (WRMR) <1. Rasch: The PSI items exhibited well-ordered response options. No misfit of items to the model. Box B: Test-retest, ICC = 
0.70, sample size not reported.  Box F: Hypotheses about convergent/divergent validity confirmed (correlation to BSA r = 0.5, less to non-related 
measures). Expected known group differences (according to BSA and CDAI groups) confirmed. Box I: Comparator is “clinically important change” 
based on PGA. Sparse information on properties of this measure, however it has high face validity (according to Cosmin). Nevertheless, it seems that 
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the PGA of change addresses arthritis (not skin disease) in this paper (slightly different constructs). Significant differences in PSI scores between PGA 
“responders” vs “non-responders” were reported (approximately a 6 point difference).    
Interpretation: N = 154 (in analysis except for test-retest where n was not reported). Missing data: 8% (excl.). Mean(SD) scores: 12.2(7.89) at baseline 
and 7.1(7.43) at week 12. Floor effect of individual items: 11-37% at baseline and 32.4-55.8% at week 12. Time frame test-retest: 2 weeks, 
responsiveness: 12 weeks. Ceiling effect for individual items: 4.5-7.1% at baseline and 1.9-2.6% at week 12.   
PSD Eng [61]     Excellent/+      
Results: Box D: Thorough content validity evaluation during the development of the PSI instrument ensuring the comprehensiveness and relevance. 
Study population included between 34% (concept elicitation) and 50% (cognitive interview) with PsA .  
NRS ITCH Eng[66]    Fair/+       
Results: Box D: Content validity confirmed by relevance to target population but the assessment of comprehensiveness less well described. 
Interpretability: N = 22 PsA, 12 Psoriasis.  Itching was a problem for 68% PsA patients and 100% of the psoriasis patients.   
PAIN A B C D E F G H I  
VAS Pain (HAQ) Eng[28]        Poor/?   
Results: Box I:  Responsiveness is tested in different ways but no evidence for responsiveness was achieved (small sample size of 
subanalysis/insufficient methods applied).   
Interpretability: N= 70. Missing data: 12.5% (excl.) Mean(SD), Time 1:  0.97(0.72), Time 2: 0.83(0.81).  
VAS Pain (HAQ) Eng[22]      Fair/+     
Results: Box F: Vague hypotheses and sparse information about measurement properties of comparators. Moderate/strong correlation between HAQ 
VAS pain score and tender points, function, stiffness and active joint count. 
Interpretability:  N = 99-114. Missing data: 13% (excl). Mean(SD), range score: 0.97(0.72).  Floor/ceiling effect: NS 
VAS pain Eng[43]          MID 
Interpretability: N = 200. Missing data: NS. Mean(SD) score (1st/2nd visit): 41.45(27.69)/38.65(28.84). Varying time interval (mean: 8.28 months 
between visits). MID(SD) estimates for improvement/worsening: -9.37(24.37)/13.96(22.05). Correlation between mean change in VAS pain and 
anchor (patient’s rating of change): rs = 0.448 (the authors did not aim to test responsiveness of VAS pain, only MID). Floor/ceiling effect: NS. 
VAS pain Chin[50]         Poor/? MID 
Results: Box I: Small sample size. Correlation between anchor (patient perception of change) and change in VAS pain: rs=0.30.  
Interpretability: N = 17-21 in analyses. Missing data: NS. Mean(SD) baseline scores: 1: Patients who continued treatment > 12 weeks: 67.8(23.3), 
patients treated <12 weeks: 62.7(16.8). MID for improvement: -14.71(31.25). MID for deterioration: -0.95(18.82). Effect size: -0.55, SRM: -0.49.  Time 
frame (responsiveness): up to 52 weeks. Floor/ceiling effect: NS 
VAS pain Norw[45]       MCII, PASS  
Interpretability: Total number of PsA in the study: N = 1391. No. of PsA in the analysis: n = 847. Missing data: Reported for each part of the study. 
Mean(SD) score: 51.5(21.6) at baseline and 37.8(23.1) after 3 months. The anchoring questions were given after 3 months and asked about 
satisfaction (PASS) and improvement (MCII), respectively. PASS cut-points (ROC curves): 75% sensitivity cut-off: 38. 80% specificity cut-off: 30. AUC 
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0.80(95%CI 0.77-0.83). MCII cut-points (ROC curves): 75% sensitivity cut-off: -9.00 80% specificity cut-off: -18.0 AUC(95%CI): 0.76(0.73-0.79).  
NRS pain Eng[44] Poor/?  Poor/?  Poor/?     
Results: Box B:  ICC (95%CI) = 0.83 (0.81-0.85) but number of patients in analysis (and % PsA) not specified. Box D: Not enough information to rate 
quality or results on content validity. Box F: No hypotheses or information about properties of comparators, PsA <50% of the population in most of 
the analyses. Correlation between patient-reported TJC and NRS pain reported for PsA (r=0.484) (n=57). 
 Interpretability: Total N = 462 (PsA 123, 26.6%). Number of PsA patients not reported for all analyses. Missing data: NS. Mean(SD)score (baseline): 
NS (1st assessment in reliability analysis: mean(SD) 6.4(1.2). Reliability time interval: 1 week. Floor/Ceiling effect: NS.  
SF-36 BP Eng[26] Poor/?     Fair/+     
Results: Box A:  Cronbachα 0.90, unidimensionality not sufficiently checked. Box F: Convergent validity confirmed with 5/7 hypotheses fulfilled.  
Moderate-strong correlation with measures of function and disease activity. Known group validity showing significant difference to general 
population (no hypotheses about expected (magnitude of) differences were formulated).  
Interpretability: N=113. Missing data: NS (all completed). Mean(SD) 61.5(2.47). Floor/ceiling effect: NS.  
SF-36 BP Eng[28] Poor/?        Poor/?  
Results: Box A: Unidimensionality not checked/reported. Cronbach α (0.80-0.91), no exact value was reported. Box I:  Responsiveness is tested in 
different ways but no evidence for responsiveness was achieved (small sample size of subanalysis and or insufficient methods applied).   
Interpretability: N=70, Missing data: 12.5% (excl.). Mean(SD) score at baseline/follow-up: 60.83.(23.99)/ 59.65(25.16). Floor/ceiling: NS. 
SF-36 BP Chin[40] Poor/?     Good/+    F/C 
Results: Box A:  Unidimensionality not sufficiently checked (No factor analysis). Cronbach α 0.838. Box F: Convergent validity (internal relationships): 
Scaling assumption (equal item variance, item-own scale, item-other scale) in consistency with hypotheses but for known group validity (external 
relationships) the hypotheses were vaguely stated.  
Interpretability:  N=168. Missing data: NS. Mean(SD) scale score: 48.54(21.85) Floor effect: 1.2%, Ceiling effect: 3.0%. 
SF-36 BP Chin[50]         Poor/? MID 
Results: Box I: Small sample size. Correlation between anchor (patient perception of change) and change in pain: rs=-0.41.  
Interpretability: N = 17-21 in analyses. Missing data: NS. Mean(SD)scores: a) Patients treated > 12 weeks: 30.7(12.5) and b) Patients treated <12 
weeks: 42.8(21.4).  Time frame (responsiveness): 52 weeks. MID for improvement: 12.35(19.83). MID for deterioration: -5.45(15.63). ES: 0.53, 
SRM:0.59. Floor/ceiling effect: NS 
AIMS1 Pain Eng[21]      Fair/+     
Results: Box F: Sparse information about properties of comparators. However, AIMS pain correlated with measures of disease activity and function 
but not with measures of disease severity, as hypothesized.  
Interpretability: N = 45. Missing data: NS. Mean(SD) scale score 2.1(1.7). Floor/ceiling effect: NS.  
AIMS1 Pain Eng[25]         Poor/?  
Results: Box I:  Not assessing correlation between change scores and no a priori hypotheses. AIMS1 at baseline and AIMS2 at follow up.  
Interpretability: N = 65. Missing data: NS. Mean(SD) for Pain 3.08(1.99). Floor/ceiling effect: NS  
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AIMS1 Pain Ita.[27]      Fair/+     
Results: Box F: Sparse information about properties of comparators. Divergent validity (no correlation to clinical measures of disease severity) was 
confirmed and convergent validity (correlation to measures of function and disease activity) sufficiently confirmed.  
Interpretability: N=72. Missing data: NS. Means(SD) score 4.58(3.5), range 0-10. Floor/ceiling effect: NS 
AIMS2 Pain Eng[28] Poor/?        Poor/?  
Results: Box A: Cronbach α (0.80-0.91) no exact value reported. No information on unidimensionality. Box I:  Responsiveness is tested in different 
ways but evidence not achieved (inappropriate methods/too small sample size in subanalysis). Although ‘patient’s perceived change in health’ (1 
year) seems to have face validity (according to COSMIN) as a comparator, no hypotheses about expected magnitude of correlations or the expected 
SRM are stated.   
Interpretability: N= 70. Missing data: 12.5% (excl.) Mean(SD), range: Time 1: 3.90(2.78),0.00-9.50. Time 2: 3.69(2.85), 0.00-10.00. 
AIMS2 Eng[25]         Poor/?  
Results: Box I:  Not assessing correlation between change scores and no a priori hypotheses. AIMS 1 is used at baseline and AIMS 2 after 4 years.  
Interpretability: N = 65. Missing data: NS. Mean(SD) for Pain 3.98(2.61). Floor/ceiling effect: NS  
AIMS2 Pain Eng[24]      Fair/+     
Results: A priori hypotheses about correlation with related measures of function, disease activity and disease activity sufficiently confirmed.  
(Moderate to high correlations with measures of function and disease activity (r = 0.34-0.56), but not with degree of joint deformity). 
Interpretability: N=124.  Missing data: NS. Mean(SD) score 4.10(2.64). Floor/ceiling effect: NS.  
PATIENT GLOBAL A B C D E F G H I  
Due to Psoriasis only          
NRS skin Eng[64]     Fair/+    F/C 
Results: Box F: No hypotheses stated a priori. High correlations (>0.50) with related PROMS. Multivariable regression analyses reported that NRS skin 
was explained by skin problems, functional capacity, discomfort and pain (R2 of model 0.806). 
Interpretability: N = 223. Missing data: <5%. Mean(SD) score: 4.1(3). Floor effect: ~22%. Ceiling effect: ~3%. 
VAS skin Eng[49] Good/+    Poor/?     
Results: Box B: ICC(95% CI) = 0.78(0.72-0.83). Box F:  No hypotheses or information about measurement properties of comparators. Multivariable 
regression with backward selection tested the influence of  PASI, involvement of face, genitals, hands, buttocks and/or intergluteal and feet, psoriasis 
duration, sex, age, and occupation,  The final regression model included PASI score and hand skin involvement, (R2 = 0.35). Known group validity: No 
difference in VAS joint according to PsA phenotype. 
Interpretability: N = 319. Missing items: NS. Median(IQR) score: 30(11-60). Time frame (test-retest): 1 week. Floor/ceiling effect: NS 
Due to Arthritis only          
NRS joints Eng[64]     Fair/+    F/C 
Results: Box F: No a priori hypotheses stated. Several correlations tested. High correlations (r >0.50) with related PROMs was found. Multivariable 
regression analyses reported that NRS-joints was well explained (R2 of the model 0.778) by pain (β= 0.525), fatigue (β= 0.155), work and/or leisure 
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activities (β = 0.178), depression (β = −0.104, P = 0.0193) and coping (β = 0.141). 
Interpretability: N = 223. Missing data: <5%.  Mean(SD) score: 5.6(2.5). Floor effect: ~7%. Ceiling effect: ~3%. 
NRS joints Eng[44]   Poor/?  Poor/?     
Results: Box D: Not enough information to rate quality or results on content validity. Box F: No hypotheses or information about properties of 
comparators, PsA <50% of the population in most of the analyses. Correlation between patient-reported TJC and NRS global reported for PsA 
(r=0.398) (n=57). 
 Interpretability: Total N = 462 (PsA 123, 26.6%). Number of PsA patients not reported for all analyses. Missing data: NS. Mean(SD)score (baseline): 
NS.  Floor/Ceiling effect: NS. 
VAS joints Eng[49]  Good/+    Poor/?     
Results: Box B: ICC(95% CI) = 0.86(0.81-0.89). Box F: No hypotheses or information about measurement properties of comparators. Multivariable 
regression with backward selection procedure to test the influence of TJC, dactylitis, enthestis, arthritis duration, sex, age, occupation. SJC: β(95%CI): 
0.88 (0.24–1.52), TJC: 0.76 (0.47–1.06) and dactylitis: 9.45 ( –0.10.18.99) were included in the final model. Known group validity: No difference in VAS 
Joints according to PsA arthritis phenotype (poly/oligo/mutilans/axial/distal/>1 type).  
Interpretability: N = 319. Missing data: NS. Median(IQR) score: 47(22-69). Time frame (test-retest): 1 week. Floor/ceiling effect: NS. 
Due to PsA            
PGA by NRS Eng[64]     Fair/+    F/C 
Results: Box F: Various correlations tested. No a priori hypotheses stated. High correlations (r >0.50) with related PROMs except skin PROMS (r = 0.33 
(DLQI) and r= 0.52 (NRS embarrassment)). Multivariable regression analyses found PGA to be well explained by following (R2 of the model 0.754):  
coping (β= 0.287), NRS pain (β= 0= 0.240), work and/or leisure activities (β = 0.141) and anxiety, fear and uncertainty (β = 0.109).   
Interpretability: N = 223. Missing data: <5%. Mean(SD) score: 4.8(2.7).  Floor effect: ~8%. Ceiling effect: ~3%.  
PGA by NRS Chin[53]     Fair/+     
Results: Box F: Vague hypotheses. High/moderate correlation to related PROMs (NRS Pain: rs =0.54, HAQ: rs =0.54, SF-36 MCS: rs = -0.47, SF-36 PCS: rs  
=0.49, DAS28: rs = 0.50), and less to clinician reported measures (all rs <0.4).  In multivariate regression analysis, PGA was associated with pain score, 
the PCS and MCS of the SF-36, and the PASI (these 4 variables explained 47.7% of the variance in PGA). Known group validity: Effect size for patients 
with different levels of disease severity ranged from 0.72 (social welfare dependence (y/n)) to -1.32 (fulfilment of MDA (y/n)).  
Interpretability: N = 125. Missing data: None (patients were instructed to completion). Mean(SD) score: 4.56(2.32). Floor/ceiling effect: NS 
PGA by VAS Eng[43]          MID 
Interpretability: N = 200. Missing data: NS. Mean(SD) score (1st/2nd visit): 37.21(26.63)/35.24(27.96). Varying time interval (mean: 8.28 months 
between visits).  MID(SD) estimates for improvement/worsening: -8.41(21.17)/11.53(21.03). Correlation between mean change in VAS global and 
anchor (patient’s rating of change): rs= 0.490 (the authors did not aim to test responsiveness of VAS global, only MID) Floor/ceiling effect: NS. 
PGA by VAS Eng[49]  Good/+    Poor/?     
Results: Box B: ICC(95% CI) = 0.87(0.83-0.90). Box F: No hypotheses or information about measurement properties of comparators. Multivariable 
regression with backward selection showed no impact of anxiety or depression on PGA. Final regression modal (R2 = 0.73) showed that PGA was more 
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influenced by patient joint assessment (VAS joints): β(95%CI): 0.63(0.57–0.69) than Patient Skin Assessment (VAS skin): 0.30(0.27–0.37). 
Interpretability: N = 319. Missing data: NS. Median(IRQ) score: 49(25-66). Time frame (test-retest): 1 week. Floor/ceiling effect: NS. 
PGA by VAS Chin[50]         Poor/? MID 
Results: Box I: Small sample size. Correlation between anchor (patient perception of change) and change in VAS global: rs=0.31.  
Interpretability: N = 17-21 in analyses. Missing data: NS. Mean(SD) baseline scores: 1: Treated > 12 / <12 weeks: 67.8(20.5)/58.2(16.6). MID (improve) 
/(deterioration) -11.76(25.06)/-2.86(18.88). Effect size: -0.50, SRM: -0.55. Time frame (responsiveness): up to 52 weeks.  Floor/ceiling effect: NS 
PGA by VAS Norw[45]        MCII, PASS 
Interpretability: N = 1391. No. of PsA in the analysis: n = 847. Missing data: Reported for each study part. Mean(SD) score: 48.4(22.2) at baseline and 
35.0(22.6) after 3 months. The anchoring questions were given after 3 months and asked about satisfaction (PASS) and improvement (MCII), 
respectively. PASS cut-points (ROC curves): 75% sensitivity cut-off: 35, 80% specificity cut-off: 25. AUC(95%CI): 0.78(0.75-0.81). MCII Cut-points (ROC 
curves): 75% sensitivity cut-off: -8.00, 80% specificity cut-off: -19.0 AUC(95%CI): 0.75(0.72-0.79). 
PGA by VAS Ital[63]      Fair/+     
Results: Box F: Correlations between PGA and different measures of disease activity reported but a priori hypotheses were very sparse. PGA had 
moderate to high correlation with composite disease activity measures and PhGA, and less correlation to unrelated measures like CRP. Good 
concordance between MDA and PGA<20 mm during follow up (kappa=0.72-0.74) Interpretability: N = 124 (minimum n = 75). Median(IQR) score at 
baseline: 59(45-70).  Floor/ceiling effect: NS  
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Table D continued     
 
Identified PROMs listed 
according to Domain 
category 
Reliability 
 COSMIN BOX (A-C) 
Validity 
 COSMIN BOX (D-H) 
Responsiveness 
COSMIN BOX: I 
 
 
 (I) 
Relevant 
info on 
score in-
terpre-
tation 
Internal 
consistency 
(A) 
Reliability 
 
(B) 
Measure-
ment error 
(C) 
Content 
validity 
(D) 
Structural 
validity 
(E) 
Hypothe-
ses testing 
(F) 
Cross-cult. 
validity 
(G) 
Criterion 
validity 
(H) 
PHYSICAL FUNCTION A B C D E F G H I  
DFI Chin[34] Good/-    Good/- Poor/?    F/C 
Results: Box A,E: Rasch: Item-trait chi2 statistics: 35.7(df40, p=0.66). Person reliability: 0.85. Item separation: 3.83. Eight items showed misfit to the 
Rasch model.  PCA: No evidence of a 2nd factor. Variance explained: 76%.  DIF (sex) for 1 item and DIF (± sacroiliitis) for 1 item. Box F: No hypotheses or 
information about properties of comparators. Moderate/strong correlations with HAQ, PGA, pain (r= 0.44-0.76).   
Interpretability: N = 108. Missing data: NS. Mean(SD) score: 6.28(7.08). Floor effect: 31.1%.  
DASH Eng[29]      Good/-     
Results: Box E:  Hypotheses not convincingly fulfilled (<75%): Correlation to measures of inflammatory joint count in upper extremity (Rs = 0.65), but 
not to measures of physical function (Grip strength, ACR functional class) or to measures of upper extremity damage.   
Interpretability: N = 50. Missing data: NS. Mean(SD) score: 27.5(24.6), Median(range) score:20.8(24-80.3). Floor/ceiling effect: NS 
BASFI Chin[34] Good/+    Good/+ Poor/?    F/C 
Results: Box A,E: Rasch:  Item-trait chi2 statistics:  27.8(df 20, p=0.11). Person reliability: 0.83. Item separation: 3.33. INFIT/OUTFIT values between 0.7-
1.3. PCA:  PCA: No evidence of a second factor. Variance explained: 78%. No DIF for sex, 1 item with DIF for ± sacroiliitis). Box F:  No hypotheses or 
information about properties of comparators. Moderate/strong correlation with HAQ (r = 0.81), Pain (r = 0.52) and PGA (r = 0.49).  
Interpretability: N = 108. Missing data: NS. Mean(SD) score: 24.41(22.93).  Floor effect 18.5% 
HAQ-DI Eng[22]      Fair/-     
Results: Box F: Vague hypotheses and sparse information about measurement properties of comparators. Less than 75% of hypotheses were fulfilled. 
Confirmed moderate/strong correlation to other measures of function (ACR functional class (r= -0.59(95%CI: -0.46 to -0.7)), Grip strength -0.63(-0.50 to 
0.73)) and to measures of disease activity (Active joint count (r= 0.49(0.49 to 0.62)) and tender points (r = 0.54(0.40 to 0.66). Low correlation to other 
measures of disease activity/severity (effusion, stiffness, ERS, PASI) and to damage (ARA anatomic stage, damaged joint count). Moderate/strong 
correlation between HAQ VAS pain score and tender points, function, stiffness and active joint count. Multivariable regression identified 4 variables to 
influence on HAQ: Grip strength, ACR functional class, tender points and ESR.  
Interpretability:  N = 99-114. Missing data: 13% (excl). Mean(SD),range score: 0.50(0.58), 0.00-2.00. Mean(SD) SpA vs not SpA: 0.61(0.64) vs 0.49(0.56)) 
(p=0.26) and for Fibromyalgia vs no Fibromyalgia:  1.32(0.49) vs 0.42(0.52).  Floor/ceiling effect: NS 
HAQ-DI Eng[28] Poor/?        Poor/?  
Results: Box A: Unidimensionality not checked. Cronbach-α = 0.80-0.91. Box I: Responsiveness is tested in different ways but no evidence for 
responsiveness was achieved (small sample size of subanalysis and or insufficient methods applied).   
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Interpretability:  N = 70. Missing data: 12% (excl.) Time frame (responsiveness): 12-18 months. Mean(SD) score: T1/T2: HAQ-DI 0.49(0.54)/ 0.46(0.58). 
Floor/ceiling effect: NS 
HAQ-DI Eng[33] Good/+    Good/+     F/C 
Results: Box A,E: Rasch: Good overall model fit.  Person reliability: 0.75. Item separation: 2.06 logits. Misfit for the “Activity” item; INFIT MNSQ 1.58).    
Interpretability:  N = 134 (PsA). Missing data: NS. Mean(SD) score: 0.5(0.59).  Floor effect: 30.4%. (DIF reported for PsA vs RA) 
HAQ-DI Eng[43]          MID 
Interpretability: N = 200. Missing data: NS. Mean(SD) scores: 1st visit: 0.732(0.677), 2nd visit 0.711(0.707). Varying time interval (mean: 8.28 months 
between visits). MID(SD) estimates for much improvement/much worsening: -0.362(0.432)/0.438(0.315). Correlation between mean change in HAQ 
and anchor (patient reported level of change): rs= 0.374 (the authors did not aim to test responsiveness of HAQ, only MID).  Floor/ceiling effect: NS 
HAQ-DI Eng[51]          MID 
Interpretability: N = 161. Missing data: NS. Mean(range)score: 1.16(0.13-2.88) at baseline. MID: 0.35. Minimal very important change: 0.45.  
Floor/Ceiling effect: NS 
HAQ-DI Ital[27]      Fair/-     
Results:  No information about measurement properties of comparators. Hypotheses regarding high correlations (r>0.40) between HAQ scores and 
clinical measures of disease activity and disease severity were not sufficiently proven (less than 75%), the only moderate/strong correlations were 
between global HAQ and 1) duration of axial morning stiffness (r = 0.72) and 2) joint pain (r = 0.49).   
Interpretability:  N = 72. Missing data: NS. Mean(SD) of the 8 area scores ranging between 0.82(0.79) (grip) to 1.15(0.95) (reach). Linearly transformed 
(0-100) global HAQ score mean(SD): 28.3(21.1).  Floor/ceiling effect: NS 
HAQ-DI Chin[34] Good/+    Good/+ Poor/?    F/C 
Results: Box A,E: Rasch: Item-trait chi2 statistics: 17.4(df 16, p=0.36). Person reliability 0.84. Item separation index 2.22. INFIT/OUTFIT values in the 
accepted interval (0.7-1.3) except for two items: 1) Dressing/grooming; OUTFIT 1.16. 2) Grip; OUTFIT 1.40, INFIT 1.41. HAQ limited by short item span 
(5.63 logits). PCA: No evidence of a second factor. Variance explained: 68%. DIF for item “Grip” according to sex. Box F: No hypotheses or information 
about properties of comparators. HAQ showed moderate/strong correlation to PGA (rs = 0.54), Pain score (rs = 0.56), TJC (rs= 043) and BASFI (rs=0.81), 
Dougados-FI (rs=0.76) and SF-36 PF (rs=0.80).   
Interpretability:  N = 108. Missing data: NS. Mean(SD) score: 0.69(0.67). Floor effect: 24.5%. 
HAQ-DI Hung[42]      Fair/+     
Results: Box F: Sparse information about measurement properties of comparators. HAQ correlated to moderately/strongly to related measures: 
BASDAI (rs = 0.59), PsAQoL (rs = 0.64), PGA (rs = 0.50), Pain score (rs = 0.54). Known-group validity: Higher HAQ scores for patients with worse disease 
states. SRM (0.41-1.54).   
Interpretability: N = 183. Missing data: 6%.(excl.). Mean(SD) score: 1.0(0.7), median(range): 0.88 (0-3). Floor/ceiling effect: NS. 
HAQ-DI Chin[50]         Poor/? MID 
Results: Box I: Small sample size. Correlation between anchor (patient perception of change) and change in HAQ: rs=0.30.  
Interpretability: N = 17-21 in analyses. Missing data: NS. Mean(SD)scores: a) Patients treated > 12 weeks: 1.16(0.59) and b) Patients treated <12 weeks: 
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1.02(0.68).  Time frame (responsiveness): 52 weeks. MID for improvement: -0.27(0.06). MID for deterioration: 0.095(0.18). ES: -0.22, SRM: -0.22. 
Floor/ceiling effect: NS 
HAQ-DI Thai.[60] Poor/?     Fair/+    F/C 
Results: Box A: Unidimensionality not checked. Cronbach-α = 0.88. Box F: Sparse information about measurement properties of comparators. 
Hypothesis concerning strong correlation to BASDAI was fulfilled (r = 0.81). Moderate-strong correlation to other measures (PGA, pain, ERS, ASDAS). 
Interpretability: N = 47. Missing data: NS. Mean(SD) score: 0.47(0.47), median(range): 0.25(0-1.63). Floor effect: ~50% 
HAQ-S Eng[22]      Fair/-     
Results: Box F:  Vague hypotheses and sparse information about measurement properties of comparators. High correlation (r>0.40) between the SpA 
scales (SPAR scales) of the HAQ-S and measures of spinal involvement (Finger-floor distance, chest expansion) was hypothesized but not sufficiently 
confirmed (r<0.25). No significant difference in HAQ-S scores between PsA patients with/without axial disease.   
Interpretability: N = 99-114. Missing data: 13% (excl.). Mean(SD)/range score: 0.53(0.57)/ 0.00-2.00. Mean(SD) scores for SpA vs non-SpA: 0.63(0.61) vs 
0.43(0.51) and for Fibromyalgia vs not fibromyalgia:  1.30(0.50) vs 0.42(0.48).  Floor/ceiling effect: NS 
HAQ-SK Eng[23]      Poor/?     
Results: Box F: No hypotheses and no information about measurement properties of comparators. Poor correlations (r<0.5) between original HAQ-DI 
and new HAQ skin scales as well as between the new HAQ-skin scales and PASI. 
Interpretability: N= 114. Missing data: 3%(excl). Mean(SD) score: HAQ: 0.55(0.60), HAQ-SK: 0.56(0.58). Skin-Scale: 0.60(0.77). Floor/ceiling effect:NS 
mHAQ Norw[45]         PASS,MCII 
Interpretability: N = 1391. No. of PsA in the analysis: n = 845. Missing data: Reported for each part of the study. Mean(SD) scores: 1st visit: 0.63(0.44), 
after 3 months: 0.47(0.42). The anchoring questions were given after 3 months and asked about satisfaction (PASS) and improvement (MCII), 
respectively PASS Cut-points (ROC curves): 75% sensitivity cut-off: 0.50. 80% specificity cut-off: 0.14. AUC 0.75(95%CI 0.71-0.78). MCII Cut-points (ROC 
curves): 75% sensitivity cut-off: 0 80% specificity cut-off: -0.25. AUC(95%CI): 0.75(0.72-0.78). 
SF-36 PF Eng[33] Good/+    Good/+     F/C 
Results: Box A,E: Rasch: Good model fit, item separation 9.12 logits. No misfitting items.  
Interpretability:  N = 134 (PsA). Missing data: NS. Mean(SD) score: 60.4(27.1). Floor effect 3.1%. 
SF-36 PF Chin[34] Good/+    Good/+ Poor/?    F/C 
Results:  Box A,E: Rasch:  item-trait chi2 statistics: 24.3(df 20, p=0.23). Person reliability: 0.85. Item separation: 6.99.  INFIT/OUTFIT values between 0.7-
1.3. PCA:  No 2nd factor. Variance explained: 89%. No DIF (gender or ± sacroiliitis). Box F:  No hypotheses or information about properties of 
comparators. Moderate/strong correlation with HAQ (r= -0.80), PGA (r= -0.44) and VAS pain (r= -0.49). 
Interpretability: N = 108. Missing data: NS.  Mean(SD) score: 63.33(25.5). Floor effect (Max score): 7.4%.  
SF-36 PF Eng[26] Poor/?     Fair/+     
Results: Box A: Limited information on unidimensionality. Cronbachα 0.92. Box F: Convergent validity confirmed with 6/7 hypotheses fulfilled. 
Moderate-strong correlation with measures of function, disease activity and severity. Known group validity: Significant difference in scores compared 
to general population (but no hypotheses about expected magnitude of difference etc.) 
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Interpretability: N=113. Missing data: NS (all completed) Mean(SD) scale score: 68.8(2.65). Floor/Ceiling effect: NS  
SF-36 PF Eng[28] Poor/?        Poor/?  
Results: BOX A: Unidimensionality not checked/reported. Cronbach α (0.80-0.91), no exact value was reported.  Box I:  Responsiveness is tested in 
different ways but no evidence for was achieved (small sample size of subanalysis/insufficient methods applied).  Interpretability: N=70, Missing data: 
12.5% (excl.). Mean(SD) score at baseline/follow-up: 70.07(25.63)/72.27(26.55). Floor/ceiling: NS.  
SF-36 PF Chin[40] Poor/?     Good/+     
Results: Box A: Not sufficient reporting on unidimensionality. Cronbach α 0.913. Box F: Convergent validity (internal relationships): Scaling assumption 
(equal item variance, item-own scale, item-other scale) in consistency with hypotheses but for known group validity (external relationships) the 
hypotheses were vaguely stated.  
Interpretability:  N=168. Missing data: NS. Mean(SD) scale score: 65.5(25.3). Floor effect: 1.8%, Ceiling effect: 7.7%.  
SF-36 PF Chin[50]         Poor/? MID 
Results: Box I: Small sample size. Correlation between anchor (patient perception of change) and change in SF-36PF score: rs= -0.34.  
Interpretability: N = 17-21 in analyses. Missing data: NS. Mean(SD) baseline scores: 1: Patients treated > 12 weeks: 51.5 (23.5) and 2) Patients treated 
<12 weeks: 57.7(21.8). MID for improvement: 4.41(14.99). MID for deterioration: -6.25(18.77). Effect size: 0.35, SRM: 0.37. Time frame 
(responsiveness): up to 52 weeks.  Floor/ceiling effect: NS 
SF-36 PCS Chin[40]     Good/+ Poor/?     
Results: Box E: Structural validity assessed by PCA, and a 2 factor model was supported, explaining 69.4% of the total variance. Box F: Only known 
group validity (general population vs. PsA) and no exact hypotheses stated a priori.  
Interpretability: N=168. Missing data: NS. Mean(SD) component summary score: 31.6(14.19) 
SF-36 PCS Chin[50]                     Poor/? MID 
Results: Box I: Small sample size. Correlation between anchor (patient perception of change) and change in SF-36 PCS: rs= -0.43.  
Interpretability: N = 17-21 in analyses. Missing data: NS. Mean(SD) baseline scores: 1: Patients treated > 12 weeks: 22.3 (7.6) and 2) Patients treated 
<12 weeks: 28.0(9.3). MID for improvement: 3.74(8.51). MID for deterioration: -3.97(10.46). Effect size: 0.49, SRM: 0.55. Time frame (responsiveness): 
up to 52 weeks.  Floor/ceiling effect: NS 
CIAQ-FI Eng[44]  Poor/?  Poor/?  Poor/?    
Results: Box B: Test retest Reliability ICC 0.912 (0.894-0.931) but number of patients (total and %PsA) in analysis not stated. Box: D: Not enough 
information available for rating the quality of content validity assessment or results. Box F: Sparse hypotheses and no information about properties of 
comparators.  Most correlations reported for a mixed population (PsA<50%), for the PsA subset, the correlation between CIAQ-FI and HAQ was r = 
0.927. The correlation between CIAQ-FI and PR-TJC: r=0.605 for the PsA subset (n=57).   
Interpretability: Total N = 462 (PsA 123, 26.6%). Number of PsA patients not reported for all analyses.  
Missing data: NS. Mean(SD) scores (baseline, PsA =26.6%) CASQ-F1 2.20 (0.7). Time frame test-retest: 1 week. Floor/ceiling effect: NS.   
Table D continued     
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PHYSICAL FUNCTION A B C D E F G H I  
AIMS1 Mobility Eng [21]     Fair/-     
Results: Box H: Sparse information about properties of comparators. Less than 75% of hypotheses about correlation to measures of function, disease 
activity and severity were confirmed. 
Interpretability: N=145. Missing data: NS. Mean(SD) score: 0.5(1.1). Floor/ceiling effect: NS 
AIMS1 Physical Eng[21]     Fair/+     
Results: Box H: Sparse information about properties of comparators. Hypotheses about correlation to measures of function, disease activity and 
severity were sufficiently confirmed. 
Interpretability: N=145. Missing data: NS. Mean(SD) score: 3.8(1.5).  Floor/ceiling effect: NS 
AIMS1 Dexterity Eng[21]     Fair/+     
Results: Box H: Sparse information about properties of comparators. Hypotheses about correlation to measures of function, disease activity and 
severity were sufficiently confirmed. 
Interpretability: N=145. Missing data: NS. Mean(SD) score: 2.6(1.7).  Floor/ceiling effect: NS 
AIMS1 Household Eng[21]     Fair/+     
Results: Box H: Sparse information about properties of comparators. Hypotheses about correlation to measures of function, disease activity and 
severity were sufficiently confirmed. 
Interpretability: N=145. Missing data: NS. Mean(SD) score: 0.9(0.7).  Floor/ceiling effect: NS 
AIMS1 ADL Eng[21]      Fair/-     
Results: Box H: Sparse information about properties of comparators. Less than 75% of hypotheses about correlation to measures of function, disease 
activity and severity were confirmed. 
Interpretability: N=145. Missing data: NS. Mean(SD) score: 0.3(0.7).  Floor/ceiling effect: NS 
AIMS1 Physical Component Eng[25]        Poor/?  
Results: Box I: No hypotheses and different versions of AIMS used at baseline and follow-up (AIMS 1 and AIMS 2), no correlation between AIMS change 
scores and change scores of clinical measures reported. 
Interpretability: N= 65. Missing data: NS. Mean(SD) score Physical: 1.47(1.64). Floor/Ceiling. NS   
AIMS1 Physical Ital[27]     Fair/-     
Results:  Sparse information on properties of comparators. Seems that hypotheses only concerned 1 of the function scales (the physical activity scale) and 
hypotheses were not convincingly fulfilled (less than 75%). A “close” correlation between AIMS physical function scale and disease activity measures was 
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expected but the majority of correlations presented was with Pearson's r <0.4.  
Interpretability: N=72. Missing data: NS.  mean(SD) score: 5.97(3.1). Floor/ceiling effect: NS 
AIMS2  Physical Component[25]        Poor/?  
Results: Box I: No hypotheses and different versions of AIMS used at baseline and follow-up (AIMS 1 and AIMS 2), no correlation between AIMS change 
scores and change scores of clinical measures reported. 
Interpretability: N= 65. Missing data: NS. Mean(SD) score Physical:  1.37(1.36)Floor/Ceiling. NS   
AIMS2 Physical Component Eng[28]        Poor/?  
Results: Box I: Responsiveness is tested in different ways but no evidence for responsiveness was achieved (small sample size of subanalysis and or 
insufficient methods applied).   
Interpretability: N= 70. Missing data: 12.5% (excl.) Mean(SD), range:  Baseline: 1.04(1.20), 0.00-5.42, follow-up: 1.29(1.53), 0.00-5.35.  
AIMS2 Mobility Eng[24]      Fair/+     
Results: Box F: Hypotheses about correlation to measures of disease activity and function sufficiently fulfilled.   
Interpretability: N=124. Missing data: NS. Mean(SD) scores 1.21(1.68), range 0-7. Floor/ceiling: NS 
AIMS2 Physical Eng[24]      Fair/+     
Results: Box F: Hypotheses about correlation to measures of disease activity and function sufficiently fulfilled.   
Interpretability: N=124. Missing data: NS. Mean(SD) scores 3.04(2.77), range 0-10. Floor/ceiling: NS 
AIMS2 Dexterity Eng[24]     Fair/+     
Results: Box F: Hypotheses about correlation to measures of disease activity and function sufficiently fulfilled.   
Interpretability: N=124. Missing data: NS. Mean(SD) scores 1.58(1.97), range 0-8.5. Floor/ceiling: NS 
AIMS2 Selfcare Eng[24]      Fair/-     
Results: Box F: Hypotheses about correlation to measures of disease activity, disease severity and function not fulfilled.   
Interpretability: N=124. Missing data: NS. Mean(SD) 0.60(1.90), 0-10 
AIMS2 Household Eng[24]     Fair/-     
Results: Box F: Hypotheses about correlation to measures of disease activity, severity and function sufficiently fulfilled.   
Interpretability: N=124. Missing data: NS. Mean(SD) scores 0.52(1.05), range 0-6.25. Floor/ceiling: NS 
AIMS2 Arm Function Eng[24]     Fair/+     
Results: Box F: Hypotheses about correlation to measures of disease activity and function sufficiently fulfilled.   
Interpretability: N=124. Missing data: NS. Mean(SD) scores 0.70(1.20), range 0-5.5. Floor/ceiling: NS 
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(I) 
HRQoL/Disease impact A B C D E F G H I  
PsAQoL Eng[30] Good/+ Fair/?                 Excellent/+ Good/+ Fair/+     
Results: Box A, E: Unidimensionality checked, Cronbach-α = 0.91.  Rasch:  Item trait interaction Chi2: 96.1 (df=80; p=0.106), overall item fit mean(SD): 
0.183(1.115), person fit mean(SD): 20.232(0.807). Person separation index of 0.922.  Box B: Reliability only reported by Spearman correlation (not 
considering systemic error). Box D:  PsAQoL was developed by qualitative interviews with PsA patients and modified to obtain relevance, 
comprehensiveness and interpretability/feasibility. Box F: Vague hypotheses. Statistical methods used for correlation analyses were not reported, but 
moderate/high correlations to related measures (Nottingham Health Profile scale scores (r = 0.52-0.75), overall health VAS (r = 0.64) and quality of life 
VAS (r = 0.65)) were reported. Known group validity: Significant differences in PsAQoL scores according to disease severity level and perceived current 
health status.  
Interpretability: N = 211-286. Missing data: Excluded (8% for 2nd survey). Median(IRQ);range score: 9(5-13);0-20. Time frame (test-retest): 
approximately 2 weeks (not clearly stated). Floor/ceiling effect: NS. 
PsAQoL Eng[35]      Poor/?   Poor/?  
Results: Box F: No hypotheses and small sample size (<30).  Moderate/high baseline correlation to HAQ (rs = 0.69), PGA (rs = 0.44) and low correlation 
to (PhGA, TJC, SJC, DAS28 and PASI (all rs < 0.3). The correlation between PsAqoL and other measures were more pronounced at follow up visits (e.g., 
at 3 months, correlations to HAQ, PGA, DAS28, PhGA were all rs >0.46).  Box I: Small sample and no hypotheses. No correlations between change 
scores reported.  SRM at 3 months: 0.71 and at 6 months: 0.41.  
Interpretability: N = 28. Missing data: NS. Mean(SD) scores: 13.46(5.15) at baseline, 10.67(6.32) after 3 months and 10.5(6.92) after 6 months. Time 
frame (responsiveness): 6 months. Floor/ceiling effect: NS.  
PsAQoL Eng/Chin[71] Poor/? Fair/+  Poor/?  Fair/+     Fair  
Results:  No information on unidimensionality, Cronbach alpha = 0.92. Box B: Test-retest reliability, ICC = 0.92. Box D: Too sparse information on 
content validity in the result section (e.g., unknown comprehensiveness). Box F: Vague hypotheses. Moderate-high correlation between PsAQoL and 
pain, PGA, PhGA, SF-36 subscales and summary scores, CPDAI. Known group proven by greater PsAQoL scores in patients poorer physical health, 
higher disease activity state (CPDAI, MDA).  Box G: No cross-cultural validation performed, translation described.  
Interpretability: N=98 (67% Eng, 33% Chin), Missing data: NS. Mean(SD) scores at baseline: 4.5(5.2). Time frame (reliability) 2 weeks. Floor/Ceiling: NS 
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COSMIN BOX A B C D E F G H   I              
PsAQoL Swe[41] Good/+ Poor/?  Good/+  Fair/+ Fair   F/C 
Results: Box A: Cronbach-α = 0.91 and authors refer to another study reporting on unidimensionality. Box B: No reliability results reported. Box D: 
Comprehensiveness and relevance assessed and confirmed. Box F: Sparse information about information about measurement properties of 
comparators.  Moderate/high correlation to related measures (NHP scales: rs = 0.53-0.80, NHPD:  rs =0.87) and known group validity according to PGA 
and flare-status, all in accordance with hypotheses. Box G: No cross-cultural validity assessment only translation. Only forward translation.  
Interpretability: N = 123. Missing data: 6-33% missing responses (excl.). Mean(SD) scores: 5.8(5.2).  Floor effect: 19%, Ceiling effect 0%. 
PsAQoL Hung[42]      Fair/+     
Results: Box F: Sparse a priori hypotheses and information about measurement properties of comparators. Moderate to high correlations to HAQ (rs = 
0.64), BASDAI (rs=0.62), PGA (rs=0.52), VAS pain (rs=0.54). Known group validity: Higher scores for patients with more severe disease level, SRM (0.53 
to 1.70). 
Interpretability: N = 183. Missing data: 3% (excl.).  Mean(SD) score: 7.7(6.0). Median(range) score: 7.0(0-20). Floor/ceiling effect: NS. 
PsAQoL Dutch[55] Poor/? Good/+ Good/? Good/-  Fair/+ Fair    
Results: Box A: Unidimensionality not checked.  Cronbach α = 0.92.  Box B: rs  = 0.89 (95%CI 0.85-0.92) and Bland-Altman analysis demonstrating no 
systematic error between the administration. Box C: LoA between -5.3 and 5.1 (out of 20) but MIC not defined. Box D: 50% of patients reported that 
items were missing. Box F: Correlation to (somehow) related measures as expected (HAQ (rs = 0.72), Skin-17 Psychosocial scale (rs =0.40) and Skin-17 
Symptom scale (rs=0.46)). Known group validity: Higher scores for patients with worse PGA and higher disease activity. Box G: Only translation, no 
cross-cultural validity assessment. Only forward translation.  
Interpretability: N = 211 (134 for test-retest, 175 for internal consistency, 156 for convergent validity). Missing data: Reported (excl.) Median(range) 
score: 5.00(0-20). Time frame (test-retest): 2 weeks. Floor/ceiling effect: NS 
AIMS global score Ita.[27]     Poor/?     
Results: Box F:  No hypotheses for the global AIMS scale. Sparse information about measurement properties of comparators AIMS global score was 
related to various measures of function and disease activity, the only strong correlations found were between AIMS global score and 1) morning 
stiffness of axial joints (r=0.63) and VAS pain (r=0.64).   
Interpretability: N = 72. Missing data: NS, Mean(SD) scale scores : NS. Floor/ceiling effect: NS.  
PSAID-9 Eng[58] note Good/+    Fair/+ Good  Poor/? PASS,F/C 
Results: Box A: : Cronbach-α = 0.93 but unidimensionality not reported. According to the authors PsAID is based on a formative model and therefore 
the internal consistency is not rated. Box B: Test –retest ICC (95%CI) = 0.94(0.91-0.96). Box F: Hypotheses were vaguely stated. High/moderate 
correlations (rs= 0.408-0.845) with related measures (PGA, pain, HAQ, DLQI, SF-36 component summary scores, EQ-5D, DAS28). Box G: No cross-
cultural validation, only translation.  Box I: No hypotheses or change score correlations provided. Patients with self-reported improvement were 
included in the analyses and SRM was 0.90 (95% CI 0.88 to 0.92).     
Interpretability: N = 439 (in the validation part). Missing data: 1% (excl.). Mean scores: NS. PSAID PASS cut-off: 4. Time frame for test-retest:  2–10 
days, and for responsiveness: 10–16 weeks.    
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COSMIN BOX A B C D E F G H   I             
PsAID-12 Eng[58] note Good/+    Fair/+ Good  Poor/? PASS,F/C 
Results: Box A: Cronbach-α = 0.94 but unidimensionality not checked. According to the authors PsAID is based on a formative model and therefore 
the internal consistency is not rated. Box B:  ICC(95%CI) = 0.95(0.92-0.96). Box F: Hypotheses were vaguely stated. High/moderate correlations (rs = 
0.422-0.843) with related measures (PGA, pain, HAQ, DLQI, SF-36 component summary scores, EQ-5D, DAS28). Box G: No cross-cultural validation, 
only translation. Box I: No hypotheses about the expected SRM for the correlations or change score correlations provided.  In patients who reported 
improvement after treatment, the SRM was 0.91 (95% CI 0.89 to 0.93).    
Interpretability: N = 439 (in the validation part). Missing data: 1% (excl.). Mean scores: NS. PSAID Patient Acceptable symptom state cut-off: 4. Time 
frame for test-retest:  2–10 days, and for responsiveness: 10–16 weeks.   Floor/ceiling effect: <1%   
PsAID-9/12[68]    Excellent/+      
Results: This paper is an elaboration of the PsAID development paper by Gossec et al (above). A further description of the involvement of patient 
partners in the development of PsAID is given providing strong evidence for content validity of the questionnaire.   
PsAID-12touch Ital[72]      Fair/+  Fair/+                   MDA cut-off 
Results: Box F: Hypotheses and (psychometric) information on all comparators not thoroughly described. Convergent and know group validity 
examined, and expected relations stated a priori. PsAID-12 touch version correlated acceptably with PASDAS, DAPSA, HAQ and PhGA (rs= 0.63-0.67), 
and the ability of PsAID-12 touch to discriminate between known groups (disease activity) was comparable to other measures of disease activity and 
function with ROC AUC (95% CI) =0.937 (0.898-0.975). Box H: The touch version of PsAID was compared to the original paper PsAID version (gold 
standard) and ICC for items were all >0.80. Mean difference (limit of agreement): 022(-0.60 to 1.04) by Bland Altman plot. For both boxes, 
information on handling of missing items/data was not clearly reported.  
Interpretability: N=159. Missing data: NS. Median(SD) scores of paper vs touch version: 3.60(1.96-4.78) vs 3.17(1.93-4.54).   
 PsAID-12 touch version cut-off value for MDA: 2.5. Floor/ceiling effect: NS. Mean(SD) time of completing touch vs paper version: 1.7(2.21) vs 
2.25(2.88).   
PsAID-12 Ital[73].       Note    Note Fair/+   Cut-offs 
Results: Box F: Sparse hypotheses, convergent and known-group validity confirmed as PsAID-12 correlated well with cDAPSA, DAPSA, DLQI, PGA (rs 
0.489-0.867), and PsAID scores were increased in groups with higher compared to lower disease activity measured by cDAPSA. Box A, E: Internal 
consistency and structural validity were assessed in the study (the factor analysis found a 2-factor structure of PsAID (“symptoms” and “skin”)) but 
these properties were not rated because PsAID is based on a formative rather than reflective model. 
Interpretability: N=144. Missing data: NS. PsAID median scores in categories defined by cDAPSA disease state: Remission (REM): 0.5, Low disease 
activity (LDA) 2.6, Moderate disease activity (MoDA); 6.2, High disease activity (HAD): 7.3. Cut-off values defined:  REM≤1.4, LDA (>1.4 to ≤4.1), MoDA 
(> 4.1 to ≤6.7), HAD (>6.7).  
PAIP Ital[56]      Poor/?     
Results: Box F: No hypotheses stated a priori, sparse information on comparators. Moderate/high correlation (r>0.5) between PAIP subscales and 
presumably related measures (MOS-SF-36 subscales, McGill Pain Questionnaire subscales, Zeung Self-rating depression/anxiety scales).   
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Interpretability: N = 123 (PsA: n = 82). Missing data: NS. Mean(SD) scores: NS. Floor/ceiling effect: NS.  Floor/ceiling effect: <1%   
VITACORA-19 Span[59] Fair/+ Good/+  Good/+ Fair/+ Fair/+   Poor/? MCID,F/C 
Results: Box A,E: Unidimensionality checked. Cronbach-α = 0.95.  PCA: 1 factor explaining 55.8% of the observed variance. Box B:  ICC= 0.94. Box D: 
Relevance and comprehensiveness assessed. Box F:  Sparse information about measurement properties of comparators and vague hypotheses. 
Moderate/high correlation to EQ-5D VAS (r = 0.493), PhGA (r = 0.566), BSA (r=-0.664), DAS28 (r = 0.423).  Known group validity: Differences in scores 
between PsA patients and healthy controls. Box I:  No hypotheses, poor description of comparators and their measurement properties and no exact 
results provided (only reporting correlation between change scores: r<0.7). Effect size (0.2-0.8) for patients who experienced at least a small 
improvement in global health from 0-6 months. 
Interpretability: N = 209 PsA (n = 97 in test-retest). Missing data: Provided for each analysis (excl.). Mean(SD) score: 56.24(24.8).  MCID: 8 point.  Time 
frame test-retest: 10 days, responsiveness: 6 months. Floor, Ceiling effects: <1%.  
VITACORA-19 Turk.[69] Poor/? Fair/+   Poor/? Fair/+ Fair/    
Results: Box A: Factor analysis performed but sample size insufficient (n=61). Cronbach-α = 0.96. Box B: Test-retest with ICC reported for each item 
(0.77-0.98). No evidence that patients were stable in the interim period and no description of missing data. Box E: Sample too small for factor 
analysis. Box F: Hypotheses were vague but correlation to HAQ (-0.60), Nottingham Health Profile items (-0.54 to -0.72) and to VAS Pain (-0.43). Box 
G: Translation, no cross-cultural validation only translation.  
Interpretability:  N=61. Missing data: NS. Mean(SD) scores: 66.9(20.2). Time frame test-retest: 10-15 days.  Floor/Ceiling effect: NS   
PsoDisk Ital[62]         Poor/?  
Results: Box I: Small sample size, sparse hypotheses and no information about measurement properties of comparators. High correlation (r = 0.97) to 
PASI (measure of skin disease activity)  
Interpretability: N = 19. Missing data: NS. Mean(SD) scores at baseline ranging from 4.10(3.40) (for sleep) to 7.13(3.35) for skin involvement. PsoDisk 
change scores for each items reported at different time points showing significant difference from baseline.  Time frame (responsiveness): 48 weeks. 
Floor/ceiling effect: NS.  
CIAQ-QoL Eng[44]  Poor/?  Poor/?  Poor/?     
Results: Box B:  Test-retest: Number and % PsA patients in analysis was not specified. ICC(95%CI) 0.912(0.894-0.931). Box D: Not enough information 
to score quality or result regarding content validity. Box F:  Sparse hypotheses and no information about measurement properties of comparators and 
not stated how many PsA was included, except for correlation between CIAQ-QoL and PR-TJC (r=0.08) for PsA subset (n=57). 
Interpretability: Total N = 462 (PsA 123, 26.6%). Missing data: NS. Number of PsA patients not reported for all analyses. Mean(SD) baseline score: 
2.13 (0.9). Test-retest time interval: 1 week. Floor/ceiling effect: NS.  
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HRQoL/MULTIDIM. A B C D E F G H I  
WTP Eng[46]    Poor/?  Fair/+     
Results: (Pilot study). Box D: Content validity of the tool was reviewed by rheumatologists not PsA patients during the development phase. The 
proportion of patients confirming an impact of PsA on these domains varied between 35%-88%.  Box F:  Correlation between median WTP amounts 
were higher between related than non-related domains. However, one of the 4 domains that patients ranked as most impacted by PsA was 
associated with a lower WTP amount than some domains ranked at less impacted by PsA.  
Interpretability: N = 60. Missing data: NS.  Median(IQR) scores of WTP for relief of the 8 domains: Lowest WTP amount (concentration): 7500(1000-
50,000), highest WTP amount (Physical comfort, Sleep, work): 10,000(5000-75,000).   
IPBOD Eng[74] Poor/?   Poor/?  Poor/?     
Results: Box A: Unidimensionality not assessed and small sample size. IPBOD may be based on a formative rather than reflective model why the 
assessment of internal consistency may be irrelevant. Box D: Not enough information available. Box F: Sparse hypotheses and information on 
comparator properties. Small sample size. Moderate correlation between total IPBOD and DLQI scores (rs = 0.65) and similar correlation between 
“subscales” of IPBOD and related dimensions of DLQI 
Interpretability:  N=16. Missing data: 6% (excl.). Mean(SD) score: 4.9. Floor/ceiling effects: NS.   
FATIGUE A B C D E F G H I  
FACIT-Fatigue Eng[32] Poor/? Fair/+    Fair/+     
Results: Box A:  Unidimensionality not checked. Cronbach-α = 0.96. Box B: ICC = 0.95. Box F: Vague hypotheses. High correlation to related measures 
(mFSS score r= -0.79) and less to unrelated measures. Known group validity: Differences in scores between patients with vs. without overwhelming 
fatigue and between patients with PsA vs. general population).  
Interpretability: N = 135 (test retest: n = 73). Missing data: NS. Mean(SD) score: 35.8(12.4). Time frame (test-retest): 1 week. Floor/ceiling effect: NS.  
NRS fatigue Eng[38]      Poor/?   Poor/?  
Results: Box F: No a priori hypotheses. Correlation with related measures (GH, VAS pain, HAQ: r= 0.47-0.54). Regression analysis: At baseline and (3 
months) GH, HAQ and pain explained 29% (38%); 23% (30%); and 22% (28%) of the variance in NRS fatigue scores, respectively. 
Box I:  SRM and Effect size for the fatigue score and other measures shown only by box plots (no exact values provided). Correlation with other 
change scores not assessed and no hypotheses formulated.  
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Interpretability: N = 41. Missing data: NS. Mean(SD) scores: 5.71(2.32) at baseline and 3.96(2.06) after 3 months. Time frame (responsiveness): 3 
months. Floor/ceiling effect: NS. 
NRS fatigue Eng[44]  Poor/?  Poor/?  Poor/?     
Results:  Box B: ICC (95%CI) = 0.85(0.83-0.87) but not stated how many patients (and % PsA) included. Box D: Not enough information to rate quality 
or results on content validity. Box F: No hypotheses or information about properties of comparators, PsA < 50% of the population in most of the 
analyses. Correlation between patient-reported TJC and Fatigue reported for PsA (r=0.447) (n=57). 
 Interpretability: Total N = 462 (PsA 123, 26.6%). Number of PsA patients not reported for all analyses. Missing data: NS. Mean(SD)score (baseline): 
NS (but for 1st reliability assessment the mean(SD) score was: 7.6(0.47) (% PsA not clear).  Floor/Ceiling effect: NS. 
VAS fatigue Eng[43]          MID 
Interpretability: N = 200. Missing data: NS. Mean(SD) scores: (1st/2nd visit): 40.82(31.68)/38.30(30.42). Varying time interval (mean: 8.28 months 
between visits). MID(SD) estimates for improvement/worsening: -8.15(23.52)/3.63(27.615). Correlation between mean change in VAS fatigue and 
anchor (patient’s rating of change): rs= 0.239 (the authors did not aim to test responsiveness of VAS fatigue, only MID) Floor/Ceiling: NS.  
SF-36 VT Eng[26] Poor/?     Fair/-     
Results: Box A:  Cronbachα 0.90, insufficient information on unidimensionality. Box F:  Less than 75% of hypotheses about convergent validity 
(moderate correlation to measures of function, disease activity and severity) were confirmed.  No statistically significant difference in scores 
compared to general population (known group validity).   
Interpretability: N=113. Missing data: NS. Mean(SD) scale score: 57.5(2.52). Floor/ceiling. NS-  
SF-36 VT Chin[40] Poor(?)     Good(+)    F/C 
Results: Box A: Unidimensionality not sufficiently checked. Cronbach alpha = 0.83. Box F: Internal convergent validity hypotheses confirmed. Known 
group validity (external relationships): No a priori hypotheses. 
Interpretability: N= 168. Missing data: NS (all completed). Mean(SD) scale score: 50.42(22.01). Floor/Ceiling effect: 0.6/2.0.    
SF-36 VT Chin [50]         Poor/? MID 
Results: Box I: Small sample size. Correlation between anchor (patient perception of change) and change in vitality score: rs= -0.28.  
Interpretability: N = 17-21 in analyses. Missing data: NS. Mean(SD) baseline scores: 1: Patients treated > 12 weeks:43.9 (9.3) and 2) Patients treated 
<12 weeks: 41.8(11.2). MID for improvement: 7.94(11.46). MID for deterioration: -5.25(15.68). Effect size: 0.28, SRM: 0.35. Time frame 
(responsiveness): up to 52 weeks.  Floor/ceiling effect: NS  
PARTICIPATION A B C D E F G H I  
SRPQ (IM, SR,ST) Eng[52] Poor/? Fair/+ Fair/? Fair/+  Fair/+    MDC 
Results: Box A:  Unidimensionality not checked. SRPQ-Role importance scale: Cronbach α = 0.82, inter-item correlations: 0.09-0.75.  SRPQ- 
Satisfaction (time spent and role): Cronbach α >0.93, inter-item correlations: 0.36-0.89. Box B:  PsA group:  Role importance: ICC (95%CI) = 0.79(0.60-
0.90), Satisfaction with time spent: ICC (95%CI) = 0.94(0.88-0.97), Satisfaction with role performance: ICC(95%CI) = 0.96(0.92 to 0.98). Box C: No MIC 
defined. Box D:  Sparse information. SRPQ was evaluated by cognitive debriefing by 15 patients but proportion with PsA was not reported. Box F: 
Hypotheses generally fulfilled, correlation with related measures of participation: r = 0.66-0.68. 
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Interpretability: N = 109 (PsA=65). Missing data: NS. Mean(SD) summary scores (PsA): Importance scale: 3.81(0.48), satisfaction with time spent 
scale: 3.47(0.78) and satisfaction with role performance scale: 3.44(0.87).  MDC (PsA): 1) Role importance scale: 0.86, 2) Satisfaction with spent scale: 
0.75 and 3) Satisfaction with the role performance scale: 0.68.  Time frame (test-retest): 2-3 weeks. Floor/ceiling effect: NS.  
WPS (all subscales) 
Eng[57] 
     Fair/+   Fair/+ F/C 
Results: Box F: Hypotheses about divergent validity with low correlations (r<0.4) to unrelated measures (DAS28, CRP, PASI, HAQ-DI, SF-36 MCS, PCS, 
PsAQoL, EQ-5D, DLQI) were fulfilled. Known group validity: Differences in WPS scores between groups with different level of HRQoL (PsAQoL, SF-36), 
disease activity (DAS28, PASI) and disability (HAQ) confirmed. Box I: Hypotheses about known group validity stated a priori and confirmed with 
significantly greater improvements in household and patient workplace productivity observed in ACR20 responders versus nonresponders at week 12 
except for item/subscale 2 and 8.  
Interpretability:  N = 409. Missing data max 41% for a WPS item (not all items relevant for every patient). Missing data among patients expected to 
answer an item max. 0.7%. Mean(SD) scores reported for item 2-9. Time frame (responsiveness): 12 weeks.  Floor effect (items): Max. 77%, Ceiling 
effect: Max 6.9%.   ES for changes in work productivity for ACR20- or HAQ-DI MCID responders were small to moderate. 
AIMS1 Social activity Eng[21]     Fair/?     
Result: Sparse information about properties of comparators, and all comparators represent unrelated constructs (function, disease activitity or 
severity)  why no results score is generated  
Interpretability: N=145. Missing data: NS Mean(SD) scale score: 2.6(1.6). Floor/ceiling effect: NS 
AIMS2 Social activity Eng[24]     Fair/?     
Result: Sparse information about properties of comparators and all comparators represent unrelated constructs (function, disease activitity or 
severity), why no results score is generated. 
Interpretability: Interpretability: N = 124. Missing data: NS.  Mean(SD) scale score: 4.79(2.09). Floor/ceiling effect: NS 
AIMS2 Work Eng[24]      Fair/?     
Result: Sparse information about properties of comparators and all comparators represent unrelated constructs (function, disease activitity or 
severity) why no result is generated. 
Interpretability: N=124. Missing data: 51% (this scale is only relevant for employed patients). Mean(SD)scale score:1.41(1.80). Floor/ceiling effect: NS: 
AIMS2 Social component Eng[28]        Poor/?  
Results: Box I:  Responsiveness is tested in different ways but no evidence for responsiveness was achieved (small sample size of subanalysis and or 
insufficient methods applied).    
Interpretability: N = 80. Missing data: 12% (excl.).  Mean(SD) for scale scores at 1st/2nd visit:  3.33(1.86)/3.44(1.79). Time interval 12-18 months.  
Floor/ceiling effect: NS 
SF-36 RE Eng[26] Poor/?     Fair/?     
Results: Box A: Limited information on unidimensionality. Cronbachα 0.92. Box F: Sparse information on properties of comparators, and only 
convergent validity assessed by comparing to unrelated measures (function, disease activity, disease severity. Hypotheses about significant difference 
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between scores of PsA and general population confirmed, but no hypotheses about expected magnitude, not sufficient to generate a positive score 
for box F.  
Interpretability: N=113. Missing data: NS (all completed) Mean(SD) scale score: 71.4 (4.44)Floor/Ceiling effect: NS 
SF-36 RE Chin[40] Poor/?     Good/+    F/C 
Results: Box A:  Unidimensionality not sufficiently checked. Cronbach α 0.868. Box F: Convergent validity (internal relationships): Scaling assumption 
(equal item variance, item-own scale, item-other scale) in consistency with hypotheses but for known group validity (external relationships) the 
hypotheses were vaguely stated.  
Interpretability:  N=168. Missing data: NS. Mean(SD) scale score: 48.41(44.53) Floor effect: 39.3%, Ceiling effect: 36.9%. 
SF-36 RE Chin[50]         Poor/? MID 
Results: Box I: Small sample size. Correlation between anchor (patient perception of change) and change in SF-36 RE score: rs= -0.23.  
Interpretability: N = 17-21 in analyses. Missing data: NS. Mean(SD) baseline scores: 1: Patients treated > 12 weeks: 19.4(34.9) and 2) Patients treated 
<12 weeks: 20.5(40.0). MID for improvement: 3.96(52.60). MID for deterioration: -10.0(37.62). Effect size: 0.27, SRM: 0.26. Time frame 
(responsiveness): up to 52 weeks.  Floor/ceiling effect: NS 
SF-36 RP Eng[26]      Fair/-     
Results: Box A: Limited information on unidimensionality. Cronbachα 0.92. Box F: Sparse information on properties of comparators, hypotheses about 
correlation to related measures (function, disease activity, disease severity) not sufficiently confirmed (3/7). Statistically significant difference in 
scores compared to general population (as hypothesized) but not enough to generate a positive score for box F.  
Interpretability: N=113. Missing data: NS (all completed) Mean(SD) scale score: 65.8(4.30). Floor/Ceiling effect: NS 
SF-36 RP Chin[40] Poor/?     Good/+    F/C 
Results: Box A:  Unidimensionality not sufficiently checked. Cronbach α 0.888. Box F: Convergent validity (internal relationships): Scaling assumption 
(equal item variance, item-own scale, item-other scale) in consistency with hypotheses but for known group validity (external relationships) the 
hypotheses were vaguely stated.  
Interpretability:  N=168. Missing data: NS. Mean(SD) scale score: 41.07(42.41) Floor effect: 42.9%, Ceiling effect: 26.8%. 
SF-36 RP Chin[50]         Poor/? MID 
Results: Box I: Small sample size. Correlation between anchor (patient perception of change) and change in SF-36 RP score: rs= -0.29.  
Interpretability: N = 17-21 in analyses. Missing data: NS. Mean(SD) baseline scores: 1: Patients treated > 12 weeks: 19.4(34.9) and 2) Patients treated 
<12 weeks: 20.5(40.0). MID for improvement: 11.76(44.30). MID for deterioration: -11.25(36.70). Effect size: 0.41, SRM: 0.39. Time frame 
(responsiveness): up to 52 weeks.  Floor/ceiling effect: NS 
SF-36 SF Eng[26] Poor/?     Fair/?     
Results: Box A: Limited information on unidimensionality. Cronbachα 0.88. Box F: Sparse information on properties of comparators, convergent 
validity assessed by comparing to unrelated clinical measures (function, disease activity, disease severity). Known group validity: Significant difference 
in scores compared to the general population (as hypothesized) but insufficient information to generate a positive score for box F.  
Interpretability: N=113. Missing data: NS (all completed) Mean(SD) scale score: 65.8(4.30). Floor/Ceiling effect: NS 
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SF-36 SF Eng[28] Poor/?        Poor/?  
Results: Box A: Unidimensionality not checked/reported. Cronbach α (0.80-0.91), no exact value was reported.  Box I:  Responsiveness is tested in 
different ways but no evidence for responsiveness was achieved (small sample size of subanalysis and or insufficient methods applied).  
Interpretability: N=70, Missing data: 12.5% (excl.). Mean(SD) score at baseline/follow-up: 81.57(24.09)/ 67.27(25.79)Floor/ceiling: NS. 
SF-36 SF Chin[40] Poor/?     Good/+    F/C 
Results: Box A:  Unidimensionality not sufficiently checked. Cronbach α 0.787. Box F: Convergent validity (internal relationships): Scaling assumption 
(equal item variance, item-own scale, item-other scale) in consistency with hypotheses but for known group validity (external relationships) the 
hypotheses were vaguely stated.  
Interpretability:  N=168. Missing data: NS. Mean(SD) scale score: 66.42(26.28) Floor effect: 1.2%, Ceiling effect: 17.6%. 
SF-36 SF Chin[50]         Poor/? MID 
Results: Box I: Small sample size. Correlation between anchor (patient perception of change) and change in SF-36 Soc.F score: rs= -0.27.  
Interpretability: N = 17-21 in analyses. Missing data: NS. Mean(SD) baseline scores: 1: Patients treated > 12 weeks: 50.1(29.2) and 2) Patients treated 
<12 weeks: 55.9(31.3). MID for improvement: 5.06(22.50). MID for deterioration: -2.78(17.45). Effect size: 0.26, SRM: 0.31. Time frame 
(responsiveness): up to 52 weeks.  Floor/ceiling effect: NS 
EMOTIONAL WELL BEING A B C D E F G H I  
SF-36 MH Eng[26] Poor/?     Fair/?      
Results: Box A: Limited information on unidimensionality. Cronbachα 0.87. Box F: Sparse information on properties of comparators, convergent 
validity assessed by comparing to unrelated clinical measures (function, disease activity, disease severity). Known group validity assessed by 
comparison of scores from general population and PsA, showing no statistically significant difference. However, this is not enough information to 
generate a negative score for box F.  
Interpretability: N=113. Missing data: NS (all completed) Mean(SD) scale score:  73.0(2.21). Floor/Ceiling effect: NS 
SF-36 MH Eng[28] Poor/?        Poor/?  
Results: BOX A: Unidimensionality not checked/reported. Cronbach α (0.80-0.91), no exact value was reported.  Box I:  Responsiveness is tested in 
different ways but no evidence for responsiveness was achieved (small sample size of subanalysis and or insufficient methods applied).  
Interpretability: N=70, Missing data: 12.5% (excl.). Mean(SD) score at baseline/follow-up: 73.6(18.64)/ 67.66(23.90). Floor/ceiling: NS. 
SF-36 MH Chin[40] Poor/?     Good/+      
Results: Box A:  Unidimensionality not sufficiently checked. Cronbach α = 0.808. Box F: Convergent validity (internal relationships): Scaling assumption 
(equal item variance, item-own scale, item-other scale) in consistency with hypotheses but for known group validity (external relationships) the 
hypotheses were vaguely stated.  
Interpretability:  N=168. Missing data: NS. Mean(SD) scale score: 63.95(19.65) Floor effect: 0%, Ceiling effect:3 %. 
SF-36 MH Chin[50]         Poor/? MID 
Results: Box I: Small sample size. Correlation between anchor (patient perception of change) and change in SF-36 MH score: rs= -0.28.  
Interpretability: N = 17-21 in analyses. Missing data: NS. Mean(SD) baseline scores: 1: Patients treated > 12 weeks: 50.7 (23.1) and 2) Patients treated 
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<12 weeks: 57.5(11.5). MID for improvement: 1.41(8.36). MID for deterioration: -0.00(14.85). Effect size: 0.19, SRM: 0.31. Time frame 
(responsiveness): up to 52 weeks.  Floor/ceiling effect: NS 
SF-36 MCS Chin[40]     Good/+ Poor/?     
Results: Box E: Structural validity assessed by PCA, and a 2 factor model (PCS, MCS) was supported, explaining 69.4% of the total variance. Box F: Only 
known group validity (general population vs. PsA) and no exact hypotheses stated a priori.  
Interpretability: N=168. Missing data: NS. Mean(SD) component summary score: 45.22(12.66. ) 
SF-36 MCS Chin[50]        Poor/? MID  
Results: Box I: Small sample size. Correlation between anchor (patient perception of change) and change in SF-36 mcs: rs= -0.24  
Interpretability: N = 17-21 in analyses. Missing data: NS. Mean(SD) baseline scores: 1: Patients treated > 12 weeks: 38.8 (12.6) and 2) Patients treated 
<12 weeks: 38.8(9.2). MID for improvement: 1.77(8.60). MID for deterioration: -0.70(8.37). Effect size: 0.19, SRM: 0.28. Time frame (responsiveness): 
up to 52 weeks.  Floor/ceiling effect: NS 
AIMS1 Psyc.C. Eng[25]        Poor/?  
Box I: Correlation between change in clinical measures and scores of AIMS1 (time 1) and AIMS2 (time 2). Not assessing correlation between change 
scores and no a priori hypotheses.  
Interpretability: N = 65. Missing data: NS. Mean(SD) for scale score: 3.34(1.04). Time frame (responsiveness): 4 years.  Floor/ceiling effect: NS 
AIMS1 Anxiety Eng[21]      Fair/?     
Result: Box F: Sparse information about properties of comparators and all comparators represent unrelated constructs (function, disease activity or 
severity) why no results score is generated.  
Interpretability: N=145. Missing data: NS Mean(SD)  scale score: 1.7(0.7). Floor/ceiling effect: NS 
AIMS1 Depression Eng[21]     Fair/?     
Result: Box F: Sparse information about properties of comparators and all comparators represent unrelated constructs (function, disease activity or 
severity) why no result is generated. 
Interpretability: N=145. Missing data: NS. Mean(SD) scale score:  2.4(1.0). Floor/ceiling effect: NS 
AIMS2 Mood Eng[24]      Fair/?     
Result: Box F: Sparse information about properties of comparators and all comparators represent unrelated constructs (function, disease activity or 
severity) why no result is generated. 
Interpretability: N=124. Missing data: NS Mean(SD) scale score:  2.67(1.60). Floor/ceiling effect: NS 
AIMS2 Tension Eng[24]      Fair/?     
Result: Box F: Sparse information about properties of comparators, and all comparators represent unrelated constructs (function, disease activity or 
severity) why no result is generated. 
Interpretability: N=124. Missing data: NS Mean(SD) scale score:  4.32(1.93). Floor/ceiling effect: NS: 
AIMS2 Psyc.C. Eng[28]          Poor/?  
Results:  Box I:  Responsiveness is tested in different ways but no evidence for responsiveness was achieved (small sample size of subanalysis and or 
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insufficient methods applied).  Interpretability: N = 80. Missing data: 12% (excl.).  Mean(SD) for scale scores at 1st/2nd visit:  3.68(1.67)/3.69(2.00). 
Time interval 12-18 months.  Floor/ceiling effect: NS 
AIMS2 Psyc.C. Eng[25]         Poor/?  
Result:  Box I: Correlation between change in clinical measures and scores of AIMS1 (time 1) and AIMS2 (time 2). Not assessing correlation between 
change scores and no a priori hypotheses.  
Interpretability:  Mean(SD) scale score: 3.98(2.69) (2nd assessment, 1st assessment was AIMS1, 4 years interval.) 
mRAI (of MultiP) Eng[44]  Poor/?  Poor/?  Poor/?     
Results: Box B:  Test-retest: Number and % PsA patients in analysis was not specified. ICC (95%CI) = 0.94 (0.93-0.94) Box D: Not enough information 
available to rate quality or result of content validity assessment. Box F: Sparse hypotheses and no information about measurement properties of 
comparators and for most correlations, the proportion of PsA was <50%. Correlation between mRAI to DAS28 (r = 0.741) (%PsA not clear) and 
between mRAI and patient reported TJC: r=0.672 (PsA n=57).  
Interpretability: Total N = 462 (PsA 123, 26.6%). Number of PsA patients not reported for all analyses. Missing data: NS. Mean(SD) baseline score:  
6(0.47) (26.6% PsA). Time frame test-retest: 1 week. Floor/ceiling effect: NS.  
ECONOMIC COST           
EQ-5D-3L Norw[45]          MCII, PASS 
Interpretability: Total number of PsA in the study: N = 1391. No. of PsA in the analysis: n = 250. Missing data: Reported per analysis (excl.). Mean(SD) 
utility score:  0.49(0.29) at baseline and 0.61(0.28) after 3 months. The anchoring questions were given after 3 months and asked about satisfaction 
(PASS) and improvement (MCII), respectively.  PASS cut-points (ROC curves): 75% sensitivity cut-off: 0.69. 80% specificity cut-off: 0.73. AUC (95%CI): 
0.78 (0.72-0.84). MCII cut-points (ROC curves): 75% sensitivity cut-off: 0. 80% specificity cut-off: 0.18. AUC(95%CI): 0.678(0.61-0.75). 
EQ-5D-3L Swe[75]          PASS 
Interpretability: N=255 (PsA=23). Objective of study was to compare British (UK), hypothetical, and Swedish (SE), experience-based, EQ-5D utilities 
using data from clinical practice/cohort of patients with RA, SpA and PsA treated with anti-TNFI. Point estimates and PASS cut-off levels were 
compared: SE utilities were higher than UK utilities: Baseline mean(SD) UK/SE EQ-5D: 0.44(0.34)/0.72(0.15). PASS cut offs were stable over time for 
both the UK and SE preference:  Baseline:  Mean(SD) UK/SE EQ-5D: 0.71/0.84, follow-up: 0.71/0.82 but higher (0.11) when using SE compared to UK. 
Percentage in PASS at baseline/follow-up (18.9 % /59.9 %).  
EQ-5D-3L Hung[42]      Fair/+     
Results: Box F: Sparse hypotheses and information about measurement properties of comparators. Moderate/strong correlation (r = 0.63-0.73) with 
related measures (PsAQoL, HAQ, BASDAI, PGA, VAS pain). Known group validity: Differences in scores according disease severity, SMD: 0.46 to 1.1.  
Interpretability.  N = 183. Missing data: 3%.  Mean(SD) scores for EQ-5D utility: 0.5 (0.3). Median(range) score: 0.587 (–0.594 to 1). Scores for EQ-5D 
VAS: Mean(SD) score: 54.7 (20.0), median(range) score: 52(5–95). Floor/ceiling effect: NS.  
EQ-5D-3L Eng/Chin[54]      Fair/+    F/C 
Results: Box F: Vague hypotheses. Moderate correlation between EQ-5D utility score and related measures: SF-6D utility (rs= 0.594), SF-GH (rs = -0.44), 
PCS (rs= 0.445), MCS (rs= 0.371), EQ-VAS (rs= 0.494).  Known group validity: Differences in scores according to SF-general health status, Effect size 
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ranging from 0.62 (poor/fair vs good health state) to 0.91 (excellent/very good vs good health state).  
Interpretability: N = 86. Missing data: 1.2%. Mean(SD) score: 0.74(0.24), median(IRQ): 0.8(0.09). Bimodal score distribution. Floor effect: 2.3% had 
negative scores for EQ-5D. Ceiling effect: 20%. 
SF-6D  Eng/Chin[54]      Fair/+    F/C 
Results: Box F: Vague hypotheses. Moderate/strong correlation to related measures: EQ-5D utility (rs= 0.594), SF-GH (rs=-0.569), PCS (rs= 0.843), MCS 
(rs=0.623), EQ-VAS (rs= 0.538).  Known group validity: Differences in scores according to SF-general health status, ES ranging from 0.92 (poor/fair vs 
good health state) to 0.94 (excellent/very good vs good health state).  
Interpretability: N = 86. Missing data:  9.3% for SF-6D, reduced to 3.5% by estimating the missing by SF-36v2 protocol. Mean(SD) score:  0.68(0.13), 
median (IRQ): 0.64(0.18). Normal score distribution. Floor/ceiling effect: None.  
SF-6D Norw[45]           
Interpretability: Total number of PsA in the study: N = 1391. No. of PsA in the analysis: n = 819. Missing data: Stated for each part of the study. 
Mean(SD) scores utility: 0.60(0.12) at baseline and 0.66(0.13) at 3 months. Anchoring questions about satisfaction (PASS) and improvement (MCII), 
respectively. PASS cut-points (ROC curves): 75% sensitivity cut-off: 0.60. 80% specificity cut-off: 0.65. AUC 0.80(95%CI 0.76-0.82). MCII cut-points 
(ROC curves): 75% sensitivity cut-off: 0.01. 80% specificity cut-off: 0.07. AUC(95%CI): 0.73(0.69-0.76). Floor/ceiling effect: NS 
EQ-5D and SF-6D Eng[47]      Poor/?      Poor/?                 Score 
 distributions  
Results/Interpretability: Box F, I: The study compares utility estimates obtained from EQ-5D and SF-6D mapped to HAQ. No a priori hypotheses are 
stated about expected correlations, and no gold standard explained. It is only possible to conclude that the measurements are not similar no 
conclusion about the measurement properties for each of them can be drawn. Change in utility score during 1 year of biologic treatment is 0.09 for 
SF-6D and 0.28 for EQ-5D. EQ-5D-derived utilities are likely to produce larger QALY gains than SF-6D-derived utilities for a given change in the disease-
specific measure (HAQDI). The EQ-5D displays a bimodal distribution in more severe health states in both RA and PsA. Mean(utility scores): SF-6D: 
0.57(0.12) at baseline and 0.66(0.12) at follow up (1 year). EQ-5D: 0.49(32) at baseline and 0.77(28) at follow up. Utility scores were calculated from 
the preference-based instruments using UK population norms. 
EQ-5D-rev. Eng[48]      Poor/?   Poor/?                     Score  
                         distributions 
Results/interpretability: A revised scoring of EQ-5D is used and shown to lessen the gap between utility measures produced by SF_6D and the 
original EQ-5D utility estimates, regression analysis with HAQ-DI as independent variable show more comparable slope with the revised EQ-5D and 
the SF-6D compared to the original. However it is not possible to provide a score for the construct validity of the EQ_5D revised version because no 
hypotheses are stated a priori about expected correlations. Baseline mean(SD)/range scores original vs revised:  0.49(32)/-0.24;1.0 vs 0.62(0.21)/-
0.14;0.99. Followup: 0.77(28)/-0.24;1.0) vs 0.84(0.17)/0.046;0.9954). Change in utility 0-12 months (biologic treatment) 0.28(-0.36;0.2) vs 0.22 
(0.28;0.167) 
WTP Eng[46]    Poor/?  Fair/+     
Results: (Pilot study). Box D: Content validity of the tool was reviewed by rheumatologists not PsA patients during the development phase. The 
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proportion of patients confirming an impact of PsA on these domains varied between 35%-88%.  Box F:  Correlation between median WTP amounts 
were higher between related than non-related domains. However, one of the 4 domains that patients ranked as most impacted by PsA was 
associated with a lower WTP amount than some domains ranked at less impacted by PsA.  
Interpretability: N = 60. Missing data: NS.  Median(IQR) scores of WTP for relief of the 8 domains: Lowest WPT amount (concentration): 7500(1000-
50,000), highest WTP amount (Physical comfort, Sleep, work): 10,000(5000-75,000).   
SLEEP A B C D E F G H I  
VAS sleep Eng[43]          MID 
Interpretability: N = 200. Missing data: NS. Mean(SD) (1st/2nd visit): 37.99(32.93)/38.83(32.32). Varying time interval (mean: 8.28 months between 
visits). MID(SD) estimates for improvement/worsening: -10.97(29.74)/13.96(27.32). Correlation between mean change in VAS pain and anchor 
(patient’s rating of change): rs = 0.326 (the authors did not aim to test responsiveness of VAS pain, only MID) Floor/ceiling effect: NS. 
STIFFNESS A B C D E F G H I  
NRS stiffness Eng[44]    Poor/?  Poor/?     
Results: Box D: Not enough information to rate quality or results on content validity. Box F: No hypotheses or information about properties of 
comparators, PsA <50% of the population in most of the analyses. Correlation between patient-reported TJC and NRS stiffness (r=0.600) (in PsA 
subset n=57). 
 Interpretability: Total N = 462 (PsA 123, 26.6%). Number of PsA patients not reported for all analyses. Missing data: NS. Mean(SD)score (baseline): 
NS.  Floor/Ceiling effect: NS. 
VAS stiffness Eng[22]      Poor/?     
Results: Box F:  No hypotheses and sparse information about measurement properties of comparators. Moderate correlation to ACR functional class 
not to other measures presented.    
Interpretability: N = 99-114. Missing data: 13% (excl.). Mean(SD) score: 0.91(0.69).  Floor/ceiling effect: NS 
 
NON-COS Domains A B C D E F G H I  
SF-36 GH Eng[26]                       Poor/?     Fair/-     
Results: Box A: Cronbachα 0.82. Limited evidence for unidimensionality: Less than 75% of convergent validity hypotheses confirmed about correlation 
to measures of function, disease activity and severity. Known group validity showing significant difference to general population but not enough 
information to generate a positive score for box F. 
Interpretability: N=113. Missing data: NS (all completed) Mean(SD) scale score: 58.8(3.31). Floor/Ceiling effect: NS 
SF-36 GH Chin[40]                     Poor/?     Good/-    F/C 
Results: Box A: Unidimensionality not reported, Cronbach α = 0.749. Box F: Hypotheses about internal relationships (scaling assumptions) not 
sufficiently fulfilled item 1 of GH had higher other-scale (BP, RP, PF, VT scales) than own-scale correlations. Known group validity assessed (according 
to HAQ, BASDAI, DAS28 level) with higher SF-36GH scores in the severe groups but no hypotheses (about expected magnitude of difference) stated a 
priori.  
Interpretability: N=168. Missing data: NS (all completed). Mean(SD) score 41.53(21.00). Floor effect: 2.4. Ceiling effect: 0.  
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ACR20/ACR50/ACR70: American College of Rheumatology response criteria (20/50/70% improvement); ARA; American Rheumatism Association; ASDAS, Ankylosing 
Spondylitis Disease Activity Score;AUC, Area Under Curve; BSA; Body Surface Area (with psoriasis); CDAI, Clinical Disease Activity Index; cDAPSA, clinical Disease Activity 
index for Psoriatic Arthritis; Chin, Chinese; CPDAI, Composite Psoriatic Disease Activity Index; DAS28; Disease Activity Score-28 joints; DLQI, Dermatology Life Quality Index; 
Eng, English; ERS; Erythrocyte sedimentation rate; Excl, Excluded; FA, Factor Analysis; F/C, Floor and/or Ceiling effect reported; FI, Functional Index; Germ, German; Hung, 
Hungarian; DIF, Differential Item Functioning; ICC,  Inter-correlation coefficient; IPBOD, Inverse Psoriasis Burden of Disease questionnaire; Ital, Italian; IQR, Interquartile 
range; LoA, Limits of agreement; MCID, Minimal Clinically Important Difference; MCII, Minimal clinical important improvement; MDA, Minimal Disease Activity; MDC, 
minimal detectable change; MIC, Minimal important change; MID, Minimal important Difference; Missing data (either item responses or patients); N, Number of patients; 
NHP(D); Nottingham Health Profile(Distress index); Norw, Norwegian; NS, Not Stated; PASDAS, Psoriatic Arthritis Disease Activity Score; PASI; Psoriasis Activity and Severity 
Index; PASS, Patient acceptable symptom state; PCA, Principal component analysis; PGA, Patient Global Assessment; PhGA, Physician Global Assessment; PSD, Psoriasis 
Symptom Diary; PSI, Psoriasis Symptom Inventory; rs, Spearman correlation coefficient; r; Pearson correlation coefficient; RA, Rheumatoid arthritis; ROC, Receiver Operating 
Curve; SD, Standard deviation; SJC, Swollen Joint Count; SMD, Standard Mean Difference; SpA; spondyloarthropathy; Span, Spanish; SRM, Standard Response Mean; Swe, 
Swedish; TJC, Tender Joint Count; Turk, Turkish; VAS, Visual Analogue Scale. 
 
 
 
 
 
 
SF-36 GH Chin[50]        Poor/? MID 
Results: Box I: Small sample size. Correlation between anchor (patient perception of change) and change in SF-36 GH: rs= -0.30  
Interpretability: N = 17-21 in analyses. Missing data: NS. Mean(SD) baseline scores: 1: Patients treated > 12 weeks: 23.8 (8.0) and 2) Patients treated 
<12 weeks: 40.5(11.0). MID for improvement: -2.94(12.34). MID for deterioration: -0.3.75(15.02). Effect size: 0.25, SRM: 0.24. Time frame 
(responsiveness): up to 52 weeks.  Floor/ceiling effect: NS 
AIMS-2 Social Support Eng[24]     Fair/?     
Results: Box F: Sparse information about properties of comparators and only correlations to unrelated measures (disease activity, severity and 
function) 
Interpretability: N=124. Missing data: NS. Mean(SD) score:  1.82(1.86). Floor/Ceiling effect: NS 
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Supplementary Table E: Best-evidence synthesis of measurement properties for each instrument evaluated separately for each language version 
PROMs/scales listed 
according to COS 
Domain category 
Reliability 
 COSMIN BOX (A-C) 
Validity 
 COSMIN BOX (D-H) 
Responsiveness 
COSMIN BOX (I) 
Relevant info 
on score 
interpretation 
reported?  
Internal 
consistency 
Relia-
bility 
Measure-
ment error 
Content 
validity 
Structural 
validity 
Hypothe-
ses testing 
Cross-cult. 
Validity 
Criterion 
validity 
Sensitivity to 
change 
 A B C D E F G H I  
MSK DISEASE ACTIVITY          
BASDAI  Eng      ±    F/C 
BASDAI Span ?     –   ? F/C 
SASPA Germ +    + ?   ?  
PASE-total Eng  ?    ?   ?  
PASE-symptom Eng  ?    ?   ?  
PASE-function Eng  ?    ?   ?  
PASE-total Ital      + a  +  
PASE-symptom Ital      + a  +  
PASE-function Ital      + a  +  
PR-TJC (MultiP) Eng   ?  ?     
SKIN DISEASE ACTIVITY          
PSI  Eng ++ +   ++ +   + F/C 
PSD Eng    +++       
Worst itch NRS Eng    +       
PAIN           
VAS pain (recall 1 week) 
Eng 
     +   ? MID 
VAS pain (recall NS)          PASS, MCII 
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Norw 
VAS pain Chin         ? MID 
NRS pain Eng  ?  ?  ?     
SF-36 BP Eng ?     +   ?  
SF-36 BP Chin ?     ++ b   ? MID, F/C 
AIMS1 Pain Eng      +   ?  
AIMS1 Pain Ital      +     
AIMS2 Pain Eng ?     +   ?  
PATIENT GLOBAL           
Patient Global due to psoriasis          
NRS skin impact (1 week recall) Eng     +    F/C  
VAS skin impact (1 week recall) Eng ++    ?     
Patient global due to arthritis          
NRS joint impact (1 week recall)Eng   ?  +    F/C 
NRS joint impact (1 day recall) Eng          
VAS joint impact  Eng ++    ?     
Patient global due to PsA          
PGA by NRS (1 week recall) Eng     +     
PGA by NRS (1 week recall) Chin     +    F/C 
PGA by VAS (1 week recall) Eng ++    ?    MID 
PGA by VAS (1 week recall) Ital     ?  ?   
PGA by VAS (unknown recall) Norw         PASS, MCII 
PGA by VAS (1 week recall) Chin        ? MID 
PHYSICAL FUNCTION           
DFI Chin – –    – – ?     
DASH Eng      – –     
BASFI Chin ++    ++ ?    F/C  
HAQ-DI Eng ++    ++ –   ? F/C, MID 
HAQ-DI Ital      –     
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HAQ-DI Chin ++    ++ ?   ? F/C 
HAQ-DI Hung      +     
HAQ-DI Thai ?     +    F/C 
HAQ-S  Eng      –     
HAQ-SK Eng      ?     
mHAQ Norw          PASS, MCII 
SF-36 PF Eng ++    ++ +   ? F/C 
SF-36 PF Chin ++    ++ ++ b   ? F/C 
SF-36 PCS Chin     ++ ?   ?  
CASQ-FI Eng ?    ? ?     
AIMS1 Mobility Eng     -     
AIMS1 Physical Eng     +     
AIMS1 Dexterity Eng     +     
AIMS1 House Eng     +     
AIMS1 Physical Ital     -     
AIMS1 ADL Eng     -     
AIMS1 PC. Eng        ?  
AIMS2 PC. Eng                            ?  
AIMS2 Mobility Eng      +     
AIMS2 Physical Eng     +     
AIMS2 Dexterity Eng     +     
AIMS2 Selfcare Eng     -     
AIMS2 House. Eng     -     
AIMS2 Arm F. Eng     +     
HRQoL/MULTIDIM. PROMs   A B C D E F G H I Interpretability 
PsAQoL Eng ++ ?  +++ ++ +   ?  
PsAQol Eng/Chin ? +  ?  + a    
PsAQoL Swe ++ ?  ++  + a   F/C 
PsAQoL Hung      +     
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PsAQoL Dutch ? ++ ? – –  + a    
AIMS1 Global Ital      ?     
PsAID-9  Eng c ++  +++  + a  ? PASS, F/C  
PsAID-12 Eng c  ++  +++  + a  ? PASS, F/C    
PsAID-12touch Ital      +  +  MDA cut-off 
PsAID-12 Ital c    c +   Cut-off values 
PAIP Ital      ?     
VITACORA-19 Span + ++  ++ + +   ? MCID, F/C 
VITACORA-19 Ital ? +   ? + a    
PsoDisk Ital           ?  
CIAQ-QoL Eng ?  ?  ?     
IPBOD Eng ?   ?  ?     
FATIGUE           
FACIT-Fatigue Eng ? +    +     
NRS fatigue Eng  ?  ?  ?   ?  
VAS fatigue Eng          MID 
SF-36 VT Eng ?     -     
SF-36 VT Chin ?     ++b   ? MID, F/C 
PARTICIPATION           
SRPQ IM. Eng ? + ? +  +    MDC 
SRPQ ST Eng ? + ? +  +    MDC 
SRPQ SR Eng ? + ? +  +    MDC 
WPS Eng      +   + F/C 
AIMS1 SA Eng     ?     
AIMS2 SA Eng      ?     
AIMS2 Work Eng      ?     
AIMS2 SC Eng          ?  
SF-36 RE Eng ?     ?     
SF-36 RE Chin ?     ++ b   ?  
SF-36 RP Eng      -     
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SF-36 RP Chin ?     ++ b   ?  
SF-36 SF Eng ?     ?   ?  
SF-36 SF Chin ?     ++ b   ?  
EMOTIONAL WELL-BEING         
SF-36 MH Eng                     ?     ?   ?  
SF-36 MH Chin                       ?     ++ b   ? MID 
SF-36 MCS Chin         ?  
SF-36 MCS Chin     ++ ?   ?  
mRAI Eng  ?  ?  ?     
AIMS1 Psyc.C. Eng         ?  
AIMS1 Anxiety Eng      ?     
AIMS1 Depression Eng     ?     
AIMS2 Mood Eng      ?     
AIMS2 Tension Eng      ?     
AIMS2 Psyc.C. Eng              ?  
ECONOMIC COST           
EQ-5D-3L Norw          MCII, PASS 
EQ-5D-3L Swe           PASS 
EQ-5D-3L Hung      +     
EQ-5D-3LEng/Chin     +     F/C 
EQ-5D-3L Eng      ?   ? Utility score 
distribution 
EQ-5D-3L-rev. Eng           
SF-6D Eng      ?   ? Utility score 
distribution 
SF-6D Eng/Chin      +    F/C 
SF-6D Norw           PASS, MCII, 
WTP Eng    ?  +     
SLEEP           
VAS sleep Eng          MID 
STIFFNESS           
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Empty 
cells reflect that the measurement properties were not evaluated by any study for the given instrument.  Table 2 explains the grading of evidence (+/-/?).aOnly translation, 
no cross-cultural validation. According to COSMIN, only studies that address measurement invariance (e.g. multiple group factor analyses or DIF) between countries (or 
other groups) are considered real cross-cultural validity studies bConstruct validity – hypotheses testing was assessed regarding the internal relationships (scale 
assumptions) and not external measures.cQuestionnaire based on a formative model why internal consistency and structural validity are not rated.  AIMS, Arthritis Impact 
Measurement Scales (ADL, Activity of daily living; Arm F., Arm Function; House, Household; PC, Physical component score; Psyc.C., Psychological component score; SA, 
Social Activity, SC, Social component score); BASDAI, Bath Ankylosing Spondylitis Activity Index; BASFI, Bath Ankylosing Spondylitis Functional index; Chin, Chinese; CIAQ-FI, 
Combined Inflammatory Arthritis – Functional Impairment questionnaire; CIAQ-Qol, Combined Inflammatory Arthritis – quality of life questionnaire; COSMIN, COnsensus-
based Standards for the selection of health Measurement INstruments; DASH, Disabilities of the Arm Shoulder and Hand Outcome Measure; DFI, Dougados Functional 
Index; Eng, English; EQ-5D-3L, EuroQoL 5 Dimensions questionnaire with 3 response levels; FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy-Fatigue scale; 
F/C, Floor/Ceiling effect; Germ, German;  HAQ, Health Assessment Questionnaire (HAQ-S: Spondyloarthropathy, HAQ-SK: Skin, HAQ-DI: Disability Index); Hung, Hungarian; 
IPBOD, Inverse Psoriasis Burden of Disease questionnaire; Ital, Italian; MCID, minimal clinically important difference;  MDC, minimal detectable change; MCII, minimal 
clinical important improvement; MDA, minimal disease activity; MIC, minimal important change; MID, minimal important difference; mRAI, Modified Rheumatology 
Attitude Index; MultiP, Multidimensional Patient Reported Outcome Questionnaire; Norw, Norwegian; NRS, Numeric Rating Scale; PAIP, Psoriatic Arthritis Impact Profile; 
PASE, PsA Screening and Evaluation Questionnaire; PASS, Patient acceptable symptom state; PGA, Patient Global Assessment; PR-TJC, Patient-reported-tender-joint-count; 
PsAID, Psoriatic Arthritis Impact of Disease questionnaire; PsAQoL, PsA Quality of Life instrument; PSD; Psoriasis Symptom Diary; PSI, Psoriasis Symptom Inventory; PsoDisk 
questionnaire, no full spelling available;  SASPA, Stockerau Activity Score for Psoriatic Arthritis; SF-6D, utility tool derived from SF-36 comprising six multi-level dimensions; 
SF-36, Medical Outcome Survey Short Form 36-item Health Survey (SF-36 subscales: BP, Bodily Pain; GH, General Health; MCS, Mental Component Summary; MH, Mental 
Health;  PCS, Physical Component Summary, PF, physical function; RE, Role Emotional; RP, Role Physical; SF, Social Functioning;  VT, Vitality); Span, Spanish; SRPQ, Social 
Role Participation Questionnaire; Swe, Swedish; VAS, Visual Analogue Scale;  VITACORA-19, Spanish acronym, full name not available; WTP, Willingness to Pay 
questionnaire; WPS, Work Productivity Survey. 
 
  
NRS stiffness Eng    ?  ?     
HAQ VAS Stiffness Eng     ?     
NON-COS Domains           
SF-36 GH Eng ?     –     
SF-36 GH Chin ?     – –   ? MID,F/C 
AIMS2 Social Support Eng     ?     
           
90 
 
 
 
Reference List 
 
 (1)  Gladman DD, Antoni C, Mease P et al. Psoriatic arthritis: epidemiology, clinical features, course, and 
outcome. Ann Rheum Dis 2005;64 Suppl 2:ii14-ii17. 
 (2)  Gulati AM, Semb AG, Rollefstad S et al. On the HUNT for cardiovascular risk factors and disease in patients 
with psoriatic arthritis: population-based data from the Nord-Trondelag Health Study. Ann Rheum Dis 
2015. 
 (3)  Ogdie A, Schwartzman S, Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. Curr 
Opin Rheumatol 2015;27:118-26. 
 (4)  Gladman DD, Mease PJ, Strand V et al. Consensus on a core set of domains for psoriatic arthritis. J 
Rheumatol 2007;34:1167-70. 
 (5)  Orbai AM, de WM, Mease P et al. International patient and physician consensus on a psoriatic arthritis 
core outcome set for clinical trials. Ann Rheum Dis 2016. 
 (6)  Boers M, Kirwan JR, Wells G et al. Developing core outcome measurement sets for clinical trials: OMERACT 
filter 2.0. J Clin Epidemiol 2014;67:745-53. 
 (7)  Kalyoncu U, Ogdie A, Campbell W et al. Systematic literature review of domains assessed in psoriatic 
arthritis to inform the update of the psoriatic arthritis core domain set. RMD Open 2016;2:e000217. 
 (8)  Mokkink LB, Terwee CB, Patrick DL et al. The COSMIN study reached international consensus on taxonomy, 
terminology, and definitions of measurement properties for health-related patient-reported outcomes. J 
Clin Epidemiol 2010;63:737-45. 
 (9)  Martin Boers, John Richard Kirwan, Peter Tugwell et al.  The OMERACT handbook.  1-5-0016.  
Ref Type: Online Source 
 (10)  Boers M, Brooks P, Strand CV et al. The OMERACT filter for Outcome Measures in Rheumatology. J 
Rheumatol 1998;25:198-9. 
 (11)  Terwee CB, Mokkink LB, Knol DL et al. Rating the methodological quality in systematic reviews of studies 
on measurement properties: a scoring system for the COSMIN checklist. Qual Life Res 2012;21:651-7. 
 (12)  De Vet H.C.W, Terwee C.B., Mokkink L.B, Knol D.L. Measurement in Medicine. 2 ed. Cambridge University 
Press, 2013. 
 (13)  Cosmin.nl. COnsensus-based Standards for the selection of health Measurement INstruments.  26-9-2015.  
Ref Type: Online Source 
 (14)  Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-
analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 
2009;151:W65-W94. 
 (15)  Terwee CB, Jansma EP, Riphagen II et al. Development of a methodological PubMed search filter for 
finding studies on measurement properties of measurement instruments. Qual Life Res 2009;18:1115-23. 
 (16)  Castrejón I GLCL, et al. EULAR outcome measures library.  2016.  
91 
 
Ref Type: Online Source 
 (17)  Prinsen CA, Vohra S, Rose MR et al. How to select outcome measurement instruments for outcomes 
included in a "Core Outcome Set" - a practical guideline. Trials 2016;17:449. 
 (18)  van TM, Furlan A, Bombardier C et al. Updated method guidelines for systematic reviews in the cochrane 
collaboration back review group. Spine (Phila Pa 1976 ) 2003;28:1290-9. 
 (19)  Gerbens LA, Prinsen CA, Chalmers JR et al. Evaluation of the measurement properties of symptom 
measurement instruments for atopic eczema: a systematic review. Allergy 2017;72:146-63. 
 (20)  US Department of Health and Human Services. Guidance for industry. Patient-reported outcome 
measures: use in medical product development to support labeling claims. (2009).  2009.  
Ref Type: Online Source 
 (21)  Duffy CM, Watanabe Duffy KN, Gladman DD et al. The utility of the arthritis impact measurement scales 
for patients with psoriatic arthritis. J Rheumatol 1992;19:1727-32. 
 (22)  Blackmore MG, Gladman DD, Husted J et al. Measuring health status in psoriatic arthritis: the Health 
Assessment Questionnaire and its modification. J Rheumatol 1995;22:886-93. 
 (23)  Husted JA, Gladman DD, Long JA et al. A modified version of the Health Assessment Questionnaire (HAQ) 
for psoriatic arthritis. Clin Exp Rheumatol 1995;13:439-43. 
 (24)  Husted J, Gladman DD, Farewell VT et al. Validation of the revised and expanded version of the Arthritis 
Impact Measurement Scales for patients with psoriatic Arthritis. J Rheumatol 1996;23:1015-9. 
 (25)  Husted J, Gladman DD, Long JA et al. Relationship of the Arthritis Impact Measurement Scales to changes 
in articular status and functional performance in patients with psoriatic arthritis. J Rheumatol 
1996;23:1932-7. 
 (26)  Husted JA, Gladman DD, Farewell VT et al. Validating the SF-36 health survey questionnaire in patients 
with psoriatic arthritis. J Rheumatol 1997;24:511-7. 
 (27)  Taccari E, Spadaro A, Rinaldi T et al. Comparison of the Health Assessment Questionnaire and Arthritis 
Impact Measurement Scale in patients with psoriatic arthritis. Rev Rhum Engl Ed 1998;65:751-8. 
 (28)  Husted JA, Gladman DD, Cook RJ et al. Responsiveness of health status instruments to changes in articular 
status and perceived health in patients with psoriatic arthritis. J Rheumatol 1998;25:2146-55. 
 (29)  Navsarikar A, Gladman DD, Husted JA et al. Validity assessment of the disabilities of arm, shoulder, and 
hand questionnaire (DASH) for patients with psoriatic arthritis. J Rheumatol 1999;26:2191-4. 
 (30)  McKenna SP, Doward LC, Whalley D et al. Development of the PsAQoL: a quality of life instrument specific 
to psoriatic arthritis. Ann Rheum Dis 2004;63:162-9. 
 (31)  Taylor WJ, Harrison AA. Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid 
measure of disease activity in patients with psoriatic arthritis? Arthritis Care and Research 2004;51:311-5. 
 (32)  Chandran V, Bhella S, Schentag C et al. Functional assessment of chronic illness therapy-fatigue scale is 
valid in patients with psoriatic arthritis. Ann Rheum Dis 2007;66:936-9. 
 (33)  Taylor WJ, McPherson KM. Using Rasch analysis to compare the psychometric properties of the Short Form 
36 physical function score and the Health Assessment Questionnaire disability index in patients with 
psoriatic arthritis and rheumatoid arthritis. Arthritis Rheum 2007;57:723-9. 
92 
 
 (34)  Leung Y-Y, Tam L-S, Kun EWL et al. Comparison of 4 functional indexes in psoriatic arthritis with axial or 
peripheral disease subgroups using Rasch analyses. Journal of Rheumatology 2008;35:1613-21. 
 (35)  Healy PJ, Helliwell PS. Psoriatic arthritis quality of life instrument: an assessment of sensitivity and 
response to change. J Rheumatol 2008;35:1359-61. 
 (36)  Dominguez PL, Husni ME, Holt EW et al. Validity, reliability, and sensitivity-to-change properties of the 
psoriatic arthritis screening and evaluation questionnaire. Arch Dermatol Res 2009;301:573-9. 
 (37)  Fernandez-Sueiro JL, Willisch A, Pertega-Diaz S et al. Validity of the bath ankylosing spondylitis disease 
activity index for the evaluation of disease activity in axial psoriatic arthritis. Arthritis Care Res (Hoboken ) 
2010;62:78-85. 
 (38)  Minnock P, Kirwan J, Veale D et al. Fatigue is an independent outcome measure and is sensitive to change 
in patients with psoriatic arthritis. Clin Exp Rheumatol 2010;28:401-4. 
 (39)  Eder L, Chandran V, Shen H et al. Is ASDAS better than BASDAI as a measure of disease activity in axial 
psoriatic arthritis? Ann Rheum Dis 2010;69:2160-4. 
 (40)  Leung YY, Ho KW, Zhu TY et al. Testing scaling assumptions, reliability and validity of medical outcomes 
study short-form 36 health survey in psoriatic arthritis. Rheumatology (Oxford) 2010;49:1495-501. 
 (41)  Billing E, McKenna SP, Staun M et al. Adaptation of the Psoriatic Arthritis Quality of Life (PsAQoL) 
instrument for Sweden. Scand J Rheumatol 2010;39:223-8. 
 (42)  Brodszky V, Pentek M, Balint PV et al. Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) 
questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a 
cross-sectional survey. Scand J Rheumatol 2010;39:303-9. 
 (43)  Kwok T, Pope JE. Minimally important difference for patient-reported outcomes in psoriatic arthritis: 
Health Assessment Questionnaire and pain, fatigue, and global visual analog scales. J Rheumatol 
2010;37:1024-8. 
 (44)  El MY, El GM, Youssef SS et al. Incorporating patient reported outcome measures in clinical practice: 
Development and validation of a questionnaire for inflammatory arthritis. Clinical and Experimental 
Rheumatology 2010;28:734-44. 
 (45)  Kvamme MK, Kristiansen IS, Lie E et al. Identification of cutpoints for acceptable health status and 
important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and 
ankylosing spondylitis. J Rheumatol 2010;37:26-31. 
 (46)  Hu SW, Holt EW, Husni ME et al. Willingness-to-pay stated preferences for 8 health-related quality-of-life 
domains in psoriatic arthritis: a pilot study. Semin Arthritis Rheum 2010;39:384-97. 
 (47)  Adams R, Walsh C, Veale D et al. Understanding the relationship between the EQ-5D, SF-6D, HAQ and 
disease activity in inflammatory arthritis. PharmacoEconomics 2010;28:477-87. 
 (48)  Adams R, Craig BM, Walsh CD et al. The impact of a revised EQ-5D population scoring on preference-based 
utility scores in an inflammatory arthritis cohort. [References]. Value in Health 2011;921-7. 
 (49)  Cauli A, Gladman DD, Mathieu A et al. Patient global assessment in psoriatic arthritis: a multicenter 
GRAPPA and OMERACT study. J Rheumatol 2011;38:898-903. 
 (50)  Leung YY, Zhu TY, Tam LS et al. Minimal important difference and responsiveness to change of the SF-36 in 
patients with psoriatic arthritis receiving tumor necrosis factor-alpha blockers. J Rheumatol 2011;38:2077-
9. 
93 
 
 (51)  Mease PJ, Woolley JM, Bitman B et al. Minimally important difference of Health Assessment Questionnaire 
in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance 
and satisfaction. J Rheumatol 2011;38:2461-5. 
 (52)  Davis AM, Palaganas MP, Badley EM et al. Measuring participation in people with spondyloarthritis using 
the social role participation questionnaire. Ann Rheum Dis 2011;70:1765-9. 
 (53)  Leung Y-Y, Ho K-W, Zhu T-Y et al. Construct validity of the modified numeric rating scale of patient global 
assessment in psoriatic arthritis. Journal of Rheumatology 2012;39:844-8. 
 (54)  Leung Y-Y, Png M-E, Wee H-L et al. Comparison of EuroQol-5D and short form-6D utility scores in 
multiethnic Asian patients with psoriatic arthritis: A cross-sectional study. Journal of Rheumatology 
2013;40:859-65. 
 (55)  Wink F, Arends S, McKenna SP et al. Validity and reliability of the Dutch adaptation of the Psoriatic Arthritis 
Quality of Life (PsAQoL) Questionnaire. PLoS ONE 2013;8:e55912. 
 (56)  Coaccioli S, Bruno AA, Celi G et al. Validation of an original questionnaire for patients with psoriatic 
arthritis: the Psoriatic Arthritis Impact Profile (PAIP). Clin Ter 2014;165:e100-e108. 
 (57)  Osterhaus JT, Purcaru O. Discriminant validity, responsiveness and reliability of the arthritis-specific Work 
Productivity Survey assessing workplace and household productivity in patients with psoriatic arthritis. 
Arthritis Res Ther 2014;16:R140. 
 (58)  Gossec L, de WM, Kiltz U et al. A patient-derived and patient-reported outcome measure for assessing 
psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease 
(PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis 2014;73:1012-9. 
 (59)  Torre-Alonso JC, Gratacos J, Rey-Rey JS et al. Development and validation of a new instrument to measure 
health-related quality of life in patients with psoriatic arthritis: the VITACORA-19. J Rheumatol 
2014;41:2008-17. 
 (60)  Katchamart W, Benjamanukul S, Chiowchanwesawakit P. Validation of the Thai version of the Health 
Assessment Questionnaire for patients with psoriatic arthritis. Int J Rheum Dis 2014;17:181-5. 
 (61)  Lebwohl M, Swensen AR, Nyirady J et al. The Psoriasis Symptom Diary: development and content validity 
of a novel patient-reported outcome instrument. Int J Dermatol 2014;53:714-22. 
 (62)  Chiricozzi A, Bianchi L, Zangrilli A et al. Quality of life of psoriatic patients evaluated by a new psychometric 
assessment tool: PsoDisk. European Journal of Dermatology 2015;25:64-9. 
 (63)  Lubrano E, Perrotta FM, Parsons WJ et al. Patient's global assessment as an outcome measure for psoriatic 
arthritis in clinical practice: A surrogate for measuring low disease activity? Journal of Rheumatology 
2015;42:2332-8. 
 (64)  Talli S, Etcheto A, Fautrel B et al. Patient global assessment in psoriatic arthritis - what does it mean? An 
analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study. Joint Bone Spine 2015. 
 (65)  Leeb BF, Haindl PM, Brezinschek HP et al. Patient-centered psoriatic arthritis (PsA) activity assessment by 
Stockerau Activity Score for Psoriatic Arthritis (SASPA). BMC Musculoskelet Disord 2015;16:73. 
 (66)  Naegeli AN, Flood E, Tucker J et al. The Worst Itch Numeric Rating Scale for patients with moderate to 
severe plaque psoriasis or psoriatic arthritis. Int J Dermatol 2015;54:715-22. 
 (67)  Wilson HD, Mutebi A, Revicki DA et al. Reliability and validity of the psoriasis symptom inventory in 
patients with psoriatic arthritis. Arthritis Care Res (Hoboken ) 2015. 
94 
 
 (68)  de Wit MP, Kvien TK, Gossec L. Patient participation as an integral part of patient-reported outcomes 
development ensures the representation of the patient voice: a case study from the field of rheumatology. 
RMD Open 2015;1:e000129. 
 (69)  Tander B, Ulus Y, Terzi Y et al. Reliability and validity of the Turkish adaptation of VITACORA-19 in patients 
with psoriatic arthritis. Archives of Rheumatology 2016;31:2016. 
 (70)  Piaserico S, Gisondi P, Amerio P et al. Validation and Field Performance of the Italian Version of the 
Psoriatic Arthritis Screening and Evaluation (PASE) Questionnaire. Acta Derm Venereol 2016;96:96-101. 
 (71)  Leung YY, Thumboo J, Rouse M et al. Adaptation of Chinese and English versions of the Psoriatic Arthritis 
Quality of Life (PsAQoL) scale for use in Singapore. BMC Musculoskelet Disord 2016;17:432. 
 (72)  Salaffi F, Di CM, Carotti M et al. The Psoriatic Arthritis Impact of Disease 12-item questionnaire: 
equivalence, reliability, validity, and feasibility of the touch-screen administration versus the paper-and-
pencil version. Ther Clin Risk Manag 2016;12:631-42. 
 (73)  Di CM, Becciolini A, Lato V et al. The 12-item Psoriatic Arthritis Impact of Disease Questionnaire: Construct 
Validity, Reliability, and Interpretability in a Clinical Setting. J Rheumatol 2016. 
 (74)  Cohen JM, Halim K, Joyce CJ et al. Shedding Light on the "Hidden Psoriasis": A Pilot Study of the Inverse 
Psoriasis Burden of Disease (IPBOD) Questionnaire. J Drugs Dermatol 2016;15:1011-6. 
 (75)  Cooper A, Wallman JK, Gulfe A. What PASSes for good? Experience-based Swedish and hypothetical British 
EuroQol 5-Dimensions preference sets yield markedly different point estimates and patient acceptable 
symptom state cut-off values in chronic arthritis patients on TNF blockade. Scand J Rheumatol 
2016;45:470-3. 
 (76)  Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and 
Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), 
Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research 
Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds 
Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic 
Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), 
Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity 
in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res 
(Hoboken ) 2011;63 Suppl 11:S64-S85. 
 (77)  Orbai AM, Ogdie A. Patient-Reported Outcomes in Psoriatic Arthritis. Rheum Dis Clin North Am 
2016;42:265-83. 
 (78)  Tugwell P, Boers M, D'Agostino MA et al. Updating the OMERACT filter: implications of filter 2.0 to select 
outcome instruments through assessment of "truth": content, face, and construct validity. J Rheumatol 
2014;41:1000-4. 
 (79)  Garratt AM, Lochting I, Smedslund G et al. Measurement properties of instruments assessing self-efficacy 
in patients with rheumatic diseases. Rheumatology (Oxford) 2014;53:1161-71. 
 (80)  Hendrikx J, de Jonge MJ, Fransen J et al. Systematic review of patient-reported outcome measures 
(PROMs) for assessing disease activity in rheumatoid arthritis. RMD Open 2016;2:e000202. 
 (81)  Bartlett SJ, Orbai AM, Duncan T et al. Reliability and Validity of Selected PROMIS Measures in People with 
Rheumatoid Arthritis. PLoS One 2015;10:e0138543. 
 (82)  Strand V, Crawford B, Singh J et al. Use of "spydergrams" to present and interpret SF-36 health-related 
quality of life data across rheumatic diseases. Ann Rheum Dis 2009;68:1800-4. 
95 
 
 (83)  Martin ML, McCarrier KP, Chiou CF et al. Early development and qualitative evidence of content validity for 
the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom 
severity. J Dermatolog Treat 2013;24:255-60. 
 (84)  Bushnell DM, Martin ML, McCarrier K et al. Validation of the Psoriasis Symptom Inventory (PSI), a patient-
reported outcome measure to assess psoriasis symptom severity. J Dermatolog Treat 2013;24:356-60. 
 (85)  Strober BE, Nyirady J, Mallya UG et al. Item-level psychometric properties for a new patient-reported 
psoriasis symptom diary. Value Health 2013;16:1014-22. 
 (86)  Strober B, Zhao Y, Tran MH et al. Psychometric validation of the Psoriasis Symptom Diary using Phase III 
study data from patients with chronic plaque psoriasis. Int J Dermatol 2016;55:e147-e155. 
 
 
